A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
Tumors or cancer of the PROSTATE.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer located in bone tissue or specific BONES.
The surgical removal of one or both testicles.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
A cell line derived from cultured tumor cells.
A malignant epithelial tumor with a glandular organization.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Tosyl compounds are organic derivatives characterized by the introduction of a tosyl group, which is the sulfonate ester of p-toluenesulfonic acid (CH3C6H4SO3H), into an organic molecule through a substitution reaction.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Radium. A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra, atomic number 88, and atomic weight 226. Radium is the product of the disintegration of uranium and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
Anilides are organic compounds resulting from the reaction of aniline (a primary aromatic amine) with carboxylic acids or their derivatives, forming amides, which have various applications in pharmaceuticals and agrochemicals.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Unsaturated androstanes which are substituted with one or more hydroxyl groups in any position in the ring system.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Surgical removal or artificial destruction of gonads.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A multisubunit polycomb protein complex that catalyzes the METHYLATION of chromosomal HISTONE H3. It works in conjunction with POLYCOMB REPRESSIVE COMPLEX 1 to effect EPIGENETIC REPRESSION.
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
A metallocarboxypeptidase that is predominantly expressed as a membrane-bound enzyme. It catalyzes the hydrolysis of an unsubstituted, C-terminal glutamyl residue, typically from PTEROYLPOLYGLUTAMIC ACIDS. It was formerly classified as EC 3.4.19.8.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
Transplantation between animals of different species.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A lipid phosphatase that acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Preparations made from animal tissues or organs (ANIMAL STRUCTURES). They usually contain many components, any one of which may be pharmacologically or physiologically active. Tissue extracts may contain specific, but uncharacterized factors or proteins with specific actions.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Elements of limited time intervals, contributing to particular results or situations.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Interruption or suppression of the expression of a gene at transcriptional or translational levels.
Dissolution of bone that particularly involves the removal or loss of calcium.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Pathological processes involving the PROSTATE or its component tissues.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An anthracenedione-derived antineoplastic agent.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
A physical examination in which the qualified health care worker inserts a lubricated, gloved finger of one hand into the RECTUM and may use the other hand to press on the lower ABDOMEN or pelvic area to palpate for abnormalities in the lower rectum, and nearby organs or tissues. The method is commonly used to check the lower rectum, the PROSTATE gland in men, and the UTERUS and OVARIES in women.
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques.
A protein-serine-threonine kinase that is activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. It plays a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells.
DNA present in neoplastic tissue.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Compounds that bind to and inhibit the activation of ANDROGEN RECEPTORS.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
A saclike, glandular diverticulum on each ductus deferens in male vertebrates. It is united with the excretory duct and serves for temporary storage of semen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Antibodies produced by a single clone of cells.
Clinical management approach wherein immediate therapy is not provided but there is a period of observation during which periodic tests monitor patient and the progression of the illness. (Driffield T, Smith PC Med Decis Making. 2007 Mar-Apr;27(2):178-88)
Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone.
Adherence of cells to surfaces or to other cells.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Steroidal compounds in which one or more carbon atoms in the steroid ring system have been substituted with nitrogen atoms.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
Tumors or cancer of the LUNG.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
An enzyme that catalyzes the reduction of TESTOSTERONE to 5-ALPHA DIHYDROTESTOSTERONE.
An oxidoreductase that catalyzes the conversion of 3-oxo-delta4 steroids into their corresponding 5alpha form. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.
Steroidal compounds related to TESTOSTERONE, the major mammalian male sex hormone. Testosterone congeners include important testosterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with androgenic activities.
Carrier proteins produced in the Sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. They participate in the transport of androgens. Androgen-binding protein has the same amino acid sequence as SEX HORMONE-BINDING GLOBULIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.
Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
Enzymes that catalyze inversion of the configuration around an asymmetric carbon in a substrate having one (racemase) or more (epimerase) center(s) of asymmetry. (Dorland, 28th ed) EC 5.1.
The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
Thiohydantoin benzene derivative.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
The measurement of an organ in volume, mass, or heaviness.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The GENETIC RECOMBINATION of the parts of two or more GENES resulting in a gene with different or additional regulatory regions, or a new chimeric gene product. ONCOGENE FUSION includes an ONCOGENE as at least one of the fusion partners and such gene fusions are often detected in neoplastic cells and are transcribed into ONCOGENE FUSION PROTEINS. ARTIFICIAL GENE FUSION is carried out in vitro by RECOMBINANT DNA technology.
The use of pre-treatment imaging modalities to position the patient, delineate the target, and align the beam of radiation to achieve optimal accuracy and reduce radiation damage to surrounding non-target tissues.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Graphical representation of a statistical model containing scales for calculating the prognostic weight of a value for each individual variable. Nomograms are instruments that can be used to predict outcomes using specific clinical parameters. They use ALGORITHMS that incorporate several variables to calculate the predicted probability that a patient will achieve a particular clinical endpoint.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Conducting a biopsy procedure with the aid of a MEDICAL IMAGING modality.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
A glutathione transferase that catalyzes the conjugation of electrophilic substrates to GLUTATHIONE. This enzyme has been shown to provide cellular protection against redox-mediated damage by FREE RADICALS.
All the organs involved in reproduction and the formation and release of URINE. It includes the kidneys, ureters, BLADDER; URETHRA, and the organs of reproduction - ovaries, UTERUS; FALLOPIAN TUBES; VAGINA; and CLITORIS in women and the testes; SEMINAL VESICLES; PROSTATE; seminal ducts; and PENIS in men.
Persons living in the United States having origins in any of the black groups of Africa.
A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Individuals whose ancestral origins are in the continent of Europe.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
Inability to empty the URINARY BLADDER with voiding (URINATION).

The prostate is a small gland that is part of the male reproductive system. Its main function is to produce a fluid that, together with sperm cells from the testicles and fluids from other glands, makes up semen. This fluid nourishes and protects the sperm, helping it to survive and facilitating its movement.

The prostate is located below the bladder and in front of the rectum. It surrounds part of the urethra, the tube that carries urine and semen out of the body. This means that prostate problems can affect urination and sexual function. The prostate gland is about the size of a walnut in adult men.

Prostate health is an important aspect of male health, particularly as men age. Common prostate issues include benign prostatic hyperplasia (BPH), which is an enlarged prostate not caused by cancer, and prostate cancer, which is one of the most common types of cancer in men. Regular check-ups with a healthcare provider can help to detect any potential problems early and improve outcomes.

Prostatic neoplasms refer to abnormal growths in the prostate gland, which can be benign or malignant. The term "neoplasm" simply means new or abnormal tissue growth. When it comes to the prostate, neoplasms are often referred to as tumors.

Benign prostatic neoplasms, such as prostate adenomas, are non-cancerous overgrowths of prostate tissue. They usually grow slowly and do not spread to other parts of the body. While they can cause uncomfortable symptoms like difficulty urinating, they are generally not life-threatening.

Malignant prostatic neoplasms, on the other hand, are cancerous growths. The most common type of prostate cancer is adenocarcinoma, which arises from the glandular cells in the prostate. Prostate cancer often grows slowly and may not cause any symptoms for many years. However, some types of prostate cancer can be aggressive and spread quickly to other parts of the body, such as the bones or lymph nodes.

It's important to note that while prostate neoplasms can be concerning, early detection and treatment can significantly improve outcomes for many men. Regular check-ups with a healthcare provider are key to monitoring prostate health and catching any potential issues early on.

Prostate-Specific Antigen (PSA) is a glycoprotein enzyme produced by the epithelial cells of the prostate gland. It is primarily involved in liquefying semen after ejaculation, allowing sperm mobility.

In clinical medicine, PSA is used as a tumor marker, mainly for monitoring the treatment and recurrence of prostate cancer. Elevated levels of PSA can indicate inflammation, infection, benign prostatic hyperplasia (BPH), or prostate cancer. However, it's important to note that an elevated PSA level does not necessarily confirm cancer; further diagnostic tests like digital rectal examination, transrectal ultrasound, and prostate biopsy are often required for definitive diagnosis.

Doctors may also use PSA isoforms or derivatives, such as free PSA, total PSA, and PSA density, to help improve the specificity of cancer detection and differentiate between malignant and benign conditions.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Orchiectomy is a surgical procedure where one or both of the testicles are removed. It is also known as castration. This procedure can be performed for various reasons, including the treatment of testicular cancer, prostate cancer, or other conditions that may affect the testicles. It can also be done to reduce levels of male hormones in the body, such as in the case of transgender women undergoing gender affirming surgery. The specific medical definition may vary slightly depending on the context and the extent of the procedure.

Androgen antagonists are a class of drugs that block the action of androgens, which are hormones that contribute to male sexual development and characteristics. They work by binding to androgen receptors in cells, preventing the natural androgens from attaching and exerting their effects. This can be useful in treating conditions that are caused or worsened by androgens, such as prostate cancer, hirsutism (excessive hair growth in women), and acne. Examples of androgen antagonists include flutamide, bicalutamide, and spironolactone.

Androgens are a class of hormones that are primarily responsible for the development and maintenance of male sexual characteristics and reproductive function. Testosterone is the most well-known androgen, but other androgens include dehydroepiandrosterone (DHEA), androstenedione, and dihydrotestosterone (DHT).

Androgens are produced primarily by the testes in men and the ovaries in women, although small amounts are also produced by the adrenal glands in both sexes. They play a critical role in the development of male secondary sexual characteristics during puberty, such as the growth of facial hair, deepening of the voice, and increased muscle mass.

In addition to their role in sexual development and function, androgens also have important effects on bone density, mood, and cognitive function. Abnormal levels of androgens can contribute to a variety of medical conditions, including infertility, erectile dysfunction, acne, hirsutism (excessive hair growth), and prostate cancer.

Androgen receptors (ARs) are a type of nuclear receptor protein that are expressed in various tissues throughout the body. They play a critical role in the development and maintenance of male sexual characteristics and reproductive function. ARs are activated by binding to androgens, which are steroid hormones such as testosterone and dihydrotestosterone (DHT). Once activated, ARs function as transcription factors that regulate gene expression, ultimately leading to various cellular responses.

In the context of medical definitions, androgen receptors can be defined as follows:

Androgen receptors are a type of nuclear receptor protein that bind to androgens, such as testosterone and dihydrotestosterone, and mediate their effects on gene expression in various tissues. They play critical roles in the development and maintenance of male sexual characteristics and reproductive function, and are involved in the pathogenesis of several medical conditions, including prostate cancer, benign prostatic hyperplasia, and androgen deficiency syndromes.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Antineoplastic agents, hormonal, are a class of drugs used to treat cancers that are sensitive to hormones. These agents work by interfering with the production or action of hormones in the body. They can be used to slow down or stop the growth of cancer cells and may also help to relieve symptoms caused by the spread of cancer.

Hormonal therapies can work in one of two ways: they can either block the production of hormones or prevent their action on cancer cells. For example, some hormonal therapies work by blocking the action of estrogen or testosterone, which are hormones that can stimulate the growth of certain types of cancer cells.

Examples of hormonal agents used to treat cancer include:

* Aromatase inhibitors (such as letrozole, anastrozole, and exemestane), which block the production of estrogen in postmenopausal women
* Selective estrogen receptor modulators (such as tamoxifen and raloxifene), which block the action of estrogen on cancer cells
* Luteinizing hormone-releasing hormone agonists (such as leuprolide, goserelin, and triptorelin), which block the production of testosterone in men
* Antiandrogens (such as bicalutamide, flutamide, and enzalutamide), which block the action of testosterone on cancer cells

Hormonal therapies are often used in combination with other treatments, such as surgery or radiation therapy. They may be used to shrink tumors before surgery, to kill any remaining cancer cells after surgery, or to help control the spread of cancer that cannot be removed by surgery. Hormonal therapies can also be used to relieve symptoms and improve quality of life in people with advanced cancer.

It's important to note that hormonal therapies are not effective for all types of cancer. They are most commonly used to treat breast, prostate, and endometrial cancers, which are known to be sensitive to hormones. Hormonal therapies may also be used to treat other types of cancer in certain situations.

Like all medications, hormonal therapies can have side effects. These can vary depending on the specific drug and the individual person. Common side effects of hormonal therapies include hot flashes, fatigue, mood changes, and sexual dysfunction. Some hormonal therapies can also cause more serious side effects, such as an increased risk of osteoporosis or blood clots. It's important to discuss the potential risks and benefits of hormonal therapy with a healthcare provider before starting treatment.

Strontium radioisotopes are radioactive isotopes of the element strontium. Strontium is an alkaline earth metal that is found in nature and has several isotopes, some of which are stable and some of which are radioactive. The radioactive isotopes of strontium, also known as strontium radionuclides, decay and emit radiation in the form of beta particles.

Strontium-89 (^89Sr) and strontium-90 (^90Sr) are two common radioisotopes of strontium that are used in medical applications. Strontium-89 is a pure beta emitter with a half-life of 50.5 days, which makes it useful for the treatment of bone pain associated with metastatic cancer. When administered, strontium-89 is taken up by bones and irradiates the bone tissue, reducing pain and improving quality of life in some patients.

Strontium-90, on the other hand, has a longer half-life of 28.8 years and emits more powerful beta particles than strontium-89. It is used as a component in radioactive waste and in some nuclear weapons, but it is not used in medical applications due to its long half-life and high radiation dose.

It's important to note that exposure to strontium radioisotopes can be harmful to human health, especially if ingested or inhaled. Therefore, handling and disposal of strontium radioisotopes require special precautions and regulations.

Estramustine is an antineoplastic agent, which is a type of medication used to treat cancer. It is a chemical compound that consists of estradiol, a form of the female hormone estrogen, combined with nitrogen mustard, a type of alkylating agent that is used in chemotherapy.

Estramustine works by binding to proteins in the cells, including those involved in the division and growth of cancer cells. This helps to prevent the cancer cells from dividing and growing, which can slow down or stop the spread of the cancer.

Estramustine is used to treat prostate cancer that has not responded to other forms of treatment, such as surgery or radiation therapy. It is usually given as a tablet that is taken by mouth, and it may be given in combination with other medications as part of a treatment plan.

Like all medications, estramustine can cause side effects, including nausea, vomiting, diarrhea, and changes in sexual function. It can also increase the risk of blood clots, so it is important to be monitored by a healthcare provider while taking this medication.

Prostatic hyperplasia, also known as benign prostatic hyperplasia (BPH), is a noncancerous enlargement of the prostate gland. The prostate gland surrounds the urethra, the tube that carries urine and semen out of the body. When the prostate gland enlarges, it can squeeze or partially block the urethra, causing problems with urination, such as a weak stream, difficulty starting or stopping the flow, and more frequent urination, especially at night. Prostatic hyperplasia is a common condition as men age and does not necessarily lead to cancer. However, it can cause significant discomfort and decreased quality of life if left untreated. Treatment options include medications, minimally invasive procedures, and surgery.

Hormone-dependent neoplasms are a type of tumor that requires the presence of specific hormones to grow and multiply. These neoplasms have receptors on their cell surfaces that bind to the hormones, leading to the activation of signaling pathways that promote cell division and growth.

Examples of hormone-dependent neoplasms include breast cancer, prostate cancer, and endometrial cancer. In breast cancer, for instance, estrogen and/or progesterone can bind to their respective receptors on the surface of cancer cells, leading to the activation of signaling pathways that promote tumor growth. Similarly, in prostate cancer, androgens such as testosterone can bind to androgen receptors on the surface of cancer cells, promoting cell division and tumor growth.

Hormone-dependent neoplasms are often treated with hormonal therapies that aim to reduce or block the production of the relevant hormones or interfere with their ability to bind to their respective receptors. This can help slow down or stop the growth of the tumor and improve outcomes for patients.

Flutamide is an anti-androgen medication, which is primarily used to treat prostate cancer. It works by blocking the action of androgens (male hormones), such as testosterone, on cancer cells. This helps to slow down or stop the growth of prostate cancer cells. Flutamide may be given in combination with other medications, such as a luteinizing hormone-releasing hormone (LHRH) agonist, to enhance its effectiveness. It is usually taken by mouth in the form of tablets.

Flutamide can have side effects, including breast tenderness and enlargement, hot flashes, nausea, vomiting, diarrhea, and loss of sexual desire. In rare cases, it may cause more serious side effects such as liver damage. It is important to be monitored by a healthcare professional while taking this medication to ensure that it is working properly and to manage any potential side effects.

A prostatectomy is a surgical procedure where all or part of the prostate gland is removed. This surgery can be performed through various approaches such as open surgery, laparoscopic surgery, or robotic-assisted surgery. The type of prostatectomy performed depends on the reason for the surgery and the patient's individual circumstances.

There are two main types of prostatectomies: radical and simple. A radical prostatectomy is a surgical procedure to remove the entire prostate gland, seminal vesicles, and surrounding lymph nodes. This type of prostatectomy is typically performed as a treatment for prostate cancer.

A simple prostatectomy, on the other hand, involves removing only the inner part of the prostate gland that is causing symptoms such as difficulty urinating or bladder obstruction. Simple prostatectomies are usually performed to alleviate benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland.

Regardless of the type of prostatectomy, potential risks and complications include bleeding, infection, urinary incontinence, erectile dysfunction, and changes in sexual function. It is important for patients to discuss these risks with their healthcare provider before undergoing surgery.

Tosyl compounds are organic compounds that contain the tosyl group (p-toluenesulfonyl, -SO2C6H4CH3) as a substituent. The tosyl group is a protecting group or a good leaving group in organic reactions. Tosyl compounds are often prepared by reacting alcohols or amines with p-toluenesulfonyl chloride (TsCl) in the presence of a base.

The general formula for a tosyl compound can be represented as R-OTs, where R represents an organic group such as an alkyl, aryl, or heteroaryl group. Tosyl compounds are widely used in organic synthesis due to their versatility and reactivity.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Castration-resistant prostate cancer (CRPC) is a more advanced form of prostate cancer that no longer responds to treatments that lower levels of male hormones, such as orchiectomy (surgical removal of the testicles) or medical castration with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. Despite these interventions, the cancer continues to progress and grow. This is often due to the development of mechanisms that allow the cancer cells to produce their own male hormones or become less dependent on them for growth and survival. CRPC is a complex and heterogeneous disease with various clinical manifestations and treatment options, which may include chemotherapy, novel hormonal therapies, immunotherapy, and/or radiation therapy.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Radium is not a medical term per se, but it is a chemical element with symbol Ra and atomic number 88. It is a radioactive metal that decays spontaneously into radon gas, releasing alpha, beta, and gamma particles in the process. Radium has been used in medicine for various therapeutic purposes, such as in the treatment of cancer, due to its radiation properties.

In a medical context, radium is often used in the form of radium-223 dichloride (Xofigo), which is a radiopharmaceutical agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant prostate cancer that has spread to bones. The radioactive emissions from radium-223 help slow or halt the growth of cancer cells in the bones, reducing pain and other symptoms associated with bone metastases.

It is important to note that radium should only be used under the supervision of trained medical professionals, as it can pose significant health risks if not handled properly due to its radioactive properties.

Circulating neoplastic cells (CNCs) are defined as malignant cancer cells that have detached from the primary tumor site and are found circulating in the peripheral blood. These cells have undergone genetic and epigenetic changes, leading to uncontrolled cell growth and division, and can form new tumors at distant sites in the body, a process known as metastasis.

The presence of CNCs has been shown to be a prognostic factor for poor outcomes in various types of cancer, including breast, colon, and prostate cancer. The detection and characterization of CNCs can provide valuable information about the tumor's biology, aggressiveness, and response to therapy, allowing for more personalized treatment approaches.

However, the detection of CNCs is challenging due to their rarity in the bloodstream, with only a few cells present among billions of normal blood cells. Therefore, highly sensitive methods such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing are used for their identification and quantification.

Anilides are chemical compounds that result from the reaction between aniline (a organic compound with the formula C6H5NH2) and a carboxylic acid or its derivative. The resulting compound has the general structure R-CO-NH-C6H5, where R represents the rest of the carboxylic acid molecule.

Anilides are widely used in the pharmaceutical industry to produce various drugs, such as analgesics, anti-inflammatory agents, and antifungal agents. Some examples of anilide-based drugs include acetaminophen (also known as paracetamol), fenacetin, and flufenamic acid.

It's worth noting that some anilides have been found to have toxic effects on the liver and kidneys, so they must be used with caution and under medical supervision.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Taxoids are a class of naturally occurring compounds that are derived from the bark of the Pacific yew tree (Taxus brevifolia) and other species of the genus Taxus. They are known for their antineoplastic (cancer-fighting) properties and have been used in chemotherapy to treat various types of cancer, including ovarian, breast, and lung cancer.

The most well-known taxoid is paclitaxel (also known by the brand name Taxol), which was first discovered in the 1960s and has since become a widely used cancer drug. Paclitaxel works by stabilizing microtubules, which are important components of the cell's skeleton, and preventing them from disassembling. This disrupts the normal function of the cell's mitotic spindle, leading to cell cycle arrest and ultimately apoptosis (programmed cell death).

Other taxoids that have been developed for clinical use include docetaxel (Taxotere), which is a semi-synthetic analogue of paclitaxel, and cabazitaxel (Jevtana), which is a second-generation taxoid. These drugs have similar mechanisms of action to paclitaxel but may have different pharmacokinetic properties or be effective against cancer cells that have developed resistance to other taxoids.

While taxoids have been successful in treating certain types of cancer, they can also cause significant side effects, including neutropenia (low white blood cell count), anemia (low red blood cell count), and peripheral neuropathy (nerve damage). As with all chemotherapy drugs, the use of taxoids must be carefully balanced against their potential benefits and risks.

Androstenols are a type of steroid compound that is found in both animals and humans. They are classified as pheromones, which are chemicals that can affect the behavior or physiology of other members of the same species. Androstenols are found in high concentrations in male sweat, and they have been suggested to play a role in human sexual attraction and communication.

In particular, androstenols are thought to have a positive and calming effect on people, and may help to reduce stress and anxiety. They have also been shown to increase feelings of approachability and friendliness between individuals. Some studies have suggested that androstenols may be particularly effective at enhancing social interactions in women.

Androstenols are often used in perfumes and colognes, as well as in aromatherapy products, because of their potential to promote positive social interactions and reduce stress. However, it is important to note that the effects of androstenols on human behavior and physiology are still not fully understood, and more research is needed to confirm their role in human communication and attraction.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

"Nude mice" is a term used in the field of laboratory research to describe a strain of mice that have been genetically engineered to lack a functional immune system. Specifically, nude mice lack a thymus gland and have a mutation in the FOXN1 gene, which results in a failure to develop a mature T-cell population. This means that they are unable to mount an effective immune response against foreign substances or organisms.

The name "nude" refers to the fact that these mice also have a lack of functional hair follicles, resulting in a hairless or partially hairless phenotype. This feature is actually a secondary consequence of the same genetic mutation that causes their immune deficiency.

Nude mice are commonly used in research because their weakened immune system makes them an ideal host for transplanted tumors, tissues, and cells from other species, including humans. This allows researchers to study the behavior of these foreign substances in a living organism without the complication of an immune response. However, it's important to note that because nude mice lack a functional immune system, they must be kept in sterile conditions and are more susceptible to infection than normal mice.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Castration is a surgical procedure to remove the testicles in males or ovaries in females. In males, it is also known as orchiectomy. This procedure results in the inability to produce sex hormones and gametes (sperm in men and eggs in women), and can be done for various reasons such as medical treatment for certain types of cancer, to reduce sexual urges in individuals with criminal tendencies, or as a form of birth control in animals.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Leuprolide is a synthetic hormonal analog of gonadotropin-releasing hormone (GnRH or LHRH). It acts as a potent agonist of GnRH receptors, leading to the suppression of pituitary gland's secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This, in turn, results in decreased levels of sex hormones such as testosterone and estrogen.

Leuprolide is used clinically for the treatment of various conditions related to hormonal imbalances, including:
- Prostate cancer: Leuprolide can help slow down the growth of prostate cancer cells by reducing testosterone levels in the body.
- Endometriosis: By lowering estrogen levels, leuprolide can alleviate symptoms associated with endometriosis such as pelvic pain and menstrual irregularities.
- Central precocious puberty: Leuprolide is used to delay the onset of puberty in children who experience it prematurely by inhibiting the release of gonadotropins.
- Uterine fibroids: Lowering estrogen levels with leuprolide can help shrink uterine fibroids and reduce symptoms like heavy menstrual bleeding and pelvic pain.

Leuprolide is available in various formulations, such as injectable depots or implants, for long-term hormonal suppression. Common side effects include hot flashes, mood changes, and potential loss of bone density due to prolonged hormone suppression.

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Polycomb Repressive Complex 2 (PRC2) is a multi-protein complex that plays a crucial role in the epigenetic regulation of gene expression, primarily through the modification of histone proteins. It is named after the Polycomb group genes that were initially identified in Drosophila melanogaster (fruit flies) due to their involvement in maintaining the repressed state of homeotic genes during development.

The core components of PRC2 include:

1. Enhancer of Zeste Homolog 2 (EZH2) or its paralog EZH1: These are histone methyltransferases that catalyze the addition of methyl groups to lysine 27 on histone H3 (H3K27). The trimethylation of this residue (H3K27me3) is a hallmark of PRC2-mediated repression.
2. Suppressor of Zeste 12 (SUZ12): This protein is essential for the stability and methyltransferase activity of the complex.
3. Embryonic Ectoderm Development (EED): This protein recognizes and binds to the H3K27me3 mark, enhancing the methyltransferase activity of EZH2/EZH1 and promoting the spreading of the repressive mark along chromatin.
4. Retinoblastoma-associated Protein 46/48 (RbAP46/48): These are histone binding proteins that facilitate the interaction between PRC2 and nucleosomes, thereby contributing to the specificity of its targeting.

PRC2 is involved in various cellular processes, such as differentiation, proliferation, and development, by modulating the expression of genes critical for these functions. Dysregulation of PRC2 has been implicated in several human diseases, including cancers, where it often exhibits aberrant activity or mislocalization, leading to altered gene expression profiles.

Transurethral Resection of Prostate (TURP) is a surgical procedure that involves the removal of the inner part of an enlarged prostate gland using a resectoscope, a tool with a tiny loop of wire at its end that is inserted into the urethra through the penis. The loop of wire is used to cut and remove the excess tissue, which is then washed out of the body. This procedure is typically performed to relieve moderate to severe urinary symptoms caused by an enlarged prostate, such as difficulty in beginning the flow of urine, a weak stream, and frequent urination, especially at night. It is one of the most common surgical procedures for treating benign prostatic hyperplasia (BPH).

Glutamate carboxypeptidase II, also known as prostate-specific membrane antigen (PSMA) or N-acetylated-alpha-linked acidic dipeptidase (NAALADase), is a type II transmembrane glycoprotein enzyme. It is primarily expressed in the prostate epithelium, but can also be found in other tissues such as the kidney, brain, and salivary glands.

PSMA plays a role in the regulation of glutamate metabolism by cleaving N-acetylaspartylglutamic acid (NAAG) to produce N-acetylaspartate (NAA) and glutamate. It has been identified as a useful biomarker for prostate cancer, with increased expression associated with more aggressive tumors.

In addition to its enzymatic activity, PSMA has been shown to have other functions, including involvement in cellular signaling pathways and regulation of angiogenesis. As a result, it is being investigated as a potential therapeutic target for the treatment of prostate cancer and other malignancies.

Suramin is a medication that has been used for the treatment of African sleeping sickness, which is caused by trypanosomes. It works as a reverse-specific protein kinase CK inhibitor and also blocks the attachment of the parasite to the host cells. Suramin is not absorbed well from the gastrointestinal tract and is administered intravenously.

It should be noted that Suramin is an experimental treatment for other conditions such as cancer, neurodegenerative diseases, viral infections and autoimmune diseases, but it's still under investigation and has not been approved by FDA for those uses.

Heterologous transplantation is a type of transplantation where an organ or tissue is transferred from one species to another. This is in contrast to allogeneic transplantation, where the donor and recipient are of the same species, or autologous transplantation, where the donor and recipient are the same individual.

In heterologous transplantation, the immune systems of the donor and recipient are significantly different, which can lead to a strong immune response against the transplanted organ or tissue. This is known as a graft-versus-host disease (GVHD), where the immune cells in the transplanted tissue attack the recipient's body.

Heterologous transplantation is not commonly performed in clinical medicine due to the high risk of rejection and GVHD. However, it may be used in research settings to study the biology of transplantation and to develop new therapies for transplant rejection.

Gonadotropin-Releasing Hormone (GnRH), also known as Luteinizing Hormone-Releasing Hormone (LHRH), is a hormonal peptide consisting of 10 amino acids. It is produced and released by the hypothalamus, an area in the brain that links the nervous system to the endocrine system via the pituitary gland.

GnRH plays a crucial role in regulating reproduction and sexual development through its control of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These gonadotropins, in turn, stimulate the gonads (ovaries or testes) to produce sex steroids and eggs or sperm.

GnRH acts on the anterior pituitary gland by binding to its specific receptors, leading to the release of FSH and LH. The hypothalamic-pituitary-gonadal axis is under negative feedback control, meaning that when sex steroid levels are high, they inhibit the release of GnRH, which subsequently decreases FSH and LH secretion.

GnRH agonists and antagonists have clinical applications in various medical conditions, such as infertility treatments, precocious puberty, endometriosis, uterine fibroids, prostate cancer, and hormone-responsive breast cancer.

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

Diphosphonates are a class of medications that are used to treat bone diseases, such as osteoporosis and Paget's disease. They work by binding to the surface of bones and inhibiting the activity of bone-resorbing cells called osteoclasts. This helps to slow down the breakdown and loss of bone tissue, which can help to reduce the risk of fractures.

Diphosphonates are typically taken orally in the form of tablets, but some forms may be given by injection. Commonly prescribed diphosphonates include alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Side effects of diphosphonates can include gastrointestinal symptoms such as nausea, heartburn, and abdominal pain. In rare cases, they may also cause esophageal ulcers or osteonecrosis of the jaw.

It is important to follow the instructions for taking diphosphonates carefully, as they must be taken on an empty stomach with a full glass of water and the patient must remain upright for at least 30 minutes after taking the medication to reduce the risk of esophageal irritation. Regular monitoring of bone density and kidney function is also recommended while taking these medications.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Prostatic Intraepithelial Neoplasia (PIN) is a term used in pathology to describe the abnormal growth of cells within the lining of the prostate gland's ducts and acini (small sacs that produce and store fluids). PIN is not considered a cancer, but it can be a precursor to prostate cancer.

There are two types of PIN: low-grade and high-grade. Low-grade PIN shows mild to moderate atypia (abnormalities in the cells), while high-grade PIN displays more significant atypia, which resembles prostate cancer. High-grade PIN is often found close to or within areas of prostate cancer, making it a potential indicator of malignancy.

However, not all cases of high-grade PIN progress to cancer, and some men with high-grade PIN may never develop prostate cancer. Nonetheless, the presence of high-grade PIN might prompt further investigation or monitoring to ensure early detection and treatment of any potential cancer development.

Radioisotopes, also known as radioactive isotopes or radionuclides, are variants of chemical elements that have unstable nuclei and emit radiation in the form of alpha particles, beta particles, gamma rays, or conversion electrons. These isotopes are formed when an element's nucleus undergoes natural or artificial radioactive decay.

Radioisotopes can be produced through various processes, including nuclear fission, nuclear fusion, and particle bombardment in a cyclotron or other types of particle accelerators. They have a wide range of applications in medicine, industry, agriculture, research, and energy production. In the medical field, radioisotopes are used for diagnostic imaging, radiation therapy, and in the labeling of molecules for research purposes.

It is important to note that handling and using radioisotopes requires proper training, safety measures, and regulatory compliance due to their ionizing radiation properties, which can pose potential health risks if not handled correctly.

Molecular targeted therapy is a type of treatment that targets specific molecules involved in the growth, progression, and spread of cancer. These molecules can be proteins, genes, or other molecules that contribute to the development of cancer. By targeting these specific molecules, molecular targeted therapy aims to block the abnormal signals that promote cancer growth and progression, thereby inhibiting or slowing down the growth of cancer cells while minimizing harm to normal cells.

Examples of molecular targeted therapies include monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, and immunotherapies that target specific immune checkpoints. These therapies can be used alone or in combination with other cancer treatments such as chemotherapy, radiation therapy, or surgery. The goal of molecular targeted therapy is to improve the effectiveness of cancer treatment while reducing side effects and improving quality of life for patients.

A xenograft model antitumor assay is a type of preclinical cancer research study that involves transplanting human tumor cells or tissues into an immunodeficient mouse. This model allows researchers to study the effects of various treatments, such as drugs or immune therapies, on human tumors in a living organism.

In this assay, human tumor cells or tissues are implanted into the mouse, typically under the skin or in another organ, where they grow and form a tumor. Once the tumor has established, the mouse is treated with the experimental therapy, and the tumor's growth is monitored over time. The response of the tumor to the treatment is then assessed by measuring changes in tumor size or weight, as well as other parameters such as survival rate and metastasis.

Xenograft model antitumor assays are useful for evaluating the efficacy and safety of new cancer therapies before they are tested in human clinical trials. They provide valuable information on how the tumors respond to treatment, drug pharmacokinetics, and toxicity, which can help researchers optimize dosing regimens and identify potential side effects. However, it is important to note that xenograft models have limitations, such as differences in tumor biology between mice and humans, and may not always predict how well a therapy will work in human patients.

Apoptosis is a programmed and controlled cell death process that occurs in multicellular organisms. It is a natural process that helps maintain tissue homeostasis by eliminating damaged, infected, or unwanted cells. During apoptosis, the cell undergoes a series of morphological changes, including cell shrinkage, chromatin condensation, and fragmentation into membrane-bound vesicles called apoptotic bodies. These bodies are then recognized and engulfed by neighboring cells or phagocytic cells, preventing an inflammatory response. Apoptosis is regulated by a complex network of intracellular signaling pathways that involve proteins such as caspases, Bcl-2 family members, and inhibitors of apoptosis (IAPs).

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Phase III clinical trials are a type of medical research study that involves testing the safety and efficacy of a new drug, device, or treatment in a large group of people. These studies typically enroll hundreds to thousands of participants, who are randomly assigned to receive either the experimental treatment or a standard of care comparison group.

The primary goal of Phase III clinical trials is to determine whether the new treatment works better than existing treatments and to assess its safety and side effects in a larger population. The data collected from these studies can help regulatory agencies like the U.S. Food and Drug Administration (FDA) decide whether to approve the new treatment for use in the general population.

Phase III clinical trials are usually conducted at multiple centers, often across different countries, to ensure that the results are generalizable to a wide range of patients. Participants may be followed for several years to assess long-term safety and efficacy outcomes.

Overall, Phase III clinical trials play a critical role in ensuring that new treatments are safe and effective before they become widely available to patients.

Cell movement, also known as cell motility, refers to the ability of cells to move independently and change their location within tissue or inside the body. This process is essential for various biological functions, including embryonic development, wound healing, immune responses, and cancer metastasis.

There are several types of cell movement, including:

1. **Crawling or mesenchymal migration:** Cells move by extending and retracting protrusions called pseudopodia or filopodia, which contain actin filaments. This type of movement is common in fibroblasts, immune cells, and cancer cells during tissue invasion and metastasis.
2. **Amoeboid migration:** Cells move by changing their shape and squeezing through tight spaces without forming protrusions. This type of movement is often observed in white blood cells (leukocytes) as they migrate through the body to fight infections.
3. **Pseudopodial extension:** Cells extend pseudopodia, which are temporary cytoplasmic projections containing actin filaments. These protrusions help the cell explore its environment and move forward.
4. **Bacterial flagellar motion:** Bacteria use a whip-like structure called a flagellum to propel themselves through their environment. The rotation of the flagellum is driven by a molecular motor in the bacterial cell membrane.
5. **Ciliary and ependymal movement:** Ciliated cells, such as those lining the respiratory tract and fallopian tubes, have hair-like structures called cilia that beat in coordinated waves to move fluids or mucus across the cell surface.

Cell movement is regulated by a complex interplay of signaling pathways, cytoskeletal rearrangements, and adhesion molecules, which enable cells to respond to environmental cues and navigate through tissues.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Tissue Microarray (TMA) analysis is a surgical pathology technique that allows for the simultaneous analysis of multiple tissue samples (known as "cores") from different patients or even different regions of the same tumor, on a single microscope slide. This technique involves the extraction of small cylindrical samples of tissue, which are then arrayed in a grid-like pattern on a recipient paraffin block. Once the TMA is created, sections can be cut and stained with various histochemical or immunohistochemical stains to evaluate the expression of specific proteins or other molecules of interest.

Tissue Array Analysis has become an important tool in biomedical research, enabling high-throughput analysis of tissue samples for molecular markers, gene expression patterns, and other features that can help inform clinical decision making, drug development, and our understanding of disease processes. It's widely used in cancer research to study the heterogeneity of tumors, identify new therapeutic targets, and evaluate patient prognosis.

Radioimmunotherapy (RIT) is a medical treatment that combines the specificity of antibodies and the therapeutic effects of radiation to target and destroy cancer cells. It involves the use of radioactive isotopes, which are attached to monoclonal antibodies, that recognize and bind to antigens expressed on the surface of cancer cells. Once bound, the radioactivity emitted from the isotope irradiates the cancer cells, causing damage to their DNA and leading to cell death. This targeted approach helps minimize radiation exposure to healthy tissues and reduces side effects compared to conventional radiotherapy techniques. RIT has been used in the treatment of various hematological malignancies, such as non-Hodgkin lymphoma, and is being investigated for solid tumors as well.

Testosterone is a steroid hormone that belongs to androsten class of hormones. It is primarily secreted by the Leydig cells in the testes of males and, to a lesser extent, by the ovaries and adrenal glands in females. Testosterone is the main male sex hormone and anabolic steroid. It plays a key role in the development of masculine characteristics, such as body hair and muscle mass, and contributes to bone density, fat distribution, red cell production, and sex drive. In females, testosterone contributes to sexual desire and bone health. Testosterone is synthesized from cholesterol and its production is regulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Indium radioisotopes refer to specific types of radioactive indium atoms, which are unstable and emit radiation as they decay. Indium is a chemical element with the symbol In and atomic number 49. Its radioisotopes are often used in medical imaging and therapy due to their unique properties.

For instance, one commonly used indium radioisotope is Indium-111 (^111In), which has a half-life of approximately 2.8 days. It emits gamma rays, making it useful for diagnostic imaging techniques such as single-photon emission computed tomography (SPECT). In clinical applications, indium-111 is often attached to specific molecules or antibodies that target particular cells or tissues in the body, allowing medical professionals to monitor biological processes and identify diseases like cancer.

Another example is Indium-113m (^113mIn), which has a half-life of about 99 minutes. It emits low-energy gamma rays and is used as a source for in vivo counting, typically in the form of indium chloride (InCl3) solution. This radioisotope can be used to measure blood flow, ventilation, and other physiological parameters.

It's important to note that handling and using radioisotopes require proper training and safety measures due to their ionizing radiation properties.

Drug resistance in neoplasms (also known as cancer drug resistance) refers to the ability of cancer cells to withstand the effects of chemotherapeutic agents or medications designed to kill or inhibit the growth of cancer cells. This can occur due to various mechanisms, including changes in the cancer cell's genetic makeup, alterations in drug targets, increased activity of drug efflux pumps, and activation of survival pathways.

Drug resistance can be intrinsic (present at the beginning of treatment) or acquired (developed during the course of treatment). It is a significant challenge in cancer therapy as it often leads to reduced treatment effectiveness, disease progression, and poor patient outcomes. Strategies to overcome drug resistance include the use of combination therapies, development of new drugs that target different mechanisms, and personalized medicine approaches that consider individual patient and tumor characteristics.

PTEN phosphohydrolase, also known as PTEN protein or phosphatase and tensin homolog deleted on chromosome ten, is a tumor suppressor protein that plays a crucial role in regulating cell growth and division. It works by dephosphorylating (removing a phosphate group from) the lipid second messenger PIP3, which is involved in signaling pathways that promote cell proliferation and survival. By negatively regulating these pathways, PTEN helps to prevent uncontrolled cell growth and tumor formation. Mutations in the PTEN gene can lead to a variety of cancer types, including breast, prostate, and endometrial cancer.

Yttrium radioisotopes are radioactive isotopes or variants of the element Yttrium, which is a rare earth metal. These radioisotopes are artificially produced and have unstable nuclei that emit radiation in the form of gamma rays or high-speed particles. Examples of yttrium radioisotopes include Yttrium-90 and Yttrium-86, which are used in medical applications such as radiotherapy for cancer treatment and molecular imaging for diagnostic purposes.

Yttrium-90 is a pure beta emitter with a half-life of 64.1 hours, making it useful for targeted radionuclide therapy. It can be used to treat liver tumors, leukemia, and lymphoma by attaching it to monoclonal antibodies or other targeting agents that selectively bind to cancer cells.

Yttrium-86 is a positron emitter with a half-life of 14.7 hours, making it useful for positron emission tomography (PET) imaging. It can be used to label radiopharmaceuticals and track their distribution in the body, providing information on the location and extent of disease.

It is important to note that handling and use of radioisotopes require specialized training and equipment due to their potential radiation hazards.

Lymphatic metastasis is the spread of cancer cells from a primary tumor to distant lymph nodes through the lymphatic system. It occurs when malignant cells break away from the original tumor, enter the lymphatic vessels, and travel to nearby or remote lymph nodes. Once there, these cancer cells can multiply and form new tumors, leading to further progression of the disease. Lymphatic metastasis is a common way for many types of cancer to spread and can have significant implications for prognosis and treatment strategies.

Tissue extracts refer to the substances or compounds that are extracted from various types of biological tissues, such as plants, animals, or microorganisms. These extracts contain bioactive molecules, including proteins, peptides, lipids, carbohydrates, nucleic acids, and other small molecules, which can have therapeutic or diagnostic potential. The process of tissue extraction involves homogenizing the tissue, followed by separation and purification of the desired components using various techniques such as centrifugation, filtration, chromatography, or precipitation.

In medical research and clinical settings, tissue extracts are often used to study the biochemical and molecular properties of cells and tissues, investigate disease mechanisms, develop diagnostic tests, and identify potential drug targets. Examples of tissue extracts include cell lysates, subcellular fractions, organelle preparations, plasma membrane extracts, nuclear extracts, and various types of protein or nucleic acid extracts. It is important to note that the quality and purity of tissue extracts can significantly impact the accuracy and reproducibility of experimental results, and appropriate controls and validation methods should be employed to ensure their proper use.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Sensitivity and specificity are statistical measures used to describe the performance of a diagnostic test or screening tool in identifying true positive and true negative results.

* Sensitivity refers to the proportion of people who have a particular condition (true positives) who are correctly identified by the test. It is also known as the "true positive rate" or "recall." A highly sensitive test will identify most or all of the people with the condition, but may also produce more false positives.
* Specificity refers to the proportion of people who do not have a particular condition (true negatives) who are correctly identified by the test. It is also known as the "true negative rate." A highly specific test will identify most or all of the people without the condition, but may also produce more false negatives.

In medical testing, both sensitivity and specificity are important considerations when evaluating a diagnostic test. High sensitivity is desirable for screening tests that aim to identify as many cases of a condition as possible, while high specificity is desirable for confirmatory tests that aim to rule out the condition in people who do not have it.

It's worth noting that sensitivity and specificity are often influenced by factors such as the prevalence of the condition in the population being tested, the threshold used to define a positive result, and the reliability and validity of the test itself. Therefore, it's important to consider these factors when interpreting the results of a diagnostic test.

Nitriles, in a medical context, refer to a class of organic compounds that contain a cyano group (-CN) bonded to a carbon atom. They are widely used in the chemical industry and can be found in various materials, including certain plastics and rubber products.

In some cases, nitriles can pose health risks if ingested, inhaled, or come into contact with the skin. Short-term exposure to high levels of nitriles can cause irritation to the eyes, nose, throat, and respiratory tract. Prolonged or repeated exposure may lead to more severe health effects, such as damage to the nervous system, liver, and kidneys.

However, it's worth noting that the medical use of nitriles is not very common. Some nitrile gloves are used in healthcare settings due to their resistance to many chemicals and because they can provide a better barrier against infectious materials compared to latex or vinyl gloves. But beyond this application, nitriles themselves are not typically used as medications or therapeutic agents.

Gene expression profiling is a laboratory technique used to measure the activity (expression) of thousands of genes at once. This technique allows researchers and clinicians to identify which genes are turned on or off in a particular cell, tissue, or organism under specific conditions, such as during health, disease, development, or in response to various treatments.

The process typically involves isolating RNA from the cells or tissues of interest, converting it into complementary DNA (cDNA), and then using microarray or high-throughput sequencing technologies to determine which genes are expressed and at what levels. The resulting data can be used to identify patterns of gene expression that are associated with specific biological states or processes, providing valuable insights into the underlying molecular mechanisms of diseases and potential targets for therapeutic intervention.

In recent years, gene expression profiling has become an essential tool in various fields, including cancer research, drug discovery, and personalized medicine, where it is used to identify biomarkers of disease, predict patient outcomes, and guide treatment decisions.

Western blotting is a laboratory technique used in molecular biology to detect and quantify specific proteins in a mixture of many different proteins. This technique is commonly used to confirm the expression of a protein of interest, determine its size, and investigate its post-translational modifications. The name "Western" blotting distinguishes this technique from Southern blotting (for DNA) and Northern blotting (for RNA).

The Western blotting procedure involves several steps:

1. Protein extraction: The sample containing the proteins of interest is first extracted, often by breaking open cells or tissues and using a buffer to extract the proteins.
2. Separation of proteins by electrophoresis: The extracted proteins are then separated based on their size by loading them onto a polyacrylamide gel and running an electric current through the gel (a process called sodium dodecyl sulfate-polyacrylamide gel electrophoresis or SDS-PAGE). This separates the proteins according to their molecular weight, with smaller proteins migrating faster than larger ones.
3. Transfer of proteins to a membrane: After separation, the proteins are transferred from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane using an electric current in a process called blotting. This creates a replica of the protein pattern on the gel but now immobilized on the membrane for further analysis.
4. Blocking: The membrane is then blocked with a blocking agent, such as non-fat dry milk or bovine serum albumin (BSA), to prevent non-specific binding of antibodies in subsequent steps.
5. Primary antibody incubation: A primary antibody that specifically recognizes the protein of interest is added and allowed to bind to its target protein on the membrane. This step may be performed at room temperature or 4°C overnight, depending on the antibody's properties.
6. Washing: The membrane is washed with a buffer to remove unbound primary antibodies.
7. Secondary antibody incubation: A secondary antibody that recognizes the primary antibody (often coupled to an enzyme or fluorophore) is added and allowed to bind to the primary antibody. This step may involve using a horseradish peroxidase (HRP)-conjugated or alkaline phosphatase (AP)-conjugated secondary antibody, depending on the detection method used later.
8. Washing: The membrane is washed again to remove unbound secondary antibodies.
9. Detection: A detection reagent is added to visualize the protein of interest by detecting the signal generated from the enzyme-conjugated or fluorophore-conjugated secondary antibody. This can be done using chemiluminescent, colorimetric, or fluorescent methods.
10. Analysis: The resulting image is analyzed to determine the presence and quantity of the protein of interest in the sample.

Western blotting is a powerful technique for identifying and quantifying specific proteins within complex mixtures. It can be used to study protein expression, post-translational modifications, protein-protein interactions, and more. However, it requires careful optimization and validation to ensure accurate and reproducible results.

Gene silencing is a process by which the expression of a gene is blocked or inhibited, preventing the production of its corresponding protein. This can occur naturally through various mechanisms such as RNA interference (RNAi), where small RNAs bind to and degrade specific mRNAs, or DNA methylation, where methyl groups are added to the DNA molecule, preventing transcription. Gene silencing can also be induced artificially using techniques such as RNAi-based therapies, antisense oligonucleotides, or CRISPR-Cas9 systems, which allow for targeted suppression of gene expression in research and therapeutic applications.

Osteolysis is a medical term that refers to the loss or resorption of bone tissue. It's a process where the body's normal bone remodeling cycle is disrupted, leading to an imbalance between bone formation and bone breakdown. This results in the progressive deterioration and destruction of bone.

Osteolysis can occur due to various reasons such as chronic inflammation, mechanical stress, or certain medical conditions like rheumatoid arthritis, Paget's disease, or bone tumors. It can also be a side effect of some medications, such as those used in cancer treatment or for managing osteoporosis.

In severe cases, osteolysis can lead to weakened bones, increased risk of fractures, and deformities. Treatment typically aims to address the underlying cause and may include medication, surgery, or lifestyle changes.

Up-regulation is a term used in molecular biology and medicine to describe an increase in the expression or activity of a gene, protein, or receptor in response to a stimulus. This can occur through various mechanisms such as increased transcription, translation, or reduced degradation of the molecule. Up-regulation can have important functional consequences, for example, enhancing the sensitivity or response of a cell to a hormone, neurotransmitter, or drug. It is a normal physiological process that can also be induced by disease or pharmacological interventions.

Prostatic diseases refer to a range of medical conditions that affect the prostate gland, a small gland that is part of the male reproductive system. The prostate is located below the bladder and surrounds the urethra, the tube that carries urine and semen out of the body. Some common prostatic diseases include:

1. Benign Prostatic Hyperplasia (BPH): This is a non-cancerous enlargement of the prostate gland that can cause difficulties with urination, such as a weak stream, frequent urination, and a feeling of incomplete bladder emptying.
2. Prostatitis: This is an inflammation or infection of the prostate gland that can cause pain, fever, difficulty urinating, and sexual dysfunction.
3. Prostate Cancer: This is a malignant tumor that develops in the prostate gland and can spread to other parts of the body. It is one of the most common types of cancer in men and can often be treated successfully if detected early.
4. Acute Bacterial Prostatitis: This is a sudden and severe infection of the prostate gland that can cause fever, chills, pain in the lower back and genital area, and difficulty urinating.
5. Chronic Bacterial Prostatitis: This is a recurring or persistent bacterial infection of the prostate gland that can cause symptoms similar to chronic pelvic pain syndrome.
6. Chronic Pelvic Pain Syndrome (CPPS): Also known as chronic nonbacterial prostatitis, this condition is characterized by ongoing pain in the pelvic area, often accompanied by urinary and sexual dysfunction. The exact cause of CPPS is not well understood, but it is thought to be related to inflammation or nerve damage in the prostate gland.

Cancer vaccines are a type of immunotherapy that stimulate the body's own immune system to recognize and destroy cancer cells. They can be prophylactic (preventive) or therapeutic (treatment) in nature. Prophylactic cancer vaccines, such as the human papillomavirus (HPV) vaccine, are designed to prevent the initial infection that can lead to certain types of cancer. Therapeutic cancer vaccines, on the other hand, are used to treat existing cancer by boosting the immune system's ability to identify and eliminate cancer cells. These vaccines typically contain specific antigens (proteins or sugars) found on the surface of cancer cells, which help the immune system to recognize and target them.

It is important to note that cancer vaccines are different from vaccines used to prevent infectious diseases, such as measles or influenza. While traditional vaccines introduce a weakened or inactivated form of a virus or bacteria to stimulate an immune response, cancer vaccines focus on training the immune system to recognize and attack cancer cells specifically.

There are several types of cancer vaccines under investigation, including:

1. Autologous cancer vaccines: These vaccines use the patient's own tumor cells, which are processed and then reintroduced into the body to stimulate an immune response.
2. Peptide-based cancer vaccines: These vaccines contain specific pieces (peptides) of proteins found on the surface of cancer cells. They are designed to trigger an immune response against cells that express these proteins.
3. Dendritic cell-based cancer vaccines: Dendritic cells are a type of immune cell responsible for presenting antigens to other immune cells, activating them to recognize and destroy infected or cancerous cells. In this approach, dendritic cells are isolated from the patient's blood, exposed to cancer antigens in the lab, and then reintroduced into the body to stimulate an immune response.
4. DNA-based cancer vaccines: These vaccines use pieces of DNA that code for specific cancer antigens. Once inside the body, these DNA fragments are taken up by cells, leading to the production of the corresponding antigen and triggering an immune response.
5. Viral vector-based cancer vaccines: In this approach, a harmless virus is modified to carry genetic material encoding cancer antigens. When introduced into the body, the virus infects cells, causing them to produce the cancer antigen and stimulating an immune response.

While some cancer vaccines have shown promising results in clinical trials, none have yet been approved for widespread use by regulatory authorities such as the US Food and Drug Administration (FDA). Researchers continue to explore and refine various vaccine strategies to improve their efficacy and safety.

Dihydrotestosterone (DHT) is a sex hormone and androgen that plays a critical role in the development and maintenance of male characteristics, such as facial hair, deep voice, and muscle mass. It is synthesized from testosterone through the action of the enzyme 5-alpha reductase. DHT is essential for the normal development of the male genitalia during fetal development and for the maturation of the sexual organs at puberty.

In addition to its role in sexual development, DHT also contributes to the growth of hair follicles, the health of the prostate gland, and the maintenance of bone density. However, an excess of DHT has been linked to certain medical conditions, such as benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness).

DHT exerts its effects by binding to androgen receptors in various tissues throughout the body. Once bound, DHT triggers a series of cellular responses that regulate gene expression and influence the growth and differentiation of cells. In some cases, these responses can lead to unwanted side effects, such as hair loss or prostate enlargement.

Medications that block the action of 5-alpha reductase, such as finasteride and dutasteride, are sometimes used to treat conditions associated with excess DHT production. These drugs work by reducing the amount of DHT available to bind to androgen receptors, thereby alleviating symptoms and slowing disease progression.

In summary, dihydrotestosterone is a potent sex hormone that plays a critical role in male sexual development and function. While it is essential for normal growth and development, an excess of DHT has been linked to certain medical conditions, such as BPH and androgenetic alopecia. Medications that block the action of 5-alpha reductase are sometimes used to treat these conditions by reducing the amount of DHT available to bind to androgen receptors.

In situ hybridization, fluorescence (FISH) is a type of molecular cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes through the use of fluorescent probes. This technique allows for the direct visualization of genetic material at a cellular level, making it possible to identify chromosomal abnormalities such as deletions, duplications, translocations, and other rearrangements.

The process involves denaturing the DNA in the sample to separate the double-stranded molecules into single strands, then adding fluorescently labeled probes that are complementary to the target DNA sequence. The probe hybridizes to the complementary sequence in the sample, and the location of the probe is detected by fluorescence microscopy.

FISH has a wide range of applications in both clinical and research settings, including prenatal diagnosis, cancer diagnosis and monitoring, and the study of gene expression and regulation. It is a powerful tool for identifying genetic abnormalities and understanding their role in human disease.

"Bone" is the hard, dense connective tissue that makes up the skeleton of vertebrate animals. It provides support and protection for the body's internal organs, and serves as a attachment site for muscles, tendons, and ligaments. Bone is composed of cells called osteoblasts and osteoclasts, which are responsible for bone formation and resorption, respectively, and an extracellular matrix made up of collagen fibers and mineral crystals.

Bones can be classified into two main types: compact bone and spongy bone. Compact bone is dense and hard, and makes up the outer layer of all bones and the shafts of long bones. Spongy bone is less dense and contains large spaces, and makes up the ends of long bones and the interior of flat and irregular bones.

The human body has 206 bones in total. They can be further classified into five categories based on their shape: long bones, short bones, flat bones, irregular bones, and sesamoid bones.

Transfection is a term used in molecular biology that refers to the process of deliberately introducing foreign genetic material (DNA, RNA or artificial gene constructs) into cells. This is typically done using chemical or physical methods, such as lipofection or electroporation. Transfection is widely used in research and medical settings for various purposes, including studying gene function, producing proteins, developing gene therapies, and creating genetically modified organisms. It's important to note that transfection is different from transduction, which is the process of introducing genetic material into cells using viruses as vectors.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

Mitoxantrone is a synthetic antineoplastic anthracenedione drug, which means it is used to treat cancer. Its medical definition can be found in various authoritative sources such as the Merck Manual or Stedman's Medical Dictionary. Here's a brief version of the definition from MedlinePlus, a service of the US National Library of Medicine:

"Mitoxantrone is used to treat certain types of cancer (e.g., breast cancer, leukemia, non-Hodgkin's lymphoma). It works by slowing or stopping the growth of cancer cells. Mitoxantrone belongs to a class of drugs known as antitumor antibiotics."

Please note that this is a simplified definition meant for general information purposes and does not include all the details that might be present in a comprehensive medical definition. Always consult a healthcare professional or refer to authoritative resources for accurate, detailed, and up-to-date information.

Oligonucleotide Array Sequence Analysis is a type of microarray analysis that allows for the simultaneous measurement of the expression levels of thousands of genes in a single sample. In this technique, oligonucleotides (short DNA sequences) are attached to a solid support, such as a glass slide, in a specific pattern. These oligonucleotides are designed to be complementary to specific target mRNA sequences from the sample being analyzed.

During the analysis, labeled RNA or cDNA from the sample is hybridized to the oligonucleotide array. The level of hybridization is then measured and used to determine the relative abundance of each target sequence in the sample. This information can be used to identify differences in gene expression between samples, which can help researchers understand the underlying biological processes involved in various diseases or developmental stages.

It's important to note that this technique requires specialized equipment and bioinformatics tools for data analysis, as well as careful experimental design and validation to ensure accurate and reproducible results.

Palliative care is a type of medical care that focuses on relieving the pain, symptoms, and stress of serious illnesses. The goal is to improve quality of life for both the patient and their family. It is provided by a team of doctors, nurses, and other specialists who work together to address the physical, emotional, social, and spiritual needs of the patient. Palliative care can be provided at any stage of an illness, alongside curative treatments, and is not dependent on prognosis.

The World Health Organization (WHO) defines palliative care as: "an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychological and spiritual."

Epithelial cells are types of cells that cover the outer surfaces of the body, line the inner surfaces of organs and glands, and form the lining of blood vessels and body cavities. They provide a protective barrier against the external environment, regulate the movement of materials between the internal and external environments, and are involved in the sense of touch, temperature, and pain. Epithelial cells can be squamous (flat and thin), cuboidal (square-shaped and of equal height), or columnar (tall and narrow) in shape and are classified based on their location and function.

Small interfering RNA (siRNA) is a type of short, double-stranded RNA molecule that plays a role in the RNA interference (RNAi) pathway. The RNAi pathway is a natural cellular process that regulates gene expression by targeting and destroying specific messenger RNA (mRNA) molecules, thereby preventing the translation of those mRNAs into proteins.

SiRNAs are typically 20-25 base pairs in length and are generated from longer double-stranded RNA precursors called hairpin RNAs or dsRNAs by an enzyme called Dicer. Once generated, siRNAs associate with a protein complex called the RNA-induced silencing complex (RISC), which uses one strand of the siRNA (the guide strand) to recognize and bind to complementary sequences in the target mRNA. The RISC then cleaves the target mRNA, leading to its degradation and the inhibition of protein synthesis.

SiRNAs have emerged as a powerful tool for studying gene function and have shown promise as therapeutic agents for a variety of diseases, including viral infections, cancer, and genetic disorders. However, their use as therapeutics is still in the early stages of development, and there are challenges associated with delivering siRNAs to specific cells and tissues in the body.

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

Neoplastic cell transformation is a process in which a normal cell undergoes genetic alterations that cause it to become cancerous or malignant. This process involves changes in the cell's DNA that result in uncontrolled cell growth and division, loss of contact inhibition, and the ability to invade surrounding tissues and metastasize (spread) to other parts of the body.

Neoplastic transformation can occur as a result of various factors, including genetic mutations, exposure to carcinogens, viral infections, chronic inflammation, and aging. These changes can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, which regulate cell growth and division.

The transformation of normal cells into cancerous cells is a complex and multi-step process that involves multiple genetic and epigenetic alterations. It is characterized by several hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.

Neoplastic cell transformation is a fundamental concept in cancer biology and is critical for understanding the molecular mechanisms underlying cancer development and progression. It also has important implications for cancer diagnosis, prognosis, and treatment, as identifying the specific genetic alterations that underlie neoplastic transformation can help guide targeted therapies and personalized medicine approaches.

Immunotherapy is a type of medical treatment that uses the body's own immune system to fight against diseases, such as cancer. It involves the use of substances (like vaccines, medications, or immune cells) that stimulate or suppress the immune system to help it recognize and destroy harmful disease-causing cells or agents, like tumor cells.

Immunotherapy can work in several ways:

1. Activating the immune system: Certain immunotherapies boost the body's natural immune responses, helping them recognize and attack cancer cells more effectively.
2. Suppressing immune system inhibitors: Some immunotherapies target and block proteins or molecules that can suppress the immune response, allowing the immune system to work more efficiently against diseases.
3. Replacing or enhancing specific immune cells: Immunotherapy can also involve administering immune cells (like T-cells) that have been genetically engineered or modified to recognize and destroy cancer cells.

Immunotherapies have shown promising results in treating various types of cancer, autoimmune diseases, and allergies. However, they can also cause side effects, as an overactive immune system may attack healthy tissues and organs. Therefore, careful monitoring is necessary during immunotherapy treatment.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

A digital rectal examination (DRE) is a medical procedure in which a healthcare professional inserts a gloved and lubricated finger into the patient's rectum to assess the health of the lower rectum, anus, and prostate gland in men. The exam allows the provider to check for abnormalities such as lumps, growths, or other abnormalities that may indicate conditions like hemorrhoids, inflammatory bowel disease, prostate cancer, or other rectal or anal issues.

During a DRE, the healthcare professional will typically ask the patient to bend over a table or lie on their side while they perform the exam. They will gently insert their finger into the rectum and feel for any abnormalities in the rectal wall, prostate gland (in men), or other nearby structures. The provider may also assess the patient's sphincter tone and check for signs of fecal impaction or constipation.

The DRE is a relatively quick and straightforward procedure that can provide valuable information about a patient's lower digestive and reproductive health. It is commonly performed during routine physical examinations, particularly for men over the age of 50, as part of prostate cancer screening. However, it may also be used to investigate specific symptoms or concerns related to the rectum, anus, or prostate gland.

Finasteride is a synthetic 4-azasteroid compound that acts as a specific inhibitor of Type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is a hormonal byproduct thought to be responsible for the development and worsening of benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), also known as male pattern baldness.

Finasteride is available in two formulations: finasteride 1 mg (Proscar) and finasteride 5 mg (Propecia). Finasteride 1 mg is used to treat BPH, while finasteride 5 mg is used for the treatment of AGA in men. The drug works by reducing the production of DHT, which in turn slows down the progression of BPH and AGA.

It's important to note that finasteride is not approved for use in women or children, and it should be used with caution in men due to potential side effects such as decreased sexual desire, difficulty in achieving an erection, and a decrease in the amount of semen produced.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Down-regulation is a process that occurs in response to various stimuli, where the number or sensitivity of cell surface receptors or the expression of specific genes is decreased. This process helps maintain homeostasis within cells and tissues by reducing the ability of cells to respond to certain signals or molecules.

In the context of cell surface receptors, down-regulation can occur through several mechanisms:

1. Receptor internalization: After binding to their ligands, receptors can be internalized into the cell through endocytosis. Once inside the cell, these receptors may be degraded or recycled back to the cell surface in smaller numbers.
2. Reduced receptor synthesis: Down-regulation can also occur at the transcriptional level, where the expression of genes encoding for specific receptors is decreased, leading to fewer receptors being produced.
3. Receptor desensitization: Prolonged exposure to a ligand can lead to a decrease in receptor sensitivity or affinity, making it more difficult for the cell to respond to the signal.

In the context of gene expression, down-regulation refers to the decreased transcription and/or stability of specific mRNAs, leading to reduced protein levels. This process can be induced by various factors, including microRNA (miRNA)-mediated regulation, histone modification, or DNA methylation.

Down-regulation is an essential mechanism in many physiological processes and can also contribute to the development of several diseases, such as cancer and neurodegenerative disorders.

Cell survival refers to the ability of a cell to continue living and functioning normally, despite being exposed to potentially harmful conditions or treatments. This can include exposure to toxins, radiation, chemotherapeutic drugs, or other stressors that can damage cells or interfere with their normal processes.

In scientific research, measures of cell survival are often used to evaluate the effectiveness of various therapies or treatments. For example, researchers may expose cells to a particular drug or treatment and then measure the percentage of cells that survive to assess its potential therapeutic value. Similarly, in toxicology studies, measures of cell survival can help to determine the safety of various chemicals or substances.

It's important to note that cell survival is not the same as cell proliferation, which refers to the ability of cells to divide and multiply. While some treatments may promote cell survival, they may also inhibit cell proliferation, making them useful for treating diseases such as cancer. Conversely, other treatments may be designed to specifically target and kill cancer cells, even if it means sacrificing some healthy cells in the process.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

DNA primers are short single-stranded DNA molecules that serve as a starting point for DNA synthesis. They are typically used in laboratory techniques such as the polymerase chain reaction (PCR) and DNA sequencing. The primer binds to a complementary sequence on the DNA template through base pairing, providing a free 3'-hydroxyl group for the DNA polymerase enzyme to add nucleotides and synthesize a new strand of DNA. This allows for specific and targeted amplification or analysis of a particular region of interest within a larger DNA molecule.

Protein-kinase B, also known as AKT, is a group of intracellular proteins that play a crucial role in various cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. The AKT family includes three isoforms: AKT1, AKT2, and AKT3, which are encoded by the genes PKBalpha, PKBbeta, and PKBgamma, respectively.

Proto-oncogene proteins c-AKT refer to the normal, non-mutated forms of these proteins that are involved in the regulation of cell growth and survival under physiological conditions. However, when these genes are mutated or overexpressed, they can become oncogenes, leading to uncontrolled cell growth and cancer development.

Activation of c-AKT occurs through a signaling cascade that begins with the binding of extracellular ligands such as insulin-like growth factor 1 (IGF-1) or epidermal growth factor (EGF) to their respective receptors on the cell surface. This triggers a series of phosphorylation events that ultimately lead to the activation of c-AKT, which then phosphorylates downstream targets involved in various cellular processes.

In summary, proto-oncogene proteins c-AKT are normal intracellular proteins that play essential roles in regulating cell growth and survival under physiological conditions. However, their dysregulation can contribute to cancer development and progression.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

A cohort study is a type of observational study in which a group of individuals who share a common characteristic or exposure are followed up over time to determine the incidence of a specific outcome or outcomes. The cohort, or group, is defined based on the exposure status (e.g., exposed vs. unexposed) and then monitored prospectively to assess for the development of new health events or conditions.

Cohort studies can be either prospective or retrospective in design. In a prospective cohort study, participants are enrolled and followed forward in time from the beginning of the study. In contrast, in a retrospective cohort study, researchers identify a cohort that has already been assembled through medical records, insurance claims, or other sources and then look back in time to assess exposure status and health outcomes.

Cohort studies are useful for establishing causality between an exposure and an outcome because they allow researchers to observe the temporal relationship between the two. They can also provide information on the incidence of a disease or condition in different populations, which can be used to inform public health policy and interventions. However, cohort studies can be expensive and time-consuming to conduct, and they may be subject to bias if participants are not representative of the population or if there is loss to follow-up.

Epithelial-mesenchymal transition (EMT) is a biological process that involves the transformation of epithelial cells into mesenchymal cells. This process is characterized by distinct changes in cell shape, behavior, and molecular markers.

Epithelial cells are typically tightly packed together and have a polarized structure with distinct apical and basal surfaces. In contrast, mesenchymal cells are elongated, spindle-shaped cells that can migrate and invade surrounding tissues.

During EMT, epithelial cells lose their polarity and cell-to-cell adhesion molecules, such as E-cadherin, and acquire mesenchymal markers, such as vimentin and N-cadherin. This transition enables the cells to become more motile and invasive, which is critical for embryonic development, wound healing, and cancer metastasis.

EMT is a complex process that involves various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog, among others. Dysregulation of EMT has been implicated in several diseases, particularly cancer, where it contributes to tumor progression, metastasis, and drug resistance.

Neoplasm grading is a system used by pathologists to classify the degree of abnormality in cells that make up a tumor (neoplasm). It provides an assessment of how quickly the tumor is likely to grow and spread. The grade helps doctors predict the prognosis and determine the best treatment options.

Neoplasm grading typically involves evaluating certain cellular features under a microscope, such as:

1. Differentiation or degree of maturity: This refers to how closely the tumor cells resemble their normal counterparts in terms of size, shape, and organization. Well-differentiated tumors have cells that look more like normal cells and are usually slower growing. Poorly differentiated tumors have cells that appear very abnormal and tend to grow and spread more aggressively.

2. Mitotic count: This is the number of times the tumor cells divide (mitosis) within a given area. A higher mitotic count indicates a faster-growing tumor.

3. Necrosis: This refers to areas of dead tissue within the tumor. A significant amount of necrosis may suggest a more aggressive tumor.

Based on these and other factors, pathologists assign a grade to the tumor using a standardized system, such as the Bloom-Richardson or Scarff-Bloom-Richardson grading systems for breast cancer or the Fuhrman grading system for kidney cancer. The grade usually consists of a number or a range (e.g., G1, G2, G3, or G4) or a combination of grades (e.g., low grade, intermediate grade, and high grade).

In general, higher-grade tumors have a worse prognosis than lower-grade tumors because they are more likely to grow quickly, invade surrounding tissues, and metastasize (spread) to other parts of the body. However, neoplasm grading is just one aspect of cancer diagnosis and treatment planning. Other factors, such as the stage of the disease, location of the tumor, patient's overall health, and specific molecular markers, are also considered when making treatment decisions.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Androgen receptor antagonists are a class of drugs that block the action of androgens, which are hormones responsible for the development and maintenance of male sexual characteristics. These drugs work by binding to the androgen receptors in cells, preventing the natural androgens such as testosterone and dihydrotestosterone from binding and exerting their effects.

Androgen receptor antagonists are often used in the treatment of prostate cancer because androgens can stimulate the growth of prostate cancer cells. By blocking the action of androgens, these drugs can help to slow or stop the growth of prostate cancer tumors. Some examples of androgen receptor antagonists include flutamide, bicalutamide, and enzalutamide.

It's important to note that androgen receptor antagonists can have side effects, including hot flashes, breast tenderness or enlargement, decreased sex drive, and impotence. Additionally, long-term use of these drugs can lead to muscle loss, bone density loss, and an increased risk of fractures. As with any medication, it's important to discuss the potential benefits and risks with a healthcare provider before starting treatment.

Imidazoles are a class of heterocyclic organic compounds that contain a double-bonded nitrogen atom and two additional nitrogen atoms in the ring. They have the chemical formula C3H4N2. In a medical context, imidazoles are commonly used as antifungal agents. Some examples of imidazole-derived antifungals include clotrimazole, miconazole, and ketoconazole. These medications work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to increased permeability and death of the fungal cells. Imidazoles may also have anti-inflammatory, antibacterial, and anticancer properties.

Transcription factors are proteins that play a crucial role in regulating gene expression by controlling the transcription of DNA to messenger RNA (mRNA). They function by binding to specific DNA sequences, known as response elements, located in the promoter region or enhancer regions of target genes. This binding can either activate or repress the initiation of transcription, depending on the properties and interactions of the particular transcription factor. Transcription factors often act as part of a complex network of regulatory proteins that determine the precise spatiotemporal patterns of gene expression during development, differentiation, and homeostasis in an organism.

Prostatitis is a medical condition that refers to inflammation of the prostate gland, which can be caused by bacterial or non-bacterial factors. It can present with various symptoms such as pain in the lower abdomen, pelvis, or genital area, difficulty and/or painful urination, ejaculation pain, and flu-like symptoms. Prostatitis can be acute or chronic, and it is important to seek medical attention for proper diagnosis and treatment.

Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. It is a complex phenomenon that can result from various stimuli, such as thermal, mechanical, or chemical irritation, and it can be acute or chronic. The perception of pain involves the activation of specialized nerve cells called nociceptors, which transmit signals to the brain via the spinal cord. These signals are then processed in different regions of the brain, leading to the conscious experience of pain. It's important to note that pain is a highly individual and subjective experience, and its perception can vary widely among individuals.

Proportional hazards models are a type of statistical analysis used in medical research to investigate the relationship between covariates (predictor variables) and survival times. The most common application of proportional hazards models is in the Cox regression model, which is named after its developer, Sir David Cox.

In a proportional hazards model, the hazard rate or risk of an event occurring at a given time is assumed to be proportional to the hazard rate of a reference group, after adjusting for the covariates. This means that the ratio of the hazard rates between any two individuals remains constant over time, regardless of their survival times.

Mathematically, the hazard function h(t) at time t for an individual with a set of covariates X can be expressed as:

h(t|X) = h0(t) \* exp(β1X1 + β2X2 + ... + βpXp)

where h0(t) is the baseline hazard function, X1, X2, ..., Xp are the covariates, and β1, β2, ..., βp are the regression coefficients that represent the effect of each covariate on the hazard rate.

The assumption of proportionality is crucial in the interpretation of the results from a Cox regression model. If the assumption is violated, then the estimated regression coefficients may be biased and misleading. Therefore, it is important to test for the proportional hazards assumption before interpreting the results of a Cox regression analysis.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Brachytherapy is a type of cancer treatment that involves placing radioactive material directly into or near the tumor site. The term "brachy" comes from the Greek word for "short," which refers to the short distance that the radiation travels. This allows for a high dose of radiation to be delivered directly to the tumor while minimizing exposure to healthy surrounding tissue.

There are two main types of brachytherapy:

1. Intracavitary brachytherapy: The radioactive material is placed inside a body cavity, such as the uterus or windpipe.
2. Interstitial brachytherapy: The radioactive material is placed directly into the tumor or surrounding tissue using needles, seeds, or catheters.

Brachytherapy can be used alone or in combination with other cancer treatments such as surgery, external beam radiation therapy, and chemotherapy. It may be recommended for a variety of cancers, including prostate, cervical, vaginal, vulvar, head and neck, and skin cancers. The specific type of brachytherapy used will depend on the size, location, and stage of the tumor.

The advantages of brachytherapy include its ability to deliver a high dose of radiation directly to the tumor while minimizing exposure to healthy tissue, which can result in fewer side effects compared to other forms of radiation therapy. Additionally, brachytherapy is often a shorter treatment course than external beam radiation therapy, with some treatments lasting only a few minutes or hours.

However, there are also potential risks and side effects associated with brachytherapy, including damage to nearby organs and tissues, bleeding, infection, and pain. Patients should discuss the benefits and risks of brachytherapy with their healthcare provider to determine if it is an appropriate treatment option for them.

5-alpha Reductase Inhibitors are a class of drugs that block the action of the enzyme 5-alpha reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). DHT is a more potent form of testosterone that plays a key role in the development and maintenance of male sexual characteristics and is involved in the pathogenesis of benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness).

By inhibiting the action of 5-alpha reductase, these drugs reduce the levels of DHT in the body, which can help to shrink the prostate gland and improve symptoms of BPH such as difficulty urinating, frequent urination, and weak urine stream. They are also used off-label to treat hair loss in men.

Examples of 5-alpha reductase inhibitors include finasteride (Proscar, Propecia) and dutasteride (Avodart). Common side effects of these drugs may include decreased libido, erectile dysfunction, and breast tenderness or enlargement.

Positron-Emission Tomography (PET) is a type of nuclear medicine imaging that uses small amounts of radioactive material, called a radiotracer, to produce detailed, three-dimensional images. This technique measures metabolic activity within the body, such as sugar metabolism, to help distinguish between healthy and diseased tissue, identify cancerous cells, or examine the function of organs.

During a PET scan, the patient is injected with a radiotracer, typically a sugar-based compound labeled with a positron-emitting radioisotope, such as fluorine-18 (^18^F). The radiotracer accumulates in cells that are metabolically active, like cancer cells. As the radiotracer decays, it emits positrons, which then collide with electrons in nearby tissue, producing gamma rays. A special camera, called a PET scanner, detects these gamma rays and uses this information to create detailed images of the body's internal structures and processes.

PET is often used in conjunction with computed tomography (CT) or magnetic resonance imaging (MRI) to provide both functional and anatomical information, allowing for more accurate diagnosis and treatment planning. Common applications include detecting cancer recurrence, staging and monitoring cancer, evaluating heart function, and assessing brain function in conditions like dementia and epilepsy.

The seminal vesicles are a pair of glands located in the male reproductive system, posterior to the urinary bladder and superior to the prostate gland. They are approximately 5 cm long and have a convoluted structure with many finger-like projections called infoldings. The primary function of seminal vesicles is to produce and secrete a significant portion of the seminal fluid, which makes up the bulk of semen along with spermatozoa from the testes and fluids from the prostate gland and bulbourethral glands.

The secretion of the seminal vesicles is rich in fructose, which serves as an energy source for sperm, as well as various proteins, enzymes, vitamins, and minerals that contribute to maintaining the optimal environment for sperm survival, nourishment, and transport. During sexual arousal and ejaculation, the smooth muscles in the walls of the seminal vesicles contract, forcing the stored secretion into the urethra, where it mixes with other fluids before being expelled from the body as semen.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Proto-oncogene proteins are normal cellular proteins that play crucial roles in various cellular processes, such as signal transduction, cell cycle regulation, and apoptosis (programmed cell death). They are involved in the regulation of cell growth, differentiation, and survival under physiological conditions.

When proto-oncogene proteins undergo mutations or aberrations in their expression levels, they can transform into oncogenic forms, leading to uncontrolled cell growth and division. These altered proteins are then referred to as oncogene products or oncoproteins. Oncogenic mutations can occur due to various factors, including genetic predisposition, environmental exposures, and aging.

Examples of proto-oncogene proteins include:

1. Ras proteins: Involved in signal transduction pathways that regulate cell growth and differentiation. Activating mutations in Ras genes are found in various human cancers.
2. Myc proteins: Regulate gene expression related to cell cycle progression, apoptosis, and metabolism. Overexpression of Myc proteins is associated with several types of cancer.
3. EGFR (Epidermal Growth Factor Receptor): A transmembrane receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation. Mutations or overexpression of EGFR are linked to various malignancies, such as lung cancer and glioblastoma.
4. Src family kinases: Intracellular tyrosine kinases that regulate signal transduction pathways involved in cell proliferation, survival, and migration. Dysregulation of Src family kinases is implicated in several types of cancer.
5. Abl kinases: Cytoplasmic tyrosine kinases that regulate various cellular processes, including cell growth, differentiation, and stress responses. Aberrant activation of Abl kinases, as seen in chronic myelogenous leukemia (CML), leads to uncontrolled cell proliferation.

Understanding the roles of proto-oncogene proteins and their dysregulation in cancer development is essential for developing targeted cancer therapies that aim to inhibit or modulate these aberrant signaling pathways.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Osteoclasts are large, multinucleated cells that are primarily responsible for bone resorption, a process in which they break down and dissolve the mineralized matrix of bones. They are derived from monocyte-macrophage precursor cells of hematopoietic origin and play a crucial role in maintaining bone homeostasis by balancing bone formation and bone resorption.

Osteoclasts adhere to the bone surface and create an isolated microenvironment, called the "resorption lacuna," between their cell membrane and the bone surface. Here, they release hydrogen ions into the lacuna through a process called proton pumping, which lowers the pH and dissolves the mineral component of the bone matrix. Additionally, osteoclasts secrete proteolytic enzymes, such as cathepsin K, that degrade the organic components, like collagen, in the bone matrix.

An imbalance in osteoclast activity can lead to various bone diseases, including osteoporosis and Paget's disease, where excessive bone resorption results in weakened and fragile bones.

A randomized controlled trial (RCT) is a type of clinical study in which participants are randomly assigned to receive either the experimental intervention or the control condition, which may be a standard of care, placebo, or no treatment. The goal of an RCT is to minimize bias and ensure that the results are due to the intervention being tested rather than other factors. This design allows for a comparison between the two groups to determine if there is a significant difference in outcomes. RCTs are often considered the gold standard for evaluating the safety and efficacy of medical interventions, as they provide a high level of evidence for causal relationships between the intervention and health outcomes.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Watchful waiting is a medical approach where monitoring and careful observation are used in place of immediate treatment for certain conditions, such as slow-growing cancers or chronic diseases. The goal is to delay active treatment until there are signs that it's necessary, thus avoiding unnecessary side effects and costs associated with early intervention. Regular follow-ups and tests are conducted to track the progression of the condition and determine if and when treatment should be initiated.

Osteoblasts are specialized bone-forming cells that are derived from mesenchymal stem cells. They play a crucial role in the process of bone formation and remodeling. Osteoblasts synthesize, secrete, and mineralize the organic matrix of bones, which is mainly composed of type I collagen.

These cells have receptors for various hormones and growth factors that regulate their activity, such as parathyroid hormone, vitamin D, and transforming growth factor-beta. When osteoblasts are not actively producing bone matrix, they can become trapped within the matrix they produce, where they differentiate into osteocytes, which are mature bone cells that play a role in maintaining bone structure and responding to mechanical stress.

Abnormalities in osteoblast function can lead to various bone diseases, such as osteoporosis, osteogenesis imperfecta, and Paget's disease of bone.

Cell adhesion refers to the binding of cells to extracellular matrices or to other cells, a process that is fundamental to the development, function, and maintenance of multicellular organisms. Cell adhesion is mediated by various cell surface receptors, such as integrins, cadherins, and immunoglobulin-like cell adhesion molecules (Ig-CAMs), which interact with specific ligands in the extracellular environment. These interactions lead to the formation of specialized junctions, such as tight junctions, adherens junctions, and desmosomes, that help to maintain tissue architecture and regulate various cellular processes, including proliferation, differentiation, migration, and survival. Disruptions in cell adhesion can contribute to a variety of diseases, including cancer, inflammation, and degenerative disorders.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Metribolone is a synthetic anabolic-androgenic steroid (AAS) drug, which is not widely used in clinical medicine. Its chemical structure and pharmacological properties are similar to the natural male hormone testosterone. It has been used in research settings to study its effects on muscle growth, bone density, and sexual development. However, due to its potential for abuse and serious side effects, it is not approved for use in many countries.

It's important to note that the possession, distribution, and use of anabolic steroids without a valid prescription is illegal and can be dangerous to one's health. It can cause a range of adverse effects such as liver damage, cardiovascular disease, hormonal imbalances, and psychological issues among others.

A needle biopsy is a medical procedure in which a thin, hollow needle is used to remove a small sample of tissue from a suspicious or abnormal area of the body. The tissue sample is then examined under a microscope to check for cancer cells or other abnormalities. Needle biopsies are often used to diagnose lumps or masses that can be felt through the skin, but they can also be guided by imaging techniques such as ultrasound, CT scan, or MRI to reach areas that cannot be felt. There are several types of needle biopsy procedures, including fine-needle aspiration (FNA) and core needle biopsy. FNA uses a thin needle and gentle suction to remove fluid and cells from the area, while core needle biopsy uses a larger needle to remove a small piece of tissue. The type of needle biopsy used depends on the location and size of the abnormal area, as well as the reason for the procedure.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

Quality of Life (QOL) is a broad, multidimensional concept that usually includes an individual's physical health, psychological state, level of independence, social relationships, personal beliefs, and their relationship to salient features of their environment. It reflects the impact of disease and treatment on a patient's overall well-being and ability to function in daily life.

The World Health Organization (WHO) defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns." It is a subjective concept, meaning it can vary greatly from person to person.

In healthcare, QOL is often used as an outcome measure in clinical trials and other research studies to assess the impact of interventions or treatments on overall patient well-being.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

I'm sorry for any confusion, but "Azasteroids" is not a medical term or concept. The term "azasteroids" is used in the field of chemistry to refer to a class of compounds that are structurally similar to steroids but have an aziridine ring (a three-membered ring containing two carbon atoms and one nitrogen atom) instead of the usual four-membered ring in the steroid structure.

These compounds may have potential applications in various fields, including medicinal chemistry, but they are not a medical concept or diagnosis. If you have any questions related to medical terminology or health concerns, I would be happy to help you with those!

DNA-binding proteins are a type of protein that have the ability to bind to DNA (deoxyribonucleic acid), the genetic material of organisms. These proteins play crucial roles in various biological processes, such as regulation of gene expression, DNA replication, repair and recombination.

The binding of DNA-binding proteins to specific DNA sequences is mediated by non-covalent interactions, including electrostatic, hydrogen bonding, and van der Waals forces. The specificity of binding is determined by the recognition of particular nucleotide sequences or structural features of the DNA molecule.

DNA-binding proteins can be classified into several categories based on their structure and function, such as transcription factors, histones, and restriction enzymes. Transcription factors are a major class of DNA-binding proteins that regulate gene expression by binding to specific DNA sequences in the promoter region of genes and recruiting other proteins to modulate transcription. Histones are DNA-binding proteins that package DNA into nucleosomes, the basic unit of chromatin structure. Restriction enzymes are DNA-binding proteins that recognize and cleave specific DNA sequences, and are widely used in molecular biology research and biotechnology applications.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Biological models, also known as physiological models or organismal models, are simplified representations of biological systems, processes, or mechanisms that are used to understand and explain the underlying principles and relationships. These models can be theoretical (conceptual or mathematical) or physical (such as anatomical models, cell cultures, or animal models). They are widely used in biomedical research to study various phenomena, including disease pathophysiology, drug action, and therapeutic interventions.

Examples of biological models include:

1. Mathematical models: These use mathematical equations and formulas to describe complex biological systems or processes, such as population dynamics, metabolic pathways, or gene regulation networks. They can help predict the behavior of these systems under different conditions and test hypotheses about their underlying mechanisms.
2. Cell cultures: These are collections of cells grown in a controlled environment, typically in a laboratory dish or flask. They can be used to study cellular processes, such as signal transduction, gene expression, or metabolism, and to test the effects of drugs or other treatments on these processes.
3. Animal models: These are living organisms, usually vertebrates like mice, rats, or non-human primates, that are used to study various aspects of human biology and disease. They can provide valuable insights into the pathophysiology of diseases, the mechanisms of drug action, and the safety and efficacy of new therapies.
4. Anatomical models: These are physical representations of biological structures or systems, such as plastic models of organs or tissues, that can be used for educational purposes or to plan surgical procedures. They can also serve as a basis for developing more sophisticated models, such as computer simulations or 3D-printed replicas.

Overall, biological models play a crucial role in advancing our understanding of biology and medicine, helping to identify new targets for therapeutic intervention, develop novel drugs and treatments, and improve human health.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

3-Oxo-5-alpha-steroid 4-dehydrogenase is an enzyme that plays a role in steroid metabolism. It is involved in the conversion of certain steroids into others by removing hydrogen atoms and adding oxygen to create double bonds in the steroid molecule. Specifically, this enzyme catalyzes the dehydrogenation of 3-oxo-5-alpha-steroids at the 4th position, which results in the formation of a 4,5-double bond.

The enzyme is found in various tissues throughout the body and is involved in the metabolism of several important steroid hormones, including cortisol, aldosterone, and androgens. It helps to regulate the levels of these hormones in the body by converting them into their active or inactive forms as needed.

Deficiencies or mutations in the 3-oxo-5-alpha-steroid 4-dehydrogenase enzyme can lead to various medical conditions, such as congenital adrenal hyperplasia, which is characterized by abnormal hormone levels and development of sexual characteristics.

Cholestenone 5 alpha-reductase is an enzyme that plays a role in the conversion of cholesterol and other steroid hormones in the body. Specifically, it catalyzes the reduction of 5,7-dihydroxycholest-4-en-3-one (also known as cholestenone) to 5α-androstan-3α,17β-diol, which is a precursor to the male sex hormone testosterone.

This enzyme is found in various tissues throughout the body, including the prostate gland, skin, and liver. In the prostate gland, 5 alpha-reductase helps regulate the growth and function of the gland by converting testosterone to dihydrotestosterone (DHT), a more potent form of the hormone.

Inhibitors of 5 alpha-reductase are sometimes used as medications to treat conditions such as benign prostatic hyperplasia (BPH) and male pattern baldness, as reducing DHT levels can help alleviate symptoms associated with these conditions.

Testosterone congeners refer to structural analogs or derivatives of testosterone, which is the primary male sex hormone and an androgen. These are compounds that have a similar chemical structure to testosterone and may exhibit similar biological activities. Testosterone congeners can be naturally occurring or synthetic and include a variety of compounds such as androgens, anabolic steroids, and estrogens. They can be used in medical treatments, but some are also misused for performance enhancement or other non-medical purposes, which can lead to various health risks and side effects.

Androgen-binding protein (ABP) is a protein that binds specifically to androgens, which are hormones such as testosterone that play a role in male sexual development and masculine characteristics. ABP is produced in the Sertoli cells of the testes and helps to regulate the levels of androgens within the testes by storing them and slowly releasing them over time. This is important for maintaining normal sperm production and male reproductive function.

ABP is also found in other tissues, including the prostate gland, where it may play a role in regulating the growth and development of this tissue. Abnormal levels of ABP have been associated with certain medical conditions, such as prostate cancer and infertility.

Genetic predisposition to disease refers to an increased susceptibility or vulnerability to develop a particular illness or condition due to inheriting specific genetic variations or mutations from one's parents. These genetic factors can make it more likely for an individual to develop a certain disease, but it does not guarantee that the person will definitely get the disease. Environmental factors, lifestyle choices, and interactions between genes also play crucial roles in determining if a genetically predisposed person will actually develop the disease. It is essential to understand that having a genetic predisposition only implies a higher risk, not an inevitable outcome.

Conformal radiotherapy is a type of external beam radiation therapy that uses advanced technology to conform the radiation beam to the shape of the tumor, allowing for more precise and targeted treatment while minimizing exposure to healthy surrounding tissue. This can help reduce the risk of side effects and improve the therapeutic ratio. Conformal radiotherapy techniques include 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT). These techniques use sophisticated imaging and treatment planning systems to create a personalized treatment plan for each patient, based on the size, shape, and location of their tumor.

Cell growth processes refer to the series of events that occur within a cell leading to an increase in its size, mass, and number of organelles. These processes are essential for the development, maintenance, and reproduction of all living organisms. The main cell growth processes include:

1. Cell Cycle: It is the sequence of events that a eukaryotic cell goes through from one cell division (mitosis) to the next. The cell cycle consists of four distinct phases: G1 phase (growth and preparation for DNA replication), S phase (DNA synthesis), G2 phase (preparation for mitosis), and M phase (mitosis or meiosis).

2. DNA Replication: It is the process by which a cell makes an identical copy of its DNA molecule before cell division. This ensures that each daughter cell receives an exact replica of the parent cell's genetic material.

3. Protein Synthesis: Cells grow by increasing their protein content, which is achieved through the process of protein synthesis. This involves transcribing DNA into mRNA (transcription) and then translating that mRNA into a specific protein sequence (translation).

4. Cellular Metabolism: It refers to the sum total of all chemical reactions that occur within a cell to maintain life. These reactions include catabolic processes, which break down nutrients to release energy, and anabolic processes, which use energy to build complex molecules like proteins, lipids, and carbohydrates.

5. Cell Signaling: Cells communicate with each other through intricate signaling pathways that help coordinate growth, differentiation, and survival. These signals can come from within the cell (intracellular) or from outside the cell (extracellular).

6. Cell Division: Also known as mitosis, it is the process by which a single cell divides into two identical daughter cells. This ensures that each new cell contains an exact copy of the parent cell's genetic material and allows for growth and repair of tissues.

7. Apoptosis: It is a programmed cell death process that helps maintain tissue homeostasis by eliminating damaged or unnecessary cells. Dysregulation of apoptosis can lead to diseases such as cancer and autoimmune disorders.

Prostatic secretory proteins are a group of proteins that are produced and secreted by the prostate gland, which is a small gland that is part of the male reproductive system. These proteins play an important role in maintaining the health and function of the reproductive system.

One of the most well-known prostatic secretory proteins is prostate-specific antigen (PSA), which is often used as a biomarker for the early detection and monitoring of prostate cancer. PSA is a protein that is produced by the cells in the prostate gland and is normally found in low levels in the blood. However, when the prostate gland becomes enlarged or cancerous, the levels of PSA in the blood can increase, making it possible to detect these conditions through a simple blood test.

Other prostatic secretory proteins include prostate-specific acid phosphatase (PSAP), prostatein, and prolactin-inducible protein (PIP). These proteins are also produced by the prostate gland and have various functions, such as helping to liquefy semen and protecting sperm from the immune system.

It is important to note that while these proteins can provide valuable information about the health of the prostate gland, they are not foolproof indicators of disease. Other factors, such as age, inflammation, and benign prostatic hyperplasia (BPH), can also affect the levels of these proteins in the blood. Therefore, it is important to consult with a healthcare professional for proper interpretation and follow-up care.

Anticarcinogenic agents are substances that prevent, inhibit or reduce the development of cancer. They can be natural or synthetic compounds that interfere with the process of carcinogenesis at various stages, such as initiation, promotion, and progression. Anticarcinogenic agents may work by preventing DNA damage, promoting DNA repair, reducing inflammation, inhibiting cell proliferation, inducing apoptosis (programmed cell death), or modulating immune responses.

Examples of anticarcinogenic agents include chemopreventive agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and retinoids; phytochemicals found in fruits, vegetables, and other plant-based foods; and medications used to treat cancer, such as chemotherapy, radiation therapy, and targeted therapies.

It is important to note that while some anticarcinogenic agents have been shown to be effective in preventing or reducing the risk of certain types of cancer, they may also have potential side effects and risks. Therefore, it is essential to consult with a healthcare professional before using any anticarcinogenic agent for cancer prevention or treatment purposes.

Racemases and epimerases are two types of enzymes that are involved in the modification of the stereochemistry of molecules, particularly amino acids and sugars. Here is a brief definition for each:

1. Racemases: These are enzymes that catalyze the interconversion of D- and L-stereoisomers of amino acids or other chiral compounds. They do this by promoting the conversion of one stereoisomer to its mirror image, resulting in a racemic mixture (a 1:1 mixture of two enantiomers). Racemases are important in various biological processes, such as the biosynthesis of some amino acids and the degradation of certain carbohydrates.

Example: Alanine racemase is an enzyme that catalyzes the conversion of L-alanine to D-alanine, which is essential for bacterial cell wall biosynthesis.

2. Epimerases: These are enzymes that convert one stereoisomer (epimer) of a chiral compound into another stereoisomer by changing the configuration at a single asymmetric carbon atom while keeping the rest of the molecule unchanged. Unlike racemases, epimerases do not produce racemic mixtures but rather create specific stereoisomers.

Example: Glucose-1-phosphate epimerase is an enzyme that converts glucose-1-phosphate to galactose-1-phosphate during the Leloir pathway, which is the primary metabolic route for lactose digestion in mammals.

Both racemases and epimerases play crucial roles in various biochemical processes, including the synthesis and degradation of essential molecules like amino acids and carbohydrates.

The rectum is the lower end of the digestive tract, located between the sigmoid colon and the anus. It serves as a storage area for feces before they are eliminated from the body. The rectum is about 12 cm long in adults and is surrounded by layers of muscle that help control defecation. The mucous membrane lining the rectum allows for the detection of stool, which triggers the reflex to have a bowel movement.

Computer-assisted radiotherapy planning (CARP) is the use of computer systems and software to assist in the process of creating a treatment plan for radiotherapy. The goal of radiotherapy is to deliver a precise and effective dose of radiation to a tumor while minimizing exposure to healthy tissue. CARP involves using imaging data, such as CT or MRI scans, to create a 3D model of the patient's anatomy. This model is then used to simulate the delivery of radiation from different angles and determine the optimal treatment plan. The use of computers in this process allows for more accurate and efficient planning, as well as the ability to easily adjust the plan as needed.

Intensity-modulated radiotherapy (IMRT) is a type of external beam radiation therapy that uses advanced technology to precisely target tumors while minimizing exposure to healthy tissues. In IMRT, the intensity of the radiation beam is modulated or varied during treatment, allowing for more conformal dose distributions and better sparing of normal structures. This is achieved through the use of computer-controlled linear accelerators that shape the radiation beam to match the three-dimensional shape of the tumor. The result is improved treatment accuracy, reduced side effects, and potentially higher cure rates compared to conventional radiotherapy techniques.

Medical mass screening, also known as population screening, is a public health service that aims to identify and detect asymptomatic individuals in a given population who have or are at risk of a specific disease. The goal is to provide early treatment, reduce morbidity and mortality, and prevent the spread of diseases within the community.

A mass screening program typically involves offering a simple, quick, and non-invasive test to a large number of people in a defined population, regardless of their risk factors or symptoms. Those who test positive are then referred for further diagnostic tests and appropriate medical interventions. Examples of mass screening programs include mammography for breast cancer detection, PSA (prostate-specific antigen) testing for prostate cancer, and fecal occult blood testing for colorectal cancer.

It is important to note that mass screening programs should be evidence-based, cost-effective, and ethically sound, with clear benefits outweighing potential harms. They should also consider factors such as the prevalence of the disease in the population, the accuracy and reliability of the screening test, and the availability and effectiveness of treatment options.

Early detection of cancer refers to the identification of malignant cells or tumors in their initial stages, before they have had a chance to grow and spread. This is typically achieved through various screening methods and tests that are designed to detect specific types of cancers. The goal of early detection is to increase the chances of successful treatment and improve the overall prognosis for patients.

Some common methods used for early cancer detection include:

1. Regular screenings such as mammograms, colonoscopies, and Pap tests, which can help identify precancerous or cancerous cells in their earliest stages.
2. Imaging tests like CT scans, MRIs, and PET scans, which can help detect tumors that may not be visible through other screening methods.
3. Blood tests that look for specific biomarkers or tumor markers, which can indicate the presence of cancer in the body.
4. Genetic testing to identify individuals who may be at higher risk of developing certain types of cancer due to inherited genetic mutations.

It's important to note that while early detection is an important tool in the fight against cancer, it is not a guarantee of successful treatment or cure. However, it can significantly improve the odds of successful treatment and increase the chances of survival for many patients.

Phenytoin is an anticonvulsant drug, which is chemically classified as a hydantoin. The term "phenylthiohydantoin" refers to the functional group that makes up the core structure of phenytoin and other related compounds. This group consists of a phenyl ring (a benzene ring with a hydrogen atom replaced by a hydrocarbon group) attached to a thiocarbonyl group (-C=S), which is in turn attached to a hydantoin ring.

The hydantoin ring is a six-membered ring containing two nitrogen atoms and two carbonyl groups, which makes it a cyclic urea derivative. Phenytoin's chemical formula is C15H14N2O2S, and its molecular structure can be represented as follows:

![Phenytoin Molecular Structure](https://www.researchgate.net/profile/Mohamed-Abdelkader-Elshaer-3/publication/327516849/figure/fig1/AS:616830886369744@1524486833308/Schematic-representation-of-phenytoin-structure.png)

Phenytoin is primarily used as an antiepileptic drug to control tonic-clonic (grand mal) and complex partial seizures. It works by stabilizing the inactive state of voltage-gated sodium channels in the brain, which reduces their excitability and helps prevent abnormal electrical activity leading to seizures.

In a medical context, "phenylthiohydantoin" is not typically used as a standalone definition but rather refers to the core structure of phenytoin and related compounds.

Radiotherapy dosage refers to the total amount of radiation energy that is absorbed by tissues or organs, typically measured in units of Gray (Gy), during a course of radiotherapy treatment. It is the product of the dose rate (the amount of radiation delivered per unit time) and the duration of treatment. The prescribed dosage for cancer treatments can range from a few Gray to more than 70 Gy, depending on the type and location of the tumor, the patient's overall health, and other factors. The goal of radiotherapy is to deliver a sufficient dosage to destroy the cancer cells while minimizing damage to surrounding healthy tissues.

Organ size refers to the volume or physical measurement of an organ in the body of an individual. It can be described in terms of length, width, and height or by using specialized techniques such as imaging studies (like CT scans or MRIs) to determine the volume. The size of an organ can vary depending on factors such as age, sex, body size, and overall health status. Changes in organ size may indicate various medical conditions, including growths, inflammation, or atrophy.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

A gene fusion, also known as a chromosomal translocation or fusion gene, is an abnormal genetic event where parts of two different genes combine to create a single, hybrid gene. This can occur due to various mechanisms such as chromosomal rearrangements, deletions, or inversions, leading to the formation of a chimeric gene with new and often altered functions.

Gene fusions can result in the production of abnormal fusion proteins that may contribute to cancer development and progression by promoting cell growth, inhibiting apoptosis (programmed cell death), or activating oncogenic signaling pathways. In some cases, gene fusions are specific to certain types of cancer and serve as valuable diagnostic markers and therapeutic targets for personalized medicine.

Image-guided radiotherapy (IGRT) is a type of radiation therapy that uses medical imaging techniques to improve the precision and accuracy of radiation delivery. It allows for real-time or periodic imaging during the course of radiation treatment, which can be used to confirm the position of the targeted tumor and make any necessary adjustments to the patient's position or the radiation beam. This helps ensure that the radiation is focused on the intended target, while minimizing exposure to surrounding healthy tissue. IGRT may be used to treat a variety of cancer types and can be delivered using various radiation therapy techniques such as 3D-conformal radiotherapy, intensity-modulated radiotherapy (IMRT), or stereotactic body radiotherapy (SBRT).

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

A nomogram is a graphical representation of a mathematical formula or equation that allows the user to quickly solve a problem by simply drawing a line between different values on the chart. In the field of medicine, nomograms are often used as a tool for predicting patient outcomes, assessing risk, or making diagnostic decisions based on specific clinical data.

For example, a nomogram may be used to estimate the probability of survival in patients with a particular type of cancer, based on factors such as age, tumor size, and stage of disease. The user would locate the appropriate values for each factor on the nomogram, draw a line connecting them, and read off the estimated probability at the intersection point.

Nomograms can be a useful and intuitive way to communicate complex medical information and help clinicians make informed decisions in a timely manner. However, it is important to note that nomograms are only as accurate as the data they are based on, and should always be used in conjunction with clinical judgment and other relevant factors.

Stromal cells, also known as stromal/stroma cells, are a type of cell found in various tissues and organs throughout the body. They are often referred to as the "connective tissue" or "supporting framework" of an organ because they play a crucial role in maintaining the structure and function of the tissue. Stromal cells include fibroblasts, adipocytes (fat cells), and various types of progenitor/stem cells. They produce and maintain the extracellular matrix, which is the non-cellular component of tissues that provides structural support and biochemical cues for other cells. Stromal cells also interact with immune cells and participate in the regulation of the immune response. In some contexts, "stromal cells" can also refer to cells found in the microenvironment of tumors, which can influence cancer growth and progression.

Tumor burden is a term used to describe the total amount of cancer in the body. It can refer to the number of tumors, the size of the tumors, or the amount of cancer cells in the body. In research and clinical trials, tumor burden is often measured to assess the effectiveness of treatments or to monitor disease progression. High tumor burden can cause various symptoms and complications, depending on the type and location of the cancer. It can also affect a person's prognosis and treatment options.

An image-guided biopsy is a medical procedure in which imaging technologies, such as ultrasound, CT (computed tomography), MRI (magnetic resonance imaging), or mammography, are used to guide the removal of tissue samples from a suspicious area in the body for further examination and diagnosis. This technique allows healthcare professionals to obtain biopsy specimens precisely and accurately, even from deep-seated or hard-to-reach locations, minimizing injury to surrounding tissues and improving diagnostic confidence. The type of imaging modality used depends on the location, size, and nature of the suspected abnormality.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Human chromosome pair 8 consists of two rod-shaped structures present in the nucleus of each cell of the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure known as a chromatin.

Human cells have 23 pairs of chromosomes, for a total of 46 chromosomes. Pair 8 is one of the autosomal pairs, meaning that it is not a sex chromosome (X or Y). Each member of chromosome pair 8 has a similar size, shape, and banding pattern, and they are identical in males and females.

Chromosome pair 8 contains several genes that are essential for various cellular functions and human development. Some of the genes located on chromosome pair 8 include those involved in the regulation of metabolism, nerve function, immune response, and cell growth and division.

Abnormalities in chromosome pair 8 can lead to genetic disorders such as Wolf-Hirschhorn syndrome, which is caused by a partial deletion of the short arm of chromosome 4, or partial trisomy 8, which results from an extra copy of all or part of chromosome 8. Both of these conditions are associated with developmental delays, intellectual disability, and various physical abnormalities.

Genotype, in genetics, refers to the complete heritable genetic makeup of an individual organism, including all of its genes. It is the set of instructions contained in an organism's DNA for the development and function of that organism. The genotype is the basis for an individual's inherited traits, and it can be contrasted with an individual's phenotype, which refers to the observable physical or biochemical characteristics of an organism that result from the expression of its genes in combination with environmental influences.

It is important to note that an individual's genotype is not necessarily identical to their genetic sequence. Some genes have multiple forms called alleles, and an individual may inherit different alleles for a given gene from each parent. The combination of alleles that an individual inherits for a particular gene is known as their genotype for that gene.

Understanding an individual's genotype can provide important information about their susceptibility to certain diseases, their response to drugs and other treatments, and their risk of passing on inherited genetic disorders to their offspring.

Single Nucleotide Polymorphism (SNP) is a type of genetic variation that occurs when a single nucleotide (A, T, C, or G) in the DNA sequence is altered. This alteration must occur in at least 1% of the population to be considered a SNP. These variations can help explain why some people are more susceptible to certain diseases than others and can also influence how an individual responds to certain medications. SNPs can serve as biological markers, helping scientists locate genes that are associated with disease. They can also provide information about an individual's ancestry and ethnic background.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

Goserelin is a synthetic hormone drug that is used to treat various types of cancer, including breast, prostate, and endometrial cancer. It is a long-acting form of a hormone called gonadotropin-releasing hormone (GnRH) agonist.

When Goserelin is administered, it initially stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, which in turn stimulate the production of sex hormones such as estrogen and testosterone. However, after a few weeks of continuous administration, Goserelin suppresses the release of FSH and LH, leading to reduced levels of sex hormones.

In cancer treatment, this reduction in sex hormones can help slow down or stop the growth of certain types of cancer cells that are sensitive to these hormones. Goserelin is typically administered as an implant under the skin every 1-3 months, depending on the specific indication and dosage regimen.

It's important to note that Goserelin can have side effects, including hot flashes, mood changes, and reduced sexual desire, among others. It may also affect bone density and increase the risk of fractures in some people. Therefore, it should be used under the close supervision of a healthcare provider.

Promoter regions in genetics refer to specific DNA sequences located near the transcription start site of a gene. They serve as binding sites for RNA polymerase and various transcription factors that regulate the initiation of gene transcription. These regulatory elements help control the rate of transcription and, therefore, the level of gene expression. Promoter regions can be composed of different types of sequences, such as the TATA box and CAAT box, and their organization and composition can vary between different genes and species.

Risk assessment in the medical context refers to the process of identifying, evaluating, and prioritizing risks to patients, healthcare workers, or the community related to healthcare delivery. It involves determining the likelihood and potential impact of adverse events or hazards, such as infectious diseases, medication errors, or medical devices failures, and implementing measures to mitigate or manage those risks. The goal of risk assessment is to promote safe and high-quality care by identifying areas for improvement and taking action to minimize harm.

Erectile dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It can have physical and psychological causes, such as underlying health conditions like diabetes, heart disease, obesity, and mental health issues like stress, anxiety, and depression. ED can also be a side effect of certain medications. Treatment options include lifestyle changes, medication, counseling, and in some cases, surgery.

Kallikreins are a group of serine proteases, which are enzymes that help to break down other proteins. They are found in various tissues and body fluids, including the pancreas, kidneys, and saliva. In the body, kallikreins play important roles in several physiological processes, such as blood pressure regulation, inflammation, and fibrinolysis (the breakdown of blood clots).

There are two main types of kallikreins: tissue kallikreins and plasma kallikreins. Tissue kallikreins are primarily involved in the activation of kininogen, a protein that leads to the production of bradykinin, a potent vasodilator that helps regulate blood pressure. Plasma kallikreins, on the other hand, play a key role in the coagulation cascade by activating factors XI and XII, which ultimately lead to the formation of a blood clot.

Abnormal levels or activity of kallikreins have been implicated in various diseases, including cancer, cardiovascular disease, and inflammatory disorders. For example, some studies suggest that certain tissue kallikreins may promote tumor growth and metastasis, while others indicate that they may have protective effects against cancer. Plasma kallikreins have also been linked to the development of thrombosis (blood clots) and inflammation in cardiovascular disease.

Overall, kallikreins are important enzymes with diverse functions in the body, and their dysregulation has been associated with various pathological conditions.

In the context of medicine, risk is the probability or likelihood of an adverse health effect or the occurrence of a negative event related to treatment or exposure to certain hazards. It is usually expressed as a ratio or percentage and can be influenced by various factors such as age, gender, lifestyle, genetics, and environmental conditions. Risk assessment involves identifying, quantifying, and prioritizing risks to make informed decisions about prevention, mitigation, or treatment strategies.

Glutathione S-transferase Pi (GSTP1) is a member of the glutathione S-transferase (GST) family, which are enzymes involved in the detoxification of xenobiotics and endogenous compounds. GSTs catalyze the conjugation of reduced glutathione to these electrophilic compounds, facilitating their excretion from the body.

GSTP1 is primarily found in the cytosol of cells and has a high affinity for a variety of substrates, including polycyclic aromatic hydrocarbons, heterocyclic amines, and certain chemotherapeutic drugs. It plays an essential role in protecting cells against oxidative stress and chemical-induced damage.

Polymorphisms in the GSTP1 gene have been associated with altered enzyme activity and susceptibility to various diseases, including cancer, neurological disorders, and respiratory diseases. The most common polymorphism in GSTP1 is a single nucleotide substitution (Ile105Val), which has been shown to reduce the enzyme's catalytic activity and increase the risk of developing certain types of cancer.

The urogenital system is a part of the human body that includes the urinary and genital systems. The urinary system consists of the kidneys, ureters, bladder, and urethra, which work together to produce, store, and eliminate urine. On the other hand, the genital system, also known as the reproductive system, is responsible for the production, development, and reproduction of offspring. In males, this includes the testes, epididymis, vas deferens, seminal vesicles, prostate gland, bulbourethral glands, and penis. In females, it includes the ovaries, fallopian tubes, uterus, vagina, mammary glands, and external genitalia.

The urogenital system is closely related anatomically and functionally. For example, in males, the urethra serves as a shared conduit for both urine and semen, while in females, the urethra and vagina are separate but adjacent structures. Additionally, some organs, such as the prostate gland in males and the Skene's glands in females, have functions that overlap between the urinary and genital systems.

Disorders of the urogenital system can affect both the urinary and reproductive functions, leading to a range of symptoms such as pain, discomfort, infection, and difficulty with urination or sexual activity. Proper care and maintenance of the urogenital system are essential for overall health and well-being.

African Americans are defined as individuals who have ancestry from any of the black racial groups of Africa. This term is often used to describe people living in the United States who have total or partial descent from enslaved African peoples. The term does not refer to a single ethnicity but is a broad term that includes various ethnic groups with diverse cultures, languages, and traditions. It's important to note that some individuals may prefer to identify as Black or of African descent rather than African American, depending on their personal identity and background.

Urology is a surgical specialty that deals with the diagnosis and treatment of diseases and conditions related to the male and female urinary tract system and the male reproductive organs. This includes the kidneys, ureters, bladder, prostate gland, and testicles. Urologists are medical doctors who have completed specialized training in this field, and they may perform various surgical procedures such as cystoscopy, lithotripsy, and radical prostatectomy to treat conditions like kidney stones, urinary tract infections, bladder cancer, enlarged prostate, and infertility.

Reproducibility of results in a medical context refers to the ability to obtain consistent and comparable findings when a particular experiment or study is repeated, either by the same researcher or by different researchers, following the same experimental protocol. It is an essential principle in scientific research that helps to ensure the validity and reliability of research findings.

In medical research, reproducibility of results is crucial for establishing the effectiveness and safety of new treatments, interventions, or diagnostic tools. It involves conducting well-designed studies with adequate sample sizes, appropriate statistical analyses, and transparent reporting of methods and findings to allow other researchers to replicate the study and confirm or refute the results.

The lack of reproducibility in medical research has become a significant concern in recent years, as several high-profile studies have failed to produce consistent findings when replicated by other researchers. This has led to increased scrutiny of research practices and a call for greater transparency, rigor, and standardization in the conduct and reporting of medical research.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

The cell cycle is a series of events that take place in a cell leading to its division and duplication. It consists of four main phases: G1 phase, S phase, G2 phase, and M phase.

During the G1 phase, the cell grows in size and synthesizes mRNA and proteins in preparation for DNA replication. In the S phase, the cell's DNA is copied, resulting in two complete sets of chromosomes. During the G2 phase, the cell continues to grow and produces more proteins and organelles necessary for cell division.

The M phase is the final stage of the cell cycle and consists of mitosis (nuclear division) and cytokinesis (cytoplasmic division). Mitosis results in two genetically identical daughter nuclei, while cytokinesis divides the cytoplasm and creates two separate daughter cells.

The cell cycle is regulated by various checkpoints that ensure the proper completion of each phase before progressing to the next. These checkpoints help prevent errors in DNA replication and division, which can lead to mutations and cancer.

The term "European Continental Ancestry Group" is a medical/ethnic classification that refers to individuals who trace their genetic ancestry to the continent of Europe. This group includes people from various ethnic backgrounds and nationalities, such as Northern, Southern, Eastern, and Western European descent. It is often used in research and medical settings for population studies or to identify genetic patterns and predispositions to certain diseases that may be more common in specific ancestral groups. However, it's important to note that this classification can oversimplify the complex genetic diversity within and between populations, and should be used with caution.

Radiotherapy, also known as radiation therapy, is a medical treatment that uses ionizing radiation to kill cancer cells, shrink tumors, and prevent the growth and spread of cancer. The radiation can be delivered externally using machines or internally via radioactive substances placed in or near the tumor. Radiotherapy works by damaging the DNA of cancer cells, which prevents them from dividing and growing. Normal cells are also affected by radiation, but they have a greater ability to repair themselves compared to cancer cells. The goal of radiotherapy is to destroy as many cancer cells as possible while minimizing damage to healthy tissue.

DNA methylation is a process by which methyl groups (-CH3) are added to the cytosine ring of DNA molecules, often at the 5' position of cytospine phosphate-deoxyguanosine (CpG) dinucleotides. This modification is catalyzed by DNA methyltransferase enzymes and results in the formation of 5-methylcytosine.

DNA methylation plays a crucial role in the regulation of gene expression, genomic imprinting, X chromosome inactivation, and suppression of transposable elements. Abnormal DNA methylation patterns have been associated with various diseases, including cancer, where tumor suppressor genes are often silenced by promoter methylation.

In summary, DNA methylation is a fundamental epigenetic modification that influences gene expression and genome stability, and its dysregulation has important implications for human health and disease.

Urination disorders, also known as lower urinary tract symptoms (LUTS), refer to a range of clinical conditions that affect the bladder and urethra, resulting in abnormalities in the storage, transportation, and evacuation of urine. These disorders can be categorized into voiding symptoms, such as hesitancy, straining, slow stream, intermittency, and terminal dribble; and storage symptoms, including frequency, urgency, nocturia, and urge incontinence.

The causes of urination disorders are diverse, encompassing congenital abnormalities, neurological conditions, infections, inflammation, medications, and age-related changes. Common underlying pathologies include bladder overactivity, detrusor muscle instability, underactive bladder, and obstruction of the urethra.

Urination disorders can significantly impact an individual's quality of life, causing physical discomfort, sleep disturbances, emotional distress, and social isolation. Accurate diagnosis and appropriate management require a comprehensive assessment of the patient's medical history, physical examination, urinalysis, and urodynamic studies. Treatment options may include behavioral modifications, pelvic floor exercises, bladder training, medications, neuromodulation, and surgical interventions.

Gene expression is the process by which the information encoded in a gene is used to synthesize a functional gene product, such as a protein or RNA molecule. This process involves several steps: transcription, RNA processing, and translation. During transcription, the genetic information in DNA is copied into a complementary RNA molecule, known as messenger RNA (mRNA). The mRNA then undergoes RNA processing, which includes adding a cap and tail to the mRNA and splicing out non-coding regions called introns. The resulting mature mRNA is then translated into a protein on ribosomes in the cytoplasm through the process of translation.

The regulation of gene expression is a complex and highly controlled process that allows cells to respond to changes in their environment, such as growth factors, hormones, and stress signals. This regulation can occur at various stages of gene expression, including transcriptional activation or repression, RNA processing, mRNA stability, and translation. Dysregulation of gene expression has been implicated in many diseases, including cancer, genetic disorders, and neurological conditions.

Androstane-3,17-diol is a steroid hormone, specifically a 17-ketosteroid, that is synthesized from the metabolism of androgens such as testosterone. It exists in two forms: 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol, which differ based on the configuration of the A ring at the 5 position. These compounds are weak androgens themselves but serve as important intermediates in steroid hormone metabolism. They can be further metabolized to form other steroid hormones or their metabolites, such as androstanediol glucuronide, which is a major urinary metabolite of testosterone and dihydrotestosterone.

Urinary retention is a medical condition in which the bladder cannot empty completely or at all, resulting in the accumulation of urine in the bladder. This can lead to discomfort, pain, and difficulty in passing urine. Urinary retention can be acute (sudden onset) or chronic (long-term). Acute urinary retention is a medical emergency that requires immediate attention, while chronic urinary retention may be managed with medications or surgery. The causes of urinary retention include nerve damage, bladder muscle weakness, prostate gland enlargement, and side effects of certain medications.

RNA (Ribonucleic acid) is a single-stranded molecule similar in structure to DNA, involved in the process of protein synthesis in the cell. It acts as a messenger carrying genetic information from DNA to the ribosomes, where proteins are produced.

A neoplasm, on the other hand, is an abnormal growth of cells, which can be benign or malignant. Benign neoplasms are not cancerous and do not invade nearby tissues or spread to other parts of the body. Malignant neoplasms, however, are cancerous and have the potential to invade surrounding tissues and spread to distant sites in the body through a process called metastasis.

Therefore, an 'RNA neoplasm' is not a recognized medical term as RNA is not a type of growth or tumor. However, there are certain types of cancer-causing viruses known as oncoviruses that contain RNA as their genetic material and can cause neoplasms. For example, human T-cell leukemia virus (HTLV-1) and hepatitis C virus (HCV) are RNA viruses that can cause certain types of cancer in humans.

The odds ratio (OR) is a statistical measure used in epidemiology and research to estimate the association between an exposure and an outcome. It represents the odds that an event will occur in one group versus the odds that it will occur in another group, assuming that all other factors are held constant.

In medical research, the odds ratio is often used to quantify the strength of the relationship between a risk factor (exposure) and a disease outcome. An OR of 1 indicates no association between the exposure and the outcome, while an OR greater than 1 suggests that there is a positive association between the two. Conversely, an OR less than 1 implies a negative association.

It's important to note that the odds ratio is not the same as the relative risk (RR), which compares the incidence rates of an outcome in two groups. While the OR can approximate the RR when the outcome is rare, they are not interchangeable and can lead to different conclusions about the association between an exposure and an outcome.

Tumor suppressor genes are a type of gene that helps to regulate and prevent cells from growing and dividing too rapidly or in an uncontrolled manner. They play a critical role in preventing the formation of tumors and cancer. When functioning properly, tumor suppressor genes help to repair damaged DNA, control the cell cycle, and trigger programmed cell death (apoptosis) when necessary. However, when these genes are mutated or altered, they can lose their ability to function correctly, leading to uncontrolled cell growth and the development of tumors. Examples of tumor suppressor genes include TP53, BRCA1, and BRCA2.

Clusterin is a protein that is widely expressed in many tissues and body fluids, including the tears, blood plasma, seminal fluid, milk, and cerebrospinal fluid. It is also known as apolipoprotein J or sulfated glycoprotein 2. Clusterin has diverse functions, including cell-cell communication, lipid transport, and protection against oxidative stress.

In the context of medicine and disease, clusterin has been studied for its potential role in several pathological processes, such as neurodegeneration, inflammation, cancer, and aging. In particular, clusterin has been implicated in the development and progression of various types of cancer, including prostate, breast, ovarian, and lung cancer. It is thought to contribute to tumor growth, invasion, and metastasis by promoting cell survival, angiogenesis, and resistance to chemotherapy.

Therefore, clusterin has been considered as a potential therapeutic target for cancer treatment, and several strategies have been developed to inhibit its expression or activity. However, more research is needed to fully understand the molecular mechanisms of clusterin in health and disease, and to translate these findings into effective clinical interventions.

Antineoplastic agents, phytogenic, also known as plant-derived anticancer drugs, are medications that are derived from plants and used to treat cancer. These agents have natural origins and work by interfering with the growth and multiplication of cancer cells, helping to slow or stop the spread of the disease. Some examples of antineoplastic agents, phytogenic include paclitaxel (Taxol), vincristine, vinblastine, and etoposide. These drugs are often used in combination with other treatments such as surgery, radiation therapy, and other medications to provide a comprehensive approach to cancer care.

Immunoenzyme techniques are a group of laboratory methods used in immunology and clinical chemistry that combine the specificity of antibody-antigen reactions with the sensitivity and amplification capabilities of enzyme reactions. These techniques are primarily used for the detection, quantitation, or identification of various analytes (such as proteins, hormones, drugs, viruses, or bacteria) in biological samples.

In immunoenzyme techniques, an enzyme is linked to an antibody or antigen, creating a conjugate. This conjugate then interacts with the target analyte in the sample, forming an immune complex. The presence and amount of this immune complex can be visualized or measured by detecting the enzymatic activity associated with it.

There are several types of immunoenzyme techniques, including:

1. Enzyme-linked Immunosorbent Assay (ELISA): A widely used method for detecting and quantifying various analytes in a sample. In ELISA, an enzyme is attached to either the capture antibody or the detection antibody. After the immune complex formation, a substrate is added that reacts with the enzyme, producing a colored product that can be measured spectrophotometrically.
2. Immunoblotting (Western blot): A method used for detecting specific proteins in a complex mixture, such as a protein extract from cells or tissues. In this technique, proteins are separated by gel electrophoresis and transferred to a membrane, where they are probed with an enzyme-conjugated antibody directed against the target protein.
3. Immunohistochemistry (IHC): A method used for detecting specific antigens in tissue sections or cells. In IHC, an enzyme-conjugated primary or secondary antibody is applied to the sample, and the presence of the antigen is visualized using a chromogenic substrate that produces a colored product at the site of the antigen-antibody interaction.
4. Immunofluorescence (IF): A method used for detecting specific antigens in cells or tissues by employing fluorophore-conjugated antibodies. The presence of the antigen is visualized using a fluorescence microscope.
5. Enzyme-linked immunosorbent assay (ELISA): A method used for detecting and quantifying specific antigens or antibodies in liquid samples, such as serum or culture supernatants. In ELISA, an enzyme-conjugated detection antibody is added after the immune complex formation, and a substrate is added that reacts with the enzyme to produce a colored product that can be measured spectrophotometrically.

These techniques are widely used in research and diagnostic laboratories for various applications, including protein characterization, disease diagnosis, and monitoring treatment responses.

Computer-assisted radiotherapy, also known as computerized radiation therapy planning or treatment planning system, is a medical procedure that utilizes advanced computer software to design and implement a radiotherapy treatment plan for patients with cancer. This process involves using imaging technologies such as CT, MRI, or PET scans to create a 3D model of the tumor and surrounding healthy tissues. The software then calculates the optimal radiation dose and beam orientation to deliver the maximum radiation to the tumor while minimizing exposure to healthy tissue.

The computer-assisted radiotherapy system allows for more precise and accurate treatment planning, which can lead to improved outcomes and reduced side effects for patients undergoing radiation therapy. It also enables clinicians to simulate and compare different treatment plans, allowing them to choose the most effective and safe option for each individual patient. Additionally, the use of computer-assisted radiotherapy can increase efficiency and streamline the treatment planning process, reducing wait times for patients and improving workflow in radiotherapy departments.

Pathologic neovascularization is the abnormal growth of new blood vessels in previously avascular tissue or excessive growth within existing vasculature, which occurs as a result of hypoxia, inflammation, or angiogenic stimuli. These newly formed vessels are often disorganized, fragile, and lack proper vessel hierarchy, leading to impaired blood flow and increased vascular permeability. Pathologic neovascularization can be observed in various diseases such as cancer, diabetic retinopathy, age-related macular degeneration, and chronic inflammation. This process contributes to disease progression by promoting tumor growth, metastasis, and edema formation, ultimately leading to tissue damage and organ dysfunction.

"Male genitalia" refers to the reproductive and sexual organs that are typically present in male individuals. These structures include:

1. Testes: A pair of oval-shaped glands located in the scrotum that produce sperm and testosterone.
2. Epididymis: A long, coiled tube that lies on the surface of each testicle where sperm matures and is stored.
3. Vas deferens: A pair of muscular tubes that transport sperm from the epididymis to the urethra.
4. Seminal vesicles: Glands that produce a fluid that mixes with sperm to create semen.
5. Prostate gland: A small gland that surrounds the urethra and produces a fluid that also mixes with sperm to create semen.
6. Bulbourethral glands (Cowper's glands): Two pea-sized glands that produce a lubricating fluid that is released into the urethra during sexual arousal.
7. Urethra: A tube that runs through the penis and carries urine from the bladder out of the body, as well as semen during ejaculation.
8. Penis: The external organ that serves as both a reproductive and excretory organ, expelling both semen and urine.

Genetic polymorphism refers to the occurrence of multiple forms (called alleles) of a particular gene within a population. These variations in the DNA sequence do not generally affect the function or survival of the organism, but they can contribute to differences in traits among individuals. Genetic polymorphisms can be caused by single nucleotide changes (SNPs), insertions or deletions of DNA segments, or other types of genetic rearrangements. They are important for understanding genetic diversity and evolution, as well as for identifying genetic factors that may contribute to disease susceptibility in humans.

The Surveillance, Epidemiology, and End Results (SEER) Program is not a medical condition or diagnosis, but rather a research program run by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH). The SEER Program collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6% of the U.S. population.

The primary goal of the SEER Program is to provide reliable, up-to-date, and accessible information about cancer incidence and survival in the United States. This information is used by researchers, clinicians, policymakers, and the public to monitor cancer trends, identify factors that influence cancer risk, inform cancer prevention and control efforts, and improve cancer care.

The SEER Program collects data on patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and survival. The program also supports research on the causes and effects of cancer, as well as the development of new methods for cancer surveillance and data analysis.

An oncogene protein fusion is a result of a genetic alteration in which parts of two different genes combine to create a hybrid gene that can contribute to the development of cancer. This fusion can lead to the production of an abnormal protein that promotes uncontrolled cell growth and division, ultimately resulting in a malignant tumor. Oncogene protein fusions are often caused by chromosomal rearrangements such as translocations, inversions, or deletions and are commonly found in various types of cancer, including leukemia and sarcoma. These genetic alterations can serve as potential targets for cancer diagnosis and therapy.

Steroid 17-alpha-hydroxylase, also known as CYP17A1, is a cytochrome P450 enzyme that plays a crucial role in steroid hormone biosynthesis. It is located in the endoplasmic reticulum of cells in the adrenal glands and gonads. This enzyme catalyzes the 17-alpha-hydroxylation and subsequent lyase cleavage of pregnenolone and progesterone, converting them into dehydroepiandrosterone (DHEA) and androstenedione, respectively. These steroid intermediates are essential for the biosynthesis of both glucocorticoids and sex steroids, including cortisol, aldosterone, estrogens, and testosterone.

Defects in the CYP17A1 gene can lead to several disorders, such as congenital adrenal hyperplasia (CAH) due to 17-alpha-hydroxylase deficiency, which is characterized by decreased production of cortisol and sex steroids and increased mineralocorticoid levels. This condition results in sexual infantilism, electrolyte imbalances, and hypertension.

Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) is a protein that binds to and regulates the bioavailability and activity of Insulin-like Growth Factors (IGFs), specifically IGF-1 and IGF-2. It plays a crucial role in the growth, development, and homeostasis of various tissues and organs by modulating IGF signaling. IGFBP-3 is the most abundant IGF binding protein in circulation and has a longer half-life than IGFs, allowing it to act as a reservoir and transport protein for IGFs. Additionally, IGFBP-3 has been found to have IGF-independent functions, including roles in cell growth, differentiation, apoptosis, and tumor suppression.

Interventional Magnetic Resonance Imaging (MRI) is a medical imaging technique that combines the diagnostic capabilities of MRI with minimally invasive image-guided procedures. It uses a strong magnetic field, radio waves, and computer software to produce detailed images of the body's internal structures and soft tissues.

In interventional MRI, the technology is used in real-time to guide the placement of needles, catheters, or other medical instruments for diagnostic or therapeutic purposes. This can include biopsies, tumor ablations, or targeted drug deliveries. The primary advantage of interventional MRI over traditional interventional radiology techniques is its ability to provide high-resolution imaging without the use of radiation, making it a safer option for certain patients. However, it requires specialized equipment and trained personnel to perform these procedures.

Fiducial markers, also known as fiducials, are small markers that are often used in medical imaging to help identify and target specific locations within the body. These markers can be made of various materials, such as metal or plastic, and are typically placed at or near the site of interest through a minimally invasive procedure.

In radiation therapy, fiducial markers are often used to help ensure that the treatment is accurately targeted to the correct location. The markers can be seen on imaging scans, such as X-rays or CT scans, and can be used to align the treatment beam with the target area. This helps to improve the precision of the radiation therapy and reduce the risk of harm to surrounding healthy tissue.

Fiducial markers may also be used in other medical procedures, such as image-guided surgery or interventional radiology, to help guide the placement of instruments or devices within the body.

Multivariate analysis is a statistical method used to examine the relationship between multiple independent variables and a dependent variable. It allows for the simultaneous examination of the effects of two or more independent variables on an outcome, while controlling for the effects of other variables in the model. This technique can be used to identify patterns, associations, and interactions among multiple variables, and is commonly used in medical research to understand complex health outcomes and disease processes. Examples of multivariate analysis methods include multiple regression, factor analysis, cluster analysis, and discriminant analysis.

Genetic transcription is the process by which the information in a strand of DNA is used to create a complementary RNA molecule. This process is the first step in gene expression, where the genetic code in DNA is converted into a form that can be used to produce proteins or functional RNAs.

During transcription, an enzyme called RNA polymerase binds to the DNA template strand and reads the sequence of nucleotide bases. As it moves along the template, it adds complementary RNA nucleotides to the growing RNA chain, creating a single-stranded RNA molecule that is complementary to the DNA template strand. Once transcription is complete, the RNA molecule may undergo further processing before it can be translated into protein or perform its functional role in the cell.

Transcription can be either "constitutive" or "regulated." Constitutive transcription occurs at a relatively constant rate and produces essential proteins that are required for basic cellular functions. Regulated transcription, on the other hand, is subject to control by various intracellular and extracellular signals, allowing cells to respond to changing environmental conditions or developmental cues.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

"Age factors" refer to the effects, changes, or differences that age can have on various aspects of health, disease, and medical care. These factors can encompass a wide range of issues, including:

1. Physiological changes: As people age, their bodies undergo numerous physical changes that can affect how they respond to medications, illnesses, and medical procedures. For example, older adults may be more sensitive to certain drugs or have weaker immune systems, making them more susceptible to infections.
2. Chronic conditions: Age is a significant risk factor for many chronic diseases, such as heart disease, diabetes, cancer, and arthritis. As a result, age-related medical issues are common and can impact treatment decisions and outcomes.
3. Cognitive decline: Aging can also lead to cognitive changes, including memory loss and decreased decision-making abilities. These changes can affect a person's ability to understand and comply with medical instructions, leading to potential complications in their care.
4. Functional limitations: Older adults may experience physical limitations that impact their mobility, strength, and balance, increasing the risk of falls and other injuries. These limitations can also make it more challenging for them to perform daily activities, such as bathing, dressing, or cooking.
5. Social determinants: Age-related factors, such as social isolation, poverty, and lack of access to transportation, can impact a person's ability to obtain necessary medical care and affect their overall health outcomes.

Understanding age factors is critical for healthcare providers to deliver high-quality, patient-centered care that addresses the unique needs and challenges of older adults. By taking these factors into account, healthcare providers can develop personalized treatment plans that consider a person's age, physical condition, cognitive abilities, and social circumstances.

Tumor suppressor proteins are a type of regulatory protein that helps control the cell cycle and prevent cells from dividing and growing in an uncontrolled manner. They work to inhibit tumor growth by preventing the formation of tumors or slowing down their progression. These proteins can repair damaged DNA, regulate gene expression, and initiate programmed cell death (apoptosis) if the damage is too severe for repair.

Mutations in tumor suppressor genes, which provide the code for these proteins, can lead to a decrease or loss of function in the resulting protein. This can result in uncontrolled cell growth and division, leading to the formation of tumors and cancer. Examples of tumor suppressor proteins include p53, Rb (retinoblastoma), and BRCA1/2.

Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25), also known as Death Receptor 3 (DR3) or APO-3, is a type of cell surface receptor that belongs to the Tumor Necrosis Factor Receptor Superfamily (TNFRSF). These receptors are involved in various biological processes such as immune regulation, inflammation, and apoptosis (programmed cell death).

TNFRSF25 is composed of an extracellular domain that binds to its ligand, Tumor Necrosis Factor-like protein 1A (TL1A), and an intracellular domain that mediates signal transduction. The binding of TL1A to TNFRSF25 can activate several signaling pathways, including the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, which regulate cell survival, proliferation, differentiation, and apoptosis.

In the context of tumors, TNFRSF25 has been found to be expressed in various types of cancer cells, including colorectal, gastric, and breast cancer. The activation of TNFRSF25 by TL1A can induce apoptosis in some cancer cells, suggesting that it may have potential as a therapeutic target for cancer treatment. However, the role of TNFRSF25 in tumor development and progression is complex and context-dependent, and further research is needed to fully understand its functions and clinical relevance.

Phosphorylation is the process of adding a phosphate group (a molecule consisting of one phosphorus atom and four oxygen atoms) to a protein or other organic molecule, which is usually done by enzymes called kinases. This post-translational modification can change the function, localization, or activity of the target molecule, playing a crucial role in various cellular processes such as signal transduction, metabolism, and regulation of gene expression. Phosphorylation is reversible, and the removal of the phosphate group is facilitated by enzymes called phosphatases.

Logistic models, specifically logistic regression models, are a type of statistical analysis used in medical and epidemiological research to identify the relationship between the risk of a certain health outcome or disease (dependent variable) and one or more independent variables, such as demographic factors, exposure variables, or other clinical measurements.

In contrast to linear regression models, logistic regression models are used when the dependent variable is binary or dichotomous in nature, meaning it can only take on two values, such as "disease present" or "disease absent." The model uses a logistic function to estimate the probability of the outcome based on the independent variables.

Logistic regression models are useful for identifying risk factors and estimating the strength of associations between exposures and health outcomes, adjusting for potential confounders, and predicting the probability of an outcome given certain values of the independent variables. They can also be used to develop clinical prediction rules or scores that can aid in decision-making and patient care.

Trans-activators are proteins that increase the transcriptional activity of a gene or a set of genes. They do this by binding to specific DNA sequences and interacting with the transcription machinery, thereby enhancing the recruitment and assembly of the complexes needed for transcription. In some cases, trans-activators can also modulate the chromatin structure to make the template more accessible to the transcription machinery.

In the context of HIV (Human Immunodeficiency Virus) infection, the term "trans-activator" is often used specifically to refer to the Tat protein. The Tat protein is a viral regulatory protein that plays a critical role in the replication of HIV by activating the transcription of the viral genome. It does this by binding to a specific RNA structure called the Trans-Activation Response Element (TAR) located at the 5' end of all nascent HIV transcripts, and recruiting cellular cofactors that enhance the processivity and efficiency of RNA polymerase II, leading to increased viral gene expression.

Cyproterone acetate is a synthetic steroid hormone with anti-androgen and progestogenic properties. It works by blocking the action of androgens (male sex hormones) in the body, which helps to reduce symptoms associated with excessive androgen production such as severe acne or hirsutism (excessive hair growth).

Cyproterone acetate is used in the treatment of conditions such as prostate cancer, where it can help to slow the growth of cancer cells by reducing the levels of androgens in the body. It is also used in the treatment of sexual deviations, such as pedophilia or exhibitionism, as it can reduce sexual desire.

In addition, cyproterone acetate is sometimes used in combination with estrogen in hormone replacement therapy for transgender women to suppress the production of testosterone and promote feminization.

It's important to note that cyproterone acetate can have significant side effects and its use should be under the close supervision of a healthcare professional.

Carotenoids are a class of pigments that are naturally occurring in various plants and fruits. They are responsible for the vibrant colors of many vegetables and fruits, such as carrots, pumpkins, tomatoes, and leafy greens. There are over 600 different types of carotenoids, with beta-carotene, alpha-carotene, lycopene, lutein, and zeaxanthin being some of the most well-known.

Carotenoids have antioxidant properties, which means they can help protect the body's cells from damage caused by free radicals. Some carotenoids, such as beta-carotene, can be converted into vitamin A in the body, which is important for maintaining healthy vision, skin, and immune function. Other carotenoids, such as lycopene and lutein, have been studied for their potential role in preventing chronic diseases, including cancer and heart disease.

In addition to being found in plant-based foods, carotenoids can also be taken as dietary supplements. However, it is generally recommended to obtain nutrients from whole foods rather than supplements whenever possible, as food provides a variety of other beneficial compounds that work together to support health.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit the expression of specific genes. This process is mediated by small RNA molecules, including microRNAs (miRNAs) and small interfering RNAs (siRNAs), that bind to complementary sequences on messenger RNA (mRNA) molecules, leading to their degradation or translation inhibition.

RNAi plays a crucial role in regulating gene expression and defending against foreign genetic elements, such as viruses and transposons. It has also emerged as an important tool for studying gene function and developing therapeutic strategies for various diseases, including cancer and viral infections.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

A "large-core needle biopsy" is a medical procedure in which a large-bore needle is used to obtain a tissue sample from the body for diagnostic examination. This type of biopsy allows for the removal of a larger piece of tissue than what can be obtained with a fine-needle aspiration biopsy, and it is often used when a mass or abnormality can be felt during a physical exam.

During the procedure, the healthcare provider will use imaging guidance (such as ultrasound, CT scan, or MRI) to help guide the needle into the appropriate location. Once the needle is in place, it is advanced into the mass or abnormality and a core of tissue is removed for analysis. The sample is then sent to a laboratory where a pathologist will examine the tissue under a microscope to determine if there are any abnormal cells present that may indicate cancer or other diseases.

Large-core needle biopsies are generally considered safe, but like all medical procedures, they do carry some risks, such as bleeding, infection, and discomfort at the biopsy site. Patients should discuss any concerns with their healthcare provider before undergoing the procedure.

Drug screening assays for antitumor agents are laboratory tests used to identify and evaluate the effectiveness of potential drugs or compounds that can inhibit the growth of tumor cells or induce their death. These assays are typically performed in vitro (in a test tube or petri dish) using cell cultures of various types of cancer cells.

The assays measure different parameters such as cell viability, proliferation, apoptosis (programmed cell death), and cytotoxicity to determine the ability of the drug to kill or inhibit the growth of tumor cells. The results of these assays can help researchers identify promising antitumor agents that can be further developed for clinical use in cancer treatment.

There are different types of drug screening assays for antitumor agents, including high-throughput screening (HTS) assays, which allow for the rapid and automated testing of a large number of compounds against various cancer cell lines. Other types of assays include phenotypic screening assays, target-based screening assays, and functional screening assays, each with its own advantages and limitations.

Overall, drug screening assays for antitumor agents play a critical role in the development of new cancer therapies by providing valuable information on the activity and safety of potential drugs, helping to identify effective treatments and reduce the time and cost associated with bringing new drugs to market.

Enzyme inhibitors are substances that bind to an enzyme and decrease its activity, preventing it from catalyzing a chemical reaction in the body. They can work by several mechanisms, including blocking the active site where the substrate binds, or binding to another site on the enzyme to change its shape and prevent substrate binding. Enzyme inhibitors are often used as drugs to treat various medical conditions, such as high blood pressure, abnormal heart rhythms, and bacterial infections. They can also be found naturally in some foods and plants, and can be used in research to understand enzyme function and regulation.

An oncogene fusion, also known as oncogenic fusion or chimeric oncogene, is a result of a genetic rearrangement where parts of two different genes combine to form a hybrid gene. This fusion can lead to the production of an abnormal protein that contributes to cancer development and progression. In many cases, one of the fused genes is a proto-oncogene, a normal gene that regulates cell growth and division. When this gene is altered through fusion, it can acquire increased activity or new functions, promoting uncontrolled cell growth and eventually leading to tumor formation. Oncogene fusions are often associated with specific types of cancer and can be used as diagnostic markers or therapeutic targets for cancer treatment.

Neoplastic stem cells, also known as cancer stem cells (CSCs), are a subpopulation of cells within a tumor that are capable of self-renewal and generating the heterogeneous lineages of cells that comprise the tumor. These cells are believed to be responsible for the initiation, maintenance, and progression of cancer, as well as its recurrence and resistance to therapy.

CSCs share some similarities with normal stem cells, such as their ability to divide asymmetrically and give rise to differentiated progeny. However, they also have distinct characteristics that distinguish them from their normal counterparts, including aberrant gene expression, altered signaling pathways, and increased resistance to apoptosis (programmed cell death).

The existence of CSCs has important implications for cancer diagnosis, treatment, and prevention. Targeting these cells specifically may be necessary to achieve durable remissions and prevent relapse, as they are thought to survive conventional therapies that target the bulk of the tumor. Further research is needed to better understand the biology of CSCs and develop effective strategies for their elimination.

A Receiver Operating Characteristic (ROC) curve is a graphical representation used in medical decision-making and statistical analysis to illustrate the performance of a binary classifier system, such as a diagnostic test or a machine learning algorithm. It's a plot that shows the tradeoff between the true positive rate (sensitivity) and the false positive rate (1 - specificity) for different threshold settings.

The x-axis of an ROC curve represents the false positive rate (the proportion of negative cases incorrectly classified as positive), while the y-axis represents the true positive rate (the proportion of positive cases correctly classified as positive). Each point on the curve corresponds to a specific decision threshold, with higher points indicating better performance.

The area under the ROC curve (AUC) is a commonly used summary measure that reflects the overall performance of the classifier. An AUC value of 1 indicates perfect discrimination between positive and negative cases, while an AUC value of 0.5 suggests that the classifier performs no better than chance.

ROC curves are widely used in healthcare to evaluate diagnostic tests, predictive models, and screening tools for various medical conditions, helping clinicians make informed decisions about patient care based on the balance between sensitivity and specificity.

Selenium is a trace element that is essential for the proper functioning of the human body. According to the medical definitions provided by the National Institutes of Health (NIH), selenium is a component of several major metabolic pathways, including thyroid hormone metabolism, antioxidant defense systems, and immune function.

Selenium is found in a variety of foods, including nuts (particularly Brazil nuts), cereals, fish, and meat. It exists in several forms, with selenomethionine being the most common form found in food. Other forms include selenocysteine, which is incorporated into proteins, and selenite and selenate, which are inorganic forms of selenium.

The recommended dietary allowance (RDA) for selenium is 55 micrograms per day for adults. While selenium deficiency is rare, chronic selenium deficiency can lead to conditions such as Keshan disease, a type of cardiomyopathy, and Kaschin-Beck disease, which affects the bones and joints.

It's important to note that while selenium is essential for health, excessive intake can be harmful. High levels of selenium can cause symptoms such as nausea, vomiting, hair loss, and neurological damage. The tolerable upper intake level (UL) for selenium is 400 micrograms per day for adults.

Tissue distribution, in the context of pharmacology and toxicology, refers to the way that a drug or xenobiotic (a chemical substance found within an organism that is not naturally produced by or expected to be present within that organism) is distributed throughout the body's tissues after administration. It describes how much of the drug or xenobiotic can be found in various tissues and organs, and is influenced by factors such as blood flow, lipid solubility, protein binding, and the permeability of cell membranes. Understanding tissue distribution is important for predicting the potential effects of a drug or toxin on different parts of the body, and for designing drugs with improved safety and efficacy profiles.

The cell nucleus is a membrane-bound organelle found in the eukaryotic cells (cells with a true nucleus). It contains most of the cell's genetic material, organized as DNA molecules in complex with proteins, RNA molecules, and histones to form chromosomes.

The primary function of the cell nucleus is to regulate and control the activities of the cell, including growth, metabolism, protein synthesis, and reproduction. It also plays a crucial role in the process of mitosis (cell division) by separating and protecting the genetic material during this process. The nuclear membrane, or nuclear envelope, surrounding the nucleus is composed of two lipid bilayers with numerous pores that allow for the selective transport of molecules between the nucleoplasm (nucleus interior) and the cytoplasm (cell exterior).

The cell nucleus is a vital structure in eukaryotic cells, and its dysfunction can lead to various diseases, including cancer and genetic disorders.

2013, "Introduction". Achard V, Putora PM, Omlin A, Zilli T, Fischer S (2022). "Metastatic Prostate Cancer: Treatment Options ... of those with metastatic prostate cancer - are the primary cause of symptoms and death from metastatic prostate cancer. ... 2021, "Metastatic hormone-sensitive prostate cancer". "Hormone Therapy for Prostate Cancer". American Cancer Society. 9 August ... 2021, "Metastatic castration-resistant prostate cancer". Teo, Rathkopf & Kantoff 2019, "Management of Metastatic Castration- ...
In addition to CPA and other medications used to treat prostate cancer, metastatic prostate cancer is itself a risk factor for ... A meta-analysis of high-dose CPA for the treatment of prostate cancer in men found that CPA was associated with a slight excess ... Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU Int. 91 (5): 455-61. ... Gillatt D (August 2006). "Antiandrogen treatments in locally advanced prostate cancer: are they all the same?". J. Cancer Res. ...
... orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate". ... April 2004). "Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European ... Denis L (May 1998). "European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996". ... November 2003). "Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study ...
Venner P (1992). "Megestrol acetate in the treatment of metastatic carcinoma of the prostate". Oncology. 49 Suppl 2 (2): 22-7. ... and in the treatment of androgen-dependent conditions like enlarged prostate and prostate cancer in men and acne and hirsutism ... preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver ... It is used at dosages of 50 to 100 mg/day in the treatment of prostate diseases. Similarly to cyproterone acetate (CPA), CMA ...
Welch HG, Gorski DH, Albertsen PC (2015). "Trends in Metastatic Breast and Prostate Cancer-Lessons in Cancer Dynamics". N Engl ... and the use of dietary treatment to manage autism. Gorski is a prolific blogger. In 2004, he began writing a blog entitled ... and cancer research and treatment. In 2010, Gorski recounted how members of the anti-vaccine blog Age of Autism wrote to the ... and in determining the potential of combinational therapies to allow reduction of the dosages in toxic conventional treatments ...
Vogelzang NJ (September 2012). "Enzalutamide--a major advance in the treatment of metastatic prostate cancer". The New England ... These medications are primarily used in the treatment of prostate cancer, but are also used for other purposes such as the ... 5α-Reductase inhibitors are used primarily in the treatment of benign prostatic hyperplasia, a condition in which the prostate ... Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for ...
"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1 ... "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1 ... First one conducted in Moffitt Cancer Center on patients with metastatic castrate-resistant prostate cancer showed outcomes ... "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67-78 ...
Vogelzang NJ (September 2012). "Enzalutamide-a major advance in the treatment of metastatic prostate cancer". The New England ... the most commonly prescribed treatment for metastatic castration resistant prostate cancer: bicalutamide. That was sold as ... "Enzalutamide for the treatment of metastatic castration-resistant prostate cancer". Drug Design, Development and Therapy. 9: ... Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer.: 488 As antiandrogens, the SAAs ...
Treatment options for patients with metastatic prostate cancer". Investigational New Drugs. 20 (2): 183-194. doi:10.1023/A: ... cancer drug resistance to develop novel treatment strategies for patients with advanced prostate cancer and other metastatic ... Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer". Clinical ... Figg is also the Co-Chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National ...
... in the treatment of stage D2 metastatic prostate cancer (mPC), and as a monotherapy at a dosage of 150 mg/day for the treatment ... Vogelzang NJ (September 2012). "Enzalutamide--a major advance in the treatment of metastatic prostate cancer". The New England ... has become the mainstay of treatment for prostate cancer. Although ADT can shrink or stabilize prostate tumors and hence ... Bicalutamide is approved for use in prostate cancer at an oral dose of 50 mg daily, but has been used in the treatment of ...
... is indicated in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer ... "Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate ... "The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer". Therapeutic Advances in Urology. ... a novel second-line treatment for metastatic castration-resistant prostate cancer". Drug Design, Development and Therapy. 5: ...
... of the combinational treatment of Custirsen and chemotherapy as a treatment of metastatic-castration-resistant prostate cancer ... In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. Custirsen was developed through a ... However, researchers suggested further studies into patients with metastatic-castration-resistant prostate cancer whom have ... April 2017). "Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate ...
Therefore, blocking these androgens can provide powerful treatment for prostate cancer, especially metastatic disease. Normally ... Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing ... Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. pp. 279-280. ... The dosages used are lower than those used in the treatment of prostate cancer. Although flutamide continues to be used for ...
ISBN 978-0-397-51418-2. High-dose estrogen therapy was the first medical treatment for metastatic prostate and breast carcinoma ... It was first found to be effective in the treatment of prostate cancer in 1941 and in the treatment of breast cancer in 1944. ... Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for ... Oral HDE for prostate cancer with diethylstilbestrol was used widely in men with prostate cancer until the mid-1960s, when it ...
2005 Guidelines:Prostate cancer/Management/Locally advanced and metastatic/Biochemical relapse alternative causes, and ... in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not ... It is used to detect metastatic progression of the prostate cancer. Biochemical recurrence Defining Biochemical Recurrence of ... implications for treatment Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a ...
IL-30 promotes prostate cancer stem-like cells viability, self-renewal ability, tumorigenic and metastatic potential, it ... Both of those functions could potentially be beneficial in treatment of some autoimmune diseases. It has been indicated that IL ... IL30 plays an important role in regulating prostate cancer stem-like cell behavior and metastatic potential. Hence targeting IL ... IL-30 was found to be expressed in prostate and breast cancer by both cancer cells and tumor- or LN-infiltrating leukocytes, ...
... was approved for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in 2010. ... autologous cellular immunotherapy for the treatment of metastatic castrate-resistant prostate cancer". Vaccine. 30 (29): 4394- ... Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: have disease ... vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer ...
"Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta- ... Prostate rectum spacers should be compatible with all prostate cancer radiotherapy treatments including 3D conformal, IMRT and ... Surgical removal of the prostate, or prostatectomy, is a common treatment either for early-stage prostate cancer or for cancer ... Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy - including brachytherapy (prostate ...
This palliative treatment for breast and prostate cancers metastatic to the bones was only approved by the Food and Drug ... The therapeutic use of 89Sr was only approved in 1993 for the palliative treatment of breast and prostate cancers metastatic to ... treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone". RadioGraphics. 9 (2): ... "Treatment of metastatic bone pain with strontium-89". International Journal of Radiation Applications and Instrumentation. Part ...
2008). "Circulating Tumor Cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate ... In studies done on prostate, breast and colon cancer patients, median survival of metastatic patients with positive samples is ... CellSearch circulating tumor cell kit premarket notification-expanded indications for use-metastatic prostate cancer" (PDF). ... phenotypes in metastatic castration-resistant prostate cancer (mCRPC)". Journal of Clinical Oncology. 32 (4_suppl): 209. doi: ...
CAM2032 is a new drug being developed for long-term treatment of prostate cancer, with development also initiated for ... Camurus has completed a Phase IIa clinical trial of CAM2032 in patients with advanced metastatic prostate cancer. CAM2038 ... The treatment was reported to be safe and well tolerated. The product is registered as a medical device in a wide range of ... Oral mucositis is a severe side-effect of chemotherapy or radiotherapy during cancer treatment, and is often a dose-limiting ...
Recently[when?], alpha emitter actinium-225 has been tested in studies as a cancer treatment for metastatic prostate cancer. Ac ... Parker, C; Nilsson, S; Heinrich, D (18 July 2013). "Alpha emitter radium-223 and survival in metastatic prostate cancer". New ... At the same time, the half-life is long enough to allow for handling and shipping the seeds to a cancer treatment center at any ... Radium-224 is a radioactive atom that is utilized as a source of alpha radiation in a newly[when?] developed cancer treatment ...
... has also been studied for the treatment of prostate cancer and HER2-negative metastatic breast cancer. Vadimezan was ...
Vladimir Mouraviev, M.D (1997). "THE GUIDED CRYOIMMUNOTHERAPY IN THE ADVANCED PROSTATE CANCER". Tumor treatment through ... colloque Metastatic Bone Disease: An Integrated Approach to Patient Care Musculoskeletal Cancer Surgery: Treatment of Sarcomas ... is an oncological treatment for various cancers that combines cryoablation of tumor with immunotherapy treatment. In-vivo ... McCarthy EF (2006). "The Toxins of William B. Coley and the Treatment of Cancer". Iowa Orthop J. 26: 154-8. PMC 1888599. PMID ...
... in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment". Clinical Genitourinary Cancer. ... Overall, CYP17A1 is an important target for inhibition in the treatment of prostate cancer because it produces androgen that is ... In the 2010s it underwent various phases of clinical studies and preclinical models as a drug against prostate cancer or breast ... ISBN 1-4160-2328-3. Vasaitis TS, Bruno RD, Njar VC (May 2011). "CYP17 inhibitors for prostate cancer therapy". The Journal of ...
"DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate". Urology ... treatment of prostate cancer and breast cancer, and other uses. By 2007, it was only used in the treatment of prostate cancer ... In the 1990s, the only approved indications for DES were treatment of advanced prostate cancer and treatment of advanced breast ... University of Chicago found estradiol benzoate and DES to be the first effective drugs for the treatment of metastatic prostate ...
... has been developed for the treatment of men with castrate-refractory, metastatic prostate cancer for several ... The only Phase III trial with satraplatin (SPARC Trial) was conducted in pretreated metastatic castrate-resistant prostate ... is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer ... The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound ...
... metastatic breast cancer and prostate cancer. Other tyrosine kinase inhibitor drugs that are in clinical trials include ... One notable example is dasatinib which has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia ... Lyn and Fgr are highly expressed in malignant prostate cells compared to normal prostate cells. When the primary prostate cells ... So the use of a tyrosine kinase inhibitor is a possible way of reducing the progression of prostate cancers. A number of ...
"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer". ... In both prostate and breast cancer, denosumab has been shown to reduce cancer treatment-induced bone loss. The HALT-prostate ... Coleman RE (2001). "Metastatic bone disease: clinical features, pathophysiology and treatment strategies". Cancer Treat. Rev. ... In this trial, they used 1901 bone metastatic prostate patients whom were also suffering with other complication of bone ...
... for the treatment of adults with metastatic colorectal cancer for whom treatment based on oxaliplatin has not worked or the ... Aflibercept was also in a phase III trial for hormone-refractory metastatic prostate cancer as of April 2011[update]. A 2016 ... is indicated for the treatment of people with metastatic colorectal cancer that is resistant to or has progressed following an ... though the authors note that the aflibercept treatment regimen has the potential to reduce treatment burden and risks from ...
Treatment for metastatic or advanced prostate cancer can help to reduce symptoms and help you feel better. ... Treatment for metastatic prostate cancer. Treatment for metastatic or advanced prostate cancer can help to reduce symptoms, ... Treatment options for metastatic prostate cancer. Treatment for metastatic prostate cancer can help to reduce symptoms, make ... Home About cancer Prostate cancer Metastatic prostate cancer Treatment for metastatic prostate cancer ...
... requires systematic treatments. These multiple therapies affect overall survival and reduce serious adverse events (SAE). They ... Metastatic Castration-Sensitive Prostate Cancer (mCSPC) requires systematic treatments. These multiple therapies affect overall ... A total of 7 trials comparing six treatments for 7287 patients were eligible. They got randomized to evaluate the effectiveness ...
Adding abiraterone acetate to androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer. ... has long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate- ... and had previously undergone local treatment. In the other study, most men had not had previous treatment to their prostate. ... This corresponds to 120 fewer death from prostate cancer per 1000 men with hormone-sensitive metastatic prostate cancer (95% CI ...
... high volume or high-risk de novo metastatic disease, ENZAMET trial, ARASENS trial, early initiation of AR pathway inhibitors, ... metastatic hormone-sensitive prostate cancer (mHSPC), ADT plus an AR pathway inhibitor, docetaxel in triplet therapy, ... From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & ... So I wanted to talk with you two about triplet therapy in metastatic hormone sensitive prostate cancer and all the new data ...
... provided statistically significant overall survival benefit and consistent safety profile in patients with advanced prostate ... About Metastatic Castration-Sensitive Prostate Cancer. Metastatic castration-sensitive prostate cancer, also known as ... as a Category 1 Preferred treatment option for patients with non-metastatic (M0) castration-resistant prostate cancer and a PSA ... as a Category 1 Preferred treatment option for patients with metastatic (M1) castration-naive prostate cancer. ‡4 The American ...
Treatment Algorithm for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) CUA Tool Card & Treatment ... Algorithm for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). PRINTABLE VERSIONS AVAILABLE. ... The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never ... The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot ...
... and treatment of metastatic and advanced prostate cancer. The earlier definition of advanced disease (bone metastasis and soft- ... ADT is an option in stage III prostate cancer and is the mainstay of treatment for metastatic prostate cancer. [3] ADT provides ... What is metastatic and advanced prostate cancer?. What is included in patient education about metastatic and advanced prostate ... encoded search term (Metastatic and Advanced Prostate Cancer) and Metastatic and Advanced Prostate Cancer What to Read Next on ...
"Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer" 9 (2014). Wang, Dian et al. "Type ... 2014). Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer. 9. Wang, Dian et al. " ... Title : Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer Personal Author(s) : Wang, ... Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer. ...
Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a ... Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. A second ... A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer ... The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one ...
... trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment ... Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer ... Treatment. This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer. ... Metastatic Castration Resistant Prostate Cancer Clinical Trial. About the Study. Metastatic. prostate cancer that no longer ...
Prior chemotherapy treatment for castration-sensitive or castration-resistant prostate cancer (docetaxel or cabazitaxel).. ... Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer. A Multi-Center, Open-Label, Randomized Phase 3 Trial ... Circulating Tumor DNA as an Independent Predictor of treatment response in Metastatic Melanoma Patients Treated with ... Prior treatment with radioligand therapy including other lutetium-labeled compounds.. Prior treatment with radium-223 (Xofigo) ...
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Metastatic Castration-Resistant ... It is under development for the treatment of unresectable and metastatic conventional chondrosarcoma, metastatic triple- ... metastatic castration resistant prostate cancer, pancreatic cancer, metastatic uveal melanoma and gynecological malignancies ... Belinostat by Acrotech Biopharma for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval. Brought ...
N2 - Objective: Metastatic prostate cancer (mPCa) patients often make complicated treatment decisions, yet decision aids to ... AB - Objective: Metastatic prostate cancer (mPCa) patients often make complicated treatment decisions, yet decision aids to ... What do men with metastatic prostate cancer consider when making treatment decisions? A mixed-methods study. In: Patient ... What do men with metastatic prostate cancer consider when making treatment decisions? A mixed-methods study. / Oswald, Laura B ...
What does this mean going forward? Yet again, this represents a possible paradigm shift in the treatment of metastatic prostate ... Cite this: New Data Change Metastatic Prostate Cancer Treatment Paradigm - Medscape - Aug 14, 2017. ... Todays topic is the management of newly diagnosed metastatic prostate cancer.. At the 2017 annual meeting of the American ... For now, however, a man with newly diagnosed metastatic prostate cancer should be presented both sets of data and, along with ...
The study identifies promising new targets for the treatment of lethal metastatic PCa and has been published in the leading ... of the Aberger group has identified a novel tumor suppressor function of the STAT3 transcription factor in metastatic prostate ... In contrast, conditional activation of Stat3 prevented metastasis via Lkb1/AMPK activation, as did treatment with the approved ...
... acetate in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate ... FDA; metastatic prostate cancer. FDA; metastatic prostate cancer. "LATITUDE was a large global trial which produced impressive ... More than 330,000 patients worldwide, including 113,000 in the U.S., have received treatment with it, and it was the number one ... acetate plus prednisone could become a standard of care for patients with metastatic high-risk castration-sensitive prostate ...
Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single ... Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single ... Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single ... Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single ...
AIHTA - Publications - Search - Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate ... Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously ...
Radiotherapy is a treatment that uses radioactivity to control cancer and relieve symptoms such as pain ... Planning your treatment. Before radiotherapy is given, the radiation oncologist will plan how best to give your treatment. You ... Coping with side-effects of metastatic prostate cancer. Metastatic prostate cancer can cause issues such as urinary problems, ... Radioactive injections for metastatic prostate cancer. Radioactive injections can help with symptoms of prostate cancer that ...
Metastatic Prostate Cancer: Current Treatment Advances. Part I of Living with Metastatic Prostate Cancer ... Oct31Metastatic Prostate Cancer: Current Treatment AdvancesPart I of Living with Metastatic Prostate Cancer. ... Metastatic Triple Negative Breast Cancer: Strategies to Cope. Part I of Living with Metastatic Triple Negative Breast Cancer ... Oct25Metastatic Triple Negative Breast Cancer: Strategies to CopePart I of Living with Metastatic Triple Negative Breast Cancer ...
Metastatic Prostate Cancer: Current Treatment Advances. Part I of Living with Metastatic Prostate Cancer ... Oct31Metastatic Prostate Cancer: Current Treatment AdvancesPart I of Living with Metastatic Prostate Cancer. ... Metastatic Triple Negative Breast Cancer: Strategies to Cope. Part I of Living with Metastatic Triple Negative Breast Cancer ... Oct25Metastatic Triple Negative Breast Cancer: Strategies to CopePart I of Living with Metastatic Triple Negative Breast Cancer ...
What are the treatment options for metastatic castration-resistant prostate cancer anno 2023?. By: D. Schrijvers MD, PhD ... Journal issues > Issue 1, January 2023 > What are the treatment options for metastatic castration-resistant prostate cancer ... Patients developing metastatic castration-resistant prostate cancer are in most instances pre-treated with androgen deprivation ... treatment and a newer androgen receptor-targeting agent in the metastatic castration-sensitive setting. ...
Novel therapies are changing treatment paradigms in metastatic prostate cancer Metastatic castration-resistant prostate cancer ... The management of metastatic GIST: current standard and investigational therapeutics Gastrointestinal stromal tumor (GIST) is ... Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions Recent years have ... Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + ...
To be presented by Robert Fine, MD, Director, Medical Oncology, The Pancreas Center and Prostate Cancer Center; Professor of ...
Prostate cancer continues to be a leading cause of cancer-related death worldwide and is the most common malignancy among ... Trending In Prostate Cancer: Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?. Prostate ... Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer-A Mechanistic Perspective. Copy Link ... Androgen deprivation therapy (ADT) has been the cornerstone of the treatment of metastatic prostate carcinoma for over 70 years ...
Treatment of Primary Tumour in Prostate Cancer Metastatic Disease: A Different Method of Clinical Management. (2015) Intl J ... Treatment of Primary Tumour in Prostate Cancer Metastatic Disease, A Different Method of Clinical Management. ... RP has a place in the treatment of locally advanced prostate cancer is supported by a few studies recently conducted in the ... RP has a place in the treatment of locally advanced prostate cancer is supported by a few studies recently conducted in the ...
2013, "Introduction". Achard V, Putora PM, Omlin A, Zilli T, Fischer S (2022). "Metastatic Prostate Cancer: Treatment Options ... of those with metastatic prostate cancer - are the primary cause of symptoms and death from metastatic prostate cancer. ... 2021, "Metastatic hormone-sensitive prostate cancer". "Hormone Therapy for Prostate Cancer". American Cancer Society. 9 August ... 2021, "Metastatic castration-resistant prostate cancer". Teo, Rathkopf & Kantoff 2019, "Management of Metastatic Castration- ...
This could implicate the critical role of early diagnosis in the treatment of SCPCa despite its aggressive nature. ... Complete Chemotherapeutic Regression of a Non-Metastatic Case of Primary Pure Small Cell Carcinoma of the Prostate Special ... Complete Chemotherapeutic Regression of a Non-Metastatic Case of Primary Pure Small Cell Carcinoma of the Prostate. Curr Urol 1 ... Pure small cell carcinoma of the prostate (SCPCa) is a very rare condition usually with poor survival after diagnosis. It seems ...
Update : New first-line treatment option for metastatic prostate cancer. Most relevant for: People with metastatic castration ... Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer. Most relevant for: People with ... metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23) ... as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23) ...
  • Treatment for metastatic or advanced prostate cancer can help to reduce symptoms, make you feel better and help you to live longer. (cancerresearchuk.org)
  • This section is about treatment for prostate cancer that has spread to another part of the body. (cancerresearchuk.org)
  • We have separate information about treatment for cancer that hasn't spread to another part of the body. (cancerresearchuk.org)
  • You might have hormone therapy for prostate cancer that has spread to another part of your body. (cancerresearchuk.org)
  • Chemotherapy is a common treatment for metastatic prostate cancer. (cancerresearchuk.org)
  • You might have radiotherapy for prostate cancer that has spread to different parts of the body. (cancerresearchuk.org)
  • Radiotherapy uses high energy waves similar to x-rays to kill prostate cancer cells. (cancerresearchuk.org)
  • Symptoms of metastatic prostate cancer include bone pain, problems passing urine and tiredness. (cancerresearchuk.org)
  • Prostate cancer can sometimes press on the tube that carries urine from the bladder. (cancerresearchuk.org)
  • Find out about the latest research into the treatment of prostate cancer. (cancerresearchuk.org)
  • Metastatic Castration-Sensitive Prostate Cancer (mCSPC) requires systematic treatments. (physiciansweekly.com)
  • The aim of this review was to find out what the effect of adding abiraterone was, in men with prostate cancer, who were receiving and still responding to hormone therapy. (cochrane.org)
  • Abiraterone acetate is a medication that blocks the effect of male sex hormones, and thereby, slows down prostate cancer growth. (cochrane.org)
  • More than 15% of men diagnosed with prostate cancer present with disease that has spread beyond the prostate. (cochrane.org)
  • Another 15% to 30% of men who undergo primary treatment will experience a return of their cancer. (cochrane.org)
  • Recent studies have looked at whether drugs that block the growth of prostate cancer cells, such as abiraterone acetate, can improve how men do. (cochrane.org)
  • In one of the studies, most of the included men had high risk prostate cancer, and had previously undergone local treatment. (cochrane.org)
  • The certainty of the evidence was moderate for quality of life, cancer-specific survival (time to death from prostate cancer), time to disease progression, and discontinued treatment due to adverse events. (cochrane.org)
  • Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. (cochrane.org)
  • To assess the effects of early abiraterone acetate, in combination with systemic ADT, for newly diagnosed metastatic hormone-sensitive prostate cancer. (cochrane.org)
  • We included randomized trials, in which men diagnosed with hormone-sensitive prostate cancer were administered abiraterone acetate and prednisolone with ADT or ADT alone. (cochrane.org)
  • Alicia Morgans converses with Matthew Smith and Kim Chi about the application of triplet therapy in metastatic hormone sensitive prostate cancer (mHSPC). (urotoday.com)
  • So I wanted to talk with you two about triplet therapy in metastatic hormone sensitive prostate cancer and all the new data that's coming out and what the implications of that data are for our clinical practices. (urotoday.com)
  • RARITAN, N.J., February 8, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. (jnj.com)
  • Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST). (jnj.com)
  • The TITAN final analysis further confirms that treatment with apalutamide can prolong overall survival and offer a clear long-term clinical benefit and established safety profile for patients with metastatic prostate cancer who are starting androgen deprivation therapy," said Dr. Kim Chi, Medical Oncologist at BC Cancer - Vancouver and principal investigator of the TITAN study. (jnj.com)
  • The TITAN final analysis data confirm the long-term clinical benefit and consistent safety profile of ERLEADA ® plus ADT without a compromise in health-related quality of life," said Mary Guckert, RN, MSN, Vice President, Development Leader, Prostate Cancer, Janssen Research & Development, LLC. (jnj.com)
  • The results show the consistency and durability of ERLEADA ® across advanced prostate cancer and underscore how ERLEADA ® can fulfill a critical need. (jnj.com)
  • ERLEADA ® has shown a statistically significant improvement in OS with a consistent safety profile in both approved indications of mCSPC (TITAN) and non-metastatic castration-resistant prostate cancer or nmCRPC (SPARTAN). (jnj.com)
  • While advanced prostate cancer was historically defined as distant metastatic disease, the current definition includes disease stages that range from recurrence of prostate-specific antigen (PSA) elevation after failure of local treatment to widespread metastasis. (medscape.com)
  • High-grade prostate cancer, particularly the percentage presence of Gleason grades 4 and 5, is associated with adverse pathologic findings and disease progression. (medscape.com)
  • Although cure of metastatic prostate cancer remains elusive, continuous advances in management have improved the outlook in these patients. (medscape.com)
  • For patient education information, see Prostate Cancer . (medscape.com)
  • Prostate cancer is the most commonly diagnosed cancer in men in the United States, and the second leading cause of cancer-related deaths. (medscape.com)
  • prostate cancer is most often diagnosed in men age 65 to 74 years, and the median age at diagnosis is 67 years. (medscape.com)
  • [ 6 ] Since the advent of prostate-specific antigen (PSA) screening, prostate cancer is being detected and treated earlier. (medscape.com)
  • Overall, incidence rates of prostate cancer began declining in 2000. (medscape.com)
  • Since 2014, however, the overall incidence has increased by 3% per year, and diagnoses of advanced-stage prostate cancer have increased by about 5% per year. (medscape.com)
  • The increase in metastatic prostate cancer was greatest (92%) in men aged 55-69 years. (medscape.com)
  • The 5-year relative survival rate for localized and regional prostate cancer is 100%, compared with 34.1% for metastatic cases. (medscape.com)
  • Since the early 1990s, prostate cancer death rates have been decreasing in men of all races and ethnicities. (medscape.com)
  • [ 5 ] Prostate cancer tends to not only be more aggressive and progressive in Black men, leading to advanced disease, but to also be of a higher grade at diagnosis. (medscape.com)
  • The most common manifestation of advanced prostate cancer is a rising prostate-specific antigen (PSA) level after failure of initial local therapy. (medscape.com)
  • We sought to describe patterns of initial radiotherapy among non-metastatic prostate cancer (PC) patients by recurrence risk groups. (cdc.gov)
  • The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). (uclahealth.org)
  • Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. (uclahealth.org)
  • 1 prior taxane-containing regimen for prostate cancer. (uclahealth.org)
  • Another hematologic or solid tumor ≥ stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. (uclahealth.org)
  • Use of products that have published anti-prostate cancer activity or are known to decrease PSA. (uclahealth.org)
  • This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer. (facingourrisk.org)
  • Prior chemotherapy treatment for castration-sensitive or castration-resistant prostate cancer (docetaxel or cabazitaxel). (orlandohealth.com)
  • Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). (pharmaceutical-technology.com)
  • According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
  • What do men with metastatic prostate cancer consider when making treatment decisions? (northwestern.edu)
  • Objective: Metastatic prostate cancer (mPCa) patients often make complicated treatment decisions, yet decision aids to facilitate shared decision-making for mPCa are uncommon. (northwestern.edu)
  • Methods: Using an exploratory sequential approach, we conducted three focus groups with 14 advanced prostate cancer survivors (n=5, n=3, n=6 in each group) to identify considerations for making treatment decisions. (northwestern.edu)
  • Dive into the research topics of 'What do men with metastatic prostate cancer consider when making treatment decisions? (northwestern.edu)
  • Today's topic is the management of newly diagnosed metastatic prostate cancer . (medscape.com)
  • Yet again, this represents a possible paradigm shift in the treatment of metastatic prostate cancer , because these data show that adding early use of abiraterone acetate with prednisone to ADT can help patients. (medscape.com)
  • For now, however, a man with newly diagnosed metastatic prostate cancer should be presented both sets of data and, along with his urologist, evaluate which of the two will be the best approach for him. (medscape.com)
  • Cite this: New Data Change Metastatic Prostate Cancer Treatment Paradigm - Medscape - Aug 14, 2017. (medscape.com)
  • An international research team led by CCS associate member Prof. Lukas Kenner (Medical University of Vienna, Austria) in collaboration with the CCS lab of the Aberger group has identified a novel tumor suppressor function of the STAT3 transcription factor in metastatic prostate cancer (mPCa) development. (cancercluster-salzburg.at)
  • The study identifies promising new targets for the treatment of lethal metastatic PCa and has been published in the leading cancer journal Molecular Cancer (Impact Factor: 37.3). (cancercluster-salzburg.at)
  • The FDA has approved a new indication for abiraterone acetate in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). (nursingcenter.com)
  • With [this] approval, abiraterone acetate plus prednisone could become a standard of care for patients with metastatic high-risk castration-sensitive prostate cancer. (nursingcenter.com)
  • Treatment with docetaxel in combination with prednisone is the standard first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). (vub.be)
  • Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. (aihta.at)
  • Radiotherapy is a treatment that uses radioactivity to control cancer and relieve symptoms such as pain. (cancer.ie)
  • Radioactive liquid injections to help with prostate cancer that has spread to the bones. (cancer.ie)
  • Metastatic prostate cancer can cause issues such as urinary problems, bone pain and weakened bones. (cancer.ie)
  • Advice and information on treatments and activities that go along with standard cancer medical treatments. (cancer.ie)
  • Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. (touchoncology.com)
  • For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. (touchoncology.com)
  • Prostate cancer continues to be a leading cause of cancer-related death worldwide and is the most common malignancy among American men after skin cancer.1 Based on estimates by the American Cancer Society, approximately 241,740 new cases are expected to be diagnosed and 28,170 men are expected to die from the disease in the US in 2012. (touchoncology.com)
  • Approximately one in six men will be diagnosed with prostate cancer during their lifetime. (touchoncology.com)
  • 1 Although patients with recurrent disease initially respond to androgen deprivation therapy (ADT), most will go on to develop castration-resistant prostate cancer (CRPC) in which the disease becomes refractory to traditional hormone therapies and cancer growth continues despite castrate levels of testosterone. (touchoncology.com)
  • While the five-year survival rate for men with advanced prostate cancer has increased from 69 % in the late 1970s to 100 % in the 2000s, 2 there have traditionally been no successful treatments that improved median overall survival in the subset of patients with CRPC. (touchoncology.com)
  • The androgen signaling pathway has recently been found to be critical in both hormone-sensitive prostate cancer and CRPC. (touchoncology.com)
  • What are the treatment options for metastatic castration-resistant prostate cancer anno 2023? (bjmo.be)
  • Patients developing metastatic castration-resistant prostate cancer are in most instances pre-treated with androgen deprivation treatment and a newer androgen receptor-targeting agent in the metastatic castration-sensitive setting. (bjmo.be)
  • RP has a place in the treatment of locally advanced prostate cancer is supported by a few studies recently conducted in the United States [5] . (ommegaonline.org)
  • Heidenreich, A., Pfister, D., Porres, D. Cytoreductive Radical Prostatectomy in Patients with prostate cancer and low volume skeletal metastases - results of a feasibility and case-control study. (ommegaonline.org)
  • Van Den Ouden, D., Hop, W.C., Schroder, F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. (ommegaonline.org)
  • Lange, P.H. Is Surgery Good for Advanced Localised Prostate Cancer? (ommegaonline.org)
  • Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database. (ommegaonline.org)
  • Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system just below the bladder. (wikipedia.org)
  • Early prostate cancer usually causes no symptoms. (wikipedia.org)
  • Most cases of prostate cancer are detected after screening tests - typically blood tests for levels of prostate-specific antigen (PSA) - indicate unusual growth of prostate tissue due to prostate tumors or other conditions affecting the prostate. (wikipedia.org)
  • Medical imaging is performed to look for cancer spread outside the prostate. (wikipedia.org)
  • Those whose cancer returns or has already spread beyond the prostate, are treated with hormone therapy that reduces levels of the male sex hormones that prostate cells need in order to survive. (wikipedia.org)
  • This halts tumor growth for a while, but eventually cancer cells grow resistant to this treatment. (wikipedia.org)
  • This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. (wikipedia.org)
  • Prostate cancer prognosis depends on how far the cancer has spread at diagnosis. (wikipedia.org)
  • The risk of developing prostate cancer increases with age, and the average age of diagnosis is 67. (wikipedia.org)
  • Those with a family history of prostate cancer are more likely to have prostate cancer themselves. (wikipedia.org)
  • Each year 1.2 million cases of prostate cancer are diagnosed, and 350,000 die of the disease, making it the second-leading cause of cancer and cancer death in men. (wikipedia.org)
  • One in eight men is diagnosed with prostate cancer in his lifetime, while one in forty dies of the disease. (wikipedia.org)
  • Major work describing prostate tumors' unusual need for male sex hormones, and the subsequent development of hormone therapies for prostate cancer, earned Charles B. Huggins the 1966 Nobel Prize in Physiology or Medicine, and Andrzej W. Schally the 1977 Nobel Prize in Physiology or Medicine. (wikipedia.org)
  • Most cases of prostate cancer are diagnosed through screening tests, when tumors are too small to cause any symptoms. (wikipedia.org)
  • More than half of men over age 50 experience some form of urination problem, typically due to issues other than prostate cancer such as benign prostatic hyperplasia (non-cancerous enlargement of the prostate). (wikipedia.org)
  • Metastases can damage the bones around them, and around a quarter of those with metastatic prostate cancer develop a bone fracture. (wikipedia.org)
  • Prostate cancer screening searches for tumors in those without symptoms. (wikipedia.org)
  • This is typically done through blood tests for levels of the protein prostate-specific antigen (PSA), which are elevated in those with enlarged prostates, whether due to prostate cancer or benign prostatic hyperplasia. (wikipedia.org)
  • It seems to show different clinical features compared to other prostate cancer subtypes, specifically adenocarcinoma. (karger.com)
  • Our tools will help match you to hereditary cancer detection, prevention and treatment studies. (facingourrisk.org)
  • Learn about organizations we work with to advocate for greater awareness, broader access to care, and better treatment and prevention options for all those who are impacted by hereditary cancer. (facingourrisk.org)
  • Learn about health insurance coverage and financial assistance for genetic services, cancer screenings, treatment and more. (facingourrisk.org)
  • Get the latest on managing your symptoms, treatment options and living with Prostate Cancer. (everydayhealth.com)
  • Chemotherapy may be most effective at controlling metastatic prostate cancer when it's received as an initial treatment, rather than when the cancer becomes resistant to hormone therapy. (everydayhealth.com)
  • Hormone therapy, also known as androgen deprivation therapy (ADT), has long been the key treatment for metastatic prostate cancer. (everydayhealth.com)
  • It helps fight prostate cancer by temporarily cutting off the production of testosterone, which is known to fuel the cancer's growth. (everydayhealth.com)
  • Understand risk factors, signs, and complications of prostate cancer treatment. (everydayhealth.com)
  • Prostate Cancer Treatment: What Are Your Options? (everydayhealth.com)
  • Diagnosed With Metastatic Castration-Resistant Prostate Cancer: What's Next? (everydayhealth.com)
  • With metastatic castration-resistant prostate cancer (mCRPC), or hormone-refractory prostate cancer, your current therapy is no longer effective in controlling the disease. (everydayhealth.com)
  • Advanced metastatic prostate cancer can be treated with hormone therapy, chemotherapy, immunotherapy, and others, to help you live a longer, better life. (everydayhealth.com)
  • For men with BRCA-mutated metastatic castration-resistant prostate cancer, this new treatment option may significantly extend life. (everydayhealth.com)
  • Delayed testing and less access to tailored, advanced treatments drive higher mortality rates for Black men with prostate cancer compared to other men. (everydayhealth.com)
  • Survival rates over 15 years for low-risk prostate cancer were the same whether men chose active surveillance, radiation, or surgery. (everydayhealth.com)
  • If you've got advanced prostate cancer, odds are you'll be rotated through a series of treatments. (everydayhealth.com)
  • With nonmetastatic castration-resistant prostate cancer, the prostate cancer no longer responds to hormone therapy, also known as androgen deprivation therapy. (everydayhealth.com)
  • Prostate cancer remains the second leading cancer-related cause of death among men in the U.S., with up to one-third of patients developing metastatic disease. (drugsnews.net)
  • The ARASENS trial is the only randomized, phase III, multi-center, double-blind, trial which was prospectively designed to compare the use of a second-generation oral androgen receptor inhibitor Darolutamide plus ADT and chemotherapy Docetaxel to ADT plus Docetaxel ( a standard-of-care ) in metastatic hormone-sensitive prostate cancer. (drugsnews.net)
  • Secondary endpoints included time to castration-resistant prostate cancer, time to pain progression, time to first symptomatic skeletal event ( SSE ), time to initiation of subsequent anticancer therapy, all evaluated at 12‐week intervals, as well as adverse events as a measure of safety and tolerability. (drugsnews.net)
  • At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. (drugsnews.net)
  • Current treatment options for men with metastatic hormone-sensitive prostate cancer include hormone therapy, such as ADT, androgen receptor pathway inhibitors plus ADT or a combination of the Docetaxel chemotherapy and ADT. (drugsnews.net)
  • Despite these treatments, a large proportion of men with mHSPC will eventually experience progression to metastatic castration-resistant prostate cancer, a condition with high morbidity and limited survival. (drugsnews.net)
  • Darolutamide is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. (drugsnews.net)
  • Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer. (curetoday.com)
  • The treatment combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) demonstrated significant improvements regarding survival without disease progression for patients with metastatic castration-resistant prostate cancer (mCRPC), according to preliminary results from a phase 3 trial. (curetoday.com)
  • Cabometyx - a tyrosine kinase inhibitor which prevents cancer cell growth - is an oral tablet that has been approved in the United States to treat several diseases, including advanced renal cell carcinoma, locally advanced or metastatic differentiated thyroid cancer and hepatocellular carcinoma for patients who have previously been treated with Nexavar (sorafenib). (curetoday.com)
  • Castration-resistant prostate cancer is when prostate cancer continues growing even though the amount of testosterone in the body reduces to very low levels, according to the National Cancer Institute. (curetoday.com)
  • These positive findings from CONTACT-02 are highly encouraging given the need for additional, non-cytotoxic or non-chemotherapeutic treatment options for this patient population," Dr. Neeraj Agarwal, professor and presidential endowed chair of cancer research at Huntsman Cancer Institute, University of Utah and the global lead investigator of the trial, said in the press release. (curetoday.com)
  • Cabometryx) in combination with (Tecentriq) represents a potential new treatment modality for patients with metastatic castration-resistant prostate cancer, and we look forward to sharing the full data at a future medical meeting. (curetoday.com)
  • Preliminary findings from the trial established that the use of Cabometyx combined with Tecentriq has demonstrated a significant improvement in progression-free survival (PFS), defined as the period during and after treatment of cancer when the disease does not worsen, during the primary analysis. (curetoday.com)
  • Patients with metastatic castration-resistant prostate cancer face a poor prognosis of less than two years, and many who progress on a novel hormonal therapy are seeking alternative treatment options to chemotherapy," said Dr. Vicki L. Goodman, executive vice president, product development and medical affairs and chief medical officer of Exelixis, in the press release. (curetoday.com)
  • With prostate cancer confirmed as the second most commonly occurring cancer in men globally, the need for innovative new therapies is extensive, especially for those whose cancer has progressed to the metastatic castration-resistant form," said Howard Mayer, executive vice president and head of research and development at Ipsen, in the press release. (curetoday.com)
  • A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine. (news-medical.net)
  • The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. (news-medical.net)
  • In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. (news-medical.net)
  • By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes. (news-medical.net)
  • Unfortunately, only 20-30% patients with cancer respond to ICI treatment. (news-medical.net)
  • JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). (globaldata.com)
  • Prostate cancer has been the most common malignant tumor in men in Poland since 2016 and is the second cause of death in this group of patients. (journalsmededu.pl)
  • The basic method of treatment in patients with advanced prostate cancer is androgen deprivation therapy, however, over time, the tumor evolves into a castration-resistant form, which poses a significant threat to the patient's life. (journalsmededu.pl)
  • Prostate cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. (journalsmededu.pl)
  • 3. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. (journalsmededu.pl)
  • Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. (journalsmededu.pl)
  • Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. (journalsmededu.pl)
  • Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. (journalsmededu.pl)
  • Prostate Cancer Prostatic Dis. (journalsmededu.pl)
  • Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial Lancet Oncol. (journalsmededu.pl)
  • 10. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. (journalsmededu.pl)
  • Apalutamide and Overall Survival in Prostate Cancer. (journalsmededu.pl)
  • Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? (journalsmededu.pl)
  • External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. (journalsmededu.pl)
  • Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. (journalsmededu.pl)
  • Continuous treatment with the androgen receptor inhibitor enzalutamide, in combination with docetaxel, significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer whose disease progressed while receiving enzalutamide alone in the phase 3b PRESIDE clinical trial. (jhoponline.com)
  • and those who demonstrate fitness for combination therapy should be considered for continuous enzalutamide combination therapy, said Elisabeth I. Heath, MD, FACP, Hartmann Endowed Chair for Prostate Cancer Research, Karmanos Cancer Institute, Detroit, MI. (jhoponline.com)
  • The addition of docetaxel in men who are progressing on enzalutamide is a treatment option due to an increase in PFS in men with metastatic castration-resistant prostate cancer," Dr Heath said. (jhoponline.com)
  • Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. (bmj.com)
  • Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and locally advanced, unresectable stage 3 non-small cell lung cancer. (bmj.com)
  • Olaparib, a poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) in select patients with metastatic castration-resistant prostate cancer (mCRPC). (bmj.com)
  • Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer. (onclive.com)
  • Sabizabulin (VERU-111) was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer (mCRPC), according to phase 1b/2 clinical trial (NCT03752099) results presented at the 2021 ESMO Congress. (onclive.com)
  • Sabizabulin, an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer who failed an androgen receptor targeting agent. (onclive.com)
  • ASCO 2019: A Phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). (larvol.com)
  • Prostate cancer is most often diagnosed at the metastatic stage in many sub-Saharan African countries. (springeropen.com)
  • A family history of prostate cancer was noted in 21 patients. (springeropen.com)
  • The majority of patients had moderately differentiated prostate cancer. (springeropen.com)
  • Metastatic prostate cancer was most often symptomatic at the time of diagnosis. (springeropen.com)
  • The objectives of this study were to analyse the current management of metastatic prostate cancer with emphasis on its epidemiological, clinical, therapeutic and evolutionary aspects in a university hospital centre in our country. (springeropen.com)
  • A family history of prostate cancer was noted in 21 patients (7.6%) including 15 first-degree relatives and 6 s-degree relatives. (springeropen.com)
  • DelveInsight's, "Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2023," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. (giridihjournal.in)
  • It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including Metastatic Castration-Resistant Prostate Cancer clinical trials and nonclinical stage products. (giridihjournal.in)
  • It also covers the Metastatic Castration-Resistant Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. (giridihjournal.in)
  • Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). (giridihjournal.in)
  • Over 75+ Metastatic Castration-Resistant Prostate Cancer companies are evaluating 75+ Metastatic Castration-Resistant Prostate Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Castration-Resistant Prostate Cancer market would significantly increase market revenue. (giridihjournal.in)
  • In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) had been successfully dosed in Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). (giridihjournal.in)
  • In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer. (giridihjournal.in)
  • In May 2022, Janux Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Company's investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). (giridihjournal.in)
  • In June 2022, Blue Earth Therapeutics announced results from a series of preclinical analyses designed to evaluate the biodistribution and potential therapeutic efficacy of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in the treatment of prostate cancer preclinical models. (giridihjournal.in)
  • Prostate Cancer Statistics. (jamanetwork.com)
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. (jamanetwork.com)
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (jamanetwork.com)
  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (jamanetwork.com)
  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. (jamanetwork.com)
  • Zoledronic Acid Prostate Cancer Study Group. (jamanetwork.com)
  • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. (jamanetwork.com)
  • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. (jamanetwork.com)
  • A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. (jamanetwork.com)
  • Alpha emitter radium-223 and survival in metastatic prostate cancer. (jamanetwork.com)
  • Extracellular vesicles (EVs) and their mimics from mesenchymal stem cells (MSCs) are promising drug carriers to improve cancer treatment, but their application is hindered by donor variations and expansion limitations of conventional tissue-derived MSCs. (biomedcentral.com)
  • To circumvent these issues, we made EV-mimicking nanovesicles from standardized MSCs derived from human induced pluripotent stem cells (iPSCs) with a theoretically limitless expandability, and examined the targeting capacity of these nanovesicles to prostate cancer. (biomedcentral.com)
  • The selective uptake of fluorescently labeled nanovesicles by prostate cancer cells vs. non-tumor cells was examined with flow cytometry. (biomedcentral.com)
  • In mice carrying subcutaneous or bone metastatic PC3 prostate cancer, the biodistribution of systemically infused nanovesicles was examined with in vivo and ex vivo imaging of DiR and luminescent signals. (biomedcentral.com)
  • The cytotoxicities of nanovesicle-encapsulated docetaxel on docetaxel-sensitive and -resistant prostate cancer cells and non-tumor cells were examined in comparison with free docetaxel. (biomedcentral.com)
  • Therapeutic effects of nanovesicle-encapsulated docetaxel were examined in mice carrying subcutaneous or bone metastatic prostate cancer by monitoring tumor growth in comparison with free docetaxel. (biomedcentral.com)
  • iPSC-MSC nanovesicles are more selectively taken up by prostate cancer cells vs. non-tumor cells in vitro compared with EVs, membrane-only EV-mimetic nanoghosts and liposomes, which is not affected by storage for up to 6 weeks. (biomedcentral.com)
  • In mouse models of subcutaneous and bone metastatic PC3 prostate cancer, systemically infused nanovesicles accumulate in tumor regions with significantly higher selectivity than liposomes. (biomedcentral.com)
  • The loading of docetaxel into nanovesicles was efficient and did not affect the selective uptake of nanovesicles by prostate cancer cells. (biomedcentral.com)
  • The cytotoxicities of nanovesicle-encapsulated docetaxel are significantly stronger on docetaxel-resistant prostate cancer cells and weaker on non-tumor cells than free docetaxel. (biomedcentral.com)
  • In mouse models of subcutaneous and bone metastatic prostate cancer, nanovesicle-encapsulated docetaxel significantly decreased the tumor growth and toxicity to white blood cells compared with free docetaxel. (biomedcentral.com)
  • Our data indicate that EV-mimicking iPSC-MSC nanovesicles are promising to improve the treatment of metastatic prostate cancer. (biomedcentral.com)
  • Prostate cancer (PCa) is the second most frequent cancer in men and the fifth leading cause of death worldwide [ 1 ]. (biomedcentral.com)
  • 30%. Nanomedicine of PCa is a promising direction, but mainstream synthesized nanoparticles cannot efficiently deliver anti-cancer agents into metastatic PCa due to the lack of active targeting capacity and the limited uptake of these nanoparticles by PCa cells [ 3 , 4 ]. (biomedcentral.com)
  • Background: Historically, endocrine therapy was used in a range of scenarios in patients with rising PSA, both as a treatment for locally advanced non-metastatic prostate cancer and PSA recurrence following curative intended therapy. (lu.se)
  • Stage 4 prostate cancer is when cancer has spread from the prostate gland to distant parts of the body. (medicalnewstoday.com)
  • Prostate cancer risk increases with age. (medicalnewstoday.com)
  • According to the National Cancer Institute, an estimated 20% of people with a prostate will experience prostate cancer in their lifetimes. (medicalnewstoday.com)
  • While doctors can detect most forms of prostate cancer in their earliest stages, the condition can progress without symptoms. (medicalnewstoday.com)
  • The advanced stages of prostate cancer occur once it has spread to other parts of the body. (medicalnewstoday.com)
  • Prostate cancer does not often progress to an advanced stage as routine testing can help diagnose and treat the condition in its earlier, more manageable stages. (medicalnewstoday.com)
  • Prostate cancer rarely reaches an advanced stage. (medicalnewstoday.com)
  • Hormone therapy is a treatment option for advanced prostate cancer, as are chemotherapy and immunotherapy . (medicalnewstoday.com)
  • Prostate cancer can spread to the bones, brain, and lungs. (medicalnewstoday.com)
  • What is advanced prostate cancer? (medicalnewstoday.com)
  • Prostate cancer occurs when cells in the prostate gland mutate and start to develop abnormally, multiplying at an uncontrolled rate. (medicalnewstoday.com)
  • After a doctor diagnoses prostate cancer, they will test to see if the cancer has spread to other areas of the body, or how much of the body is affected. (medicalnewstoday.com)
  • The doctor will assign a stage of prostate cancer from 1 to 4. (medicalnewstoday.com)
  • Stage 4 prostate cancer has spread to pelvic lymph nodes or is blocking the ureters. (medicalnewstoday.com)
  • Stage 4 prostate cancer may also have spread to the bladder, the rectum, the bones, or distant lymph nodes. (medicalnewstoday.com)
  • Even if they detect cancer in the bones, doctors still consider this prostate cancer if that is where the cancer originated. (medicalnewstoday.com)
  • This is prostate cancer that is present in one or both sides of the prostate. (medicalnewstoday.com)
  • Stage 4A prostate cancer may also have spread to nearby lymph nodes. (medicalnewstoday.com)
  • This is prostate cancer that has spread to other parts of the body. (medicalnewstoday.com)
  • Prostate cancer often spreads to the bones. (medicalnewstoday.com)
  • What is the difference between prostate cancer and advanced prostate cancer? (medicalnewstoday.com)
  • Prostate cancer occurs when cells in the prostate gland begin to grow out of control. (medicalnewstoday.com)
  • In the early stages of prostate cancer, the cancer cells are only present in the prostate and have not spread to nearby tissues. (medicalnewstoday.com)
  • Advanced prostate cancer, also known as stage 4 prostate cancer, occurs when cancer cells have spread to other areas of the body. (medicalnewstoday.com)
  • What does it mean for prostate cancer to spread? (medicalnewstoday.com)
  • As a result, many prostate cancer symptoms affect the urination process. (medicalnewstoday.com)
  • According to the Prostate Cancer Foundation, age is the biggest contributing factor to prostate cancer risk. (medicalnewstoday.com)
  • New nomograms can predict survival outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177 prostate-specific membrane antigen ( 177- Lu-PSMA), according to a study published in The Lancet Oncology . (renalandurologynews.com)
  • This research was supported by the Prostate Cancer Foundation and others. (renalandurologynews.com)
  • Combined advanced prostate cancer treatments: are they additive? (nature.com)
  • More than 50 clinical trials are currently exploring the combination of immunotherapy and other approved treatments for advanced prostate cancer. (nature.com)
  • The results from a phase II trial of sipuleucel-T with or without radium-223 in patients with metastatic castration-resistant prostate cancer were recently published with intriguing findings. (nature.com)
  • Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer. (nature.com)
  • Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. (nature.com)
  • Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (nature.com)
  • Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. (nature.com)
  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. (nature.com)
  • Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. (nature.com)
  • A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? (nature.com)
  • In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and a lower risk of the cancer worsening, researchers report in a new study. (sciencedaily.com)
  • The findings, based on data from a large observational study nested in a clinical trial, are in line with earlier studies showing a connection between regular coffee consumption and improved outcomes in patients with non-metastatic colorectal cancer. (sciencedaily.com)
  • The investigators found that in 1,171 patients treated for metastatic colorectal cancer, those who reported drinking two to three cups of coffee a day were likely to live longer overall, and had a longer time before their disease worsened, than those who didn't drink coffee. (sciencedaily.com)
  • As a result, the study doesn't provide sufficient grounds for recommending, at this point, that people with advanced or metastatic colorectal cancer start drinking coffee on a daily basis or increase their consumption of the drink, researchers say. (sciencedaily.com)
  • Epidemiological studies have found that higher coffee intake was associated with improved survival in patients with stage 3 colon cancer, but the relationship between coffee consumption and survival in patients with metastatic forms of the disease hasn't been known. (sciencedaily.com)
  • The new study drew on data from the Alliance/SWOG 80405 study, a phase III clinical trial comparing the addition of the drugs cetuximab and/or bevacizumab to standard chemotherapy in patients with previously untreated, locally advanced or metastatic colorectal cancer. (sciencedaily.com)
  • Researchers correlated this data with information on the course of the cancer after treatment. (sciencedaily.com)
  • Although it is premature to recommend a high intake of coffee as a potential treatment for colorectal cancer, our study suggests that drinking coffee is not harmful and may potentially be beneficial," says Dana-Farber's Kimmie Ng, MD, MPH, senior author of the study. (sciencedaily.com)
  • This study adds to the large body of literature supporting the importance of diet and other modifiable factors in the treatment of patients with colorectal cancer," Ng adds. (sciencedaily.com)
  • Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage. (practiceupdate.com)
  • When my husband was first diagnosed in 2008 at age 57 with Stage 2 Prostate Cancer we were heartbroken, yet hopeful. (hubpages.com)
  • Dave does have a strong family history of Prostate Cancer which is why he began PSA screenings at age 40. (hubpages.com)
  • Surgery was successful by serving it's purpose of removing the prostate, not the cancer. (hubpages.com)
  • We later learned these treatments served no purpose since the cancer had obviously already spread. (hubpages.com)
  • A bone scan revealed metastatic cancer to his hip area. (hubpages.com)
  • A bone scan revealed metastatic cancer to the spine. (hubpages.com)
  • Dave was now asymptomatic, castrate resistant and had metastatic cancer. (hubpages.com)
  • It's the only treatment available besides chemo that will destroy cancer cells. (hubpages.com)
  • Would we recommend this treatment to another patient of Prostate Cancer? (hubpages.com)
  • Dave's Prostate Cancer Journey. (hubpages.com)
  • Prostate Cancer Doctors: Are They Still Clueless? (hubpages.com)
  • NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy.Doctors who raised doubts about it received death threats. (hubpages.com)
  • Xofigo was approved in 2013 for men with metastatic Prostate Cancer. (hubpages.com)
  • Immunotherapy Combinations for Metastatic Prostate Cancer Despite multiple trials, finding effective combination immunotherapy treatments for metastatic castration resistant prostate cancer remains elusive. (medscape.com)
  • Early Mortality in ICI-Treated Cancers in Routine Practice A better understanding of the predictors of early mortality among cancer patients treated with ICIs could help guide treatment selection. (medscape.com)
  • This test is used to find out if you have harmful changes in your BRCA1 or BRCA2 genes that increase your risk of getting certain cancers, especially breast, ovarian, prostate, and pancreatic cancer. (medlineplus.gov)
  • Prostate cancer that spreads to other parts of the body (metastatic cancer). (medlineplus.gov)
  • Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. (medscape.com)
  • Most prostate cancer-related deaths are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
  • For patient education information, see the Men's Health Center and the Cancer Center , as well as Prostate Cancer . (medscape.com)
  • An estimated 1 in 10 men will develop prostate cancer in their lifetime, with the likelihood increasing with age. (medscape.com)
  • Accumulating evidence is showing that, owing to early diagnosis and treatment, the mortality rate associated with prostate cancer has declined since the 1970s. (medscape.com)
  • Despite the apparent survival advantage of early diagnosis conferred by PSA screening, a 2008 US Preventive Services Task Force statement recommended against screening for prostate cancer in men aged 75 years or older. (medscape.com)
  • The statement also concluded that the current balance of benefits versus drawbacks of prostate cancer screening in men younger than 75 years cannot be assessed because of insufficient evidence. (medscape.com)
  • As a result of its genetic linkage, prostate cancer is more common in males with a strong family history of prostate cancer. (medscape.com)
  • The mortality rate associated with prostate cancer continues to increase in Europe and in countries such as Australia, Japan, and Russia. (medscape.com)
  • Advanced prostate cancer results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
  • Prostate cancer begins in a small area of the prostate gland, an organ found only in males. (msdmanuals.com)
  • The risk of prostate cancer increases as men age. (msdmanuals.com)
  • Doctors may do a digital rectal examination to examine the prostate using a gloved finger in the rectum and a blood test (PSA) to check for prostate cancer in men without symptoms. (msdmanuals.com)
  • If cancer is suspected, ultrasonography and a biopsy of prostate tissue are done. (msdmanuals.com)
  • Treatment may involve active surveillance, removal of the prostate gland, radiation therapy, or hormonal or newer drugs to slow cancer growth. (msdmanuals.com)
  • Among men in the United States, prostate cancer is the most common cancer and one of the most common causes of cancer death. (msdmanuals.com)
  • Every year, more than 268,490 new cases are diagnosed and 34,500 people die of prostate cancer (2022 estimates). (msdmanuals.com)
  • Prostate cancer usually grows very slowly and may take decades to cause symptoms. (msdmanuals.com)
  • Thus, particularly because it occurs more often in older men, far more men have prostate cancer than die from it. (msdmanuals.com)
  • Many men with prostate cancer die from other causes without ever knowing that they had prostate cancer. (msdmanuals.com)
  • The cause of prostate cancer is not known. (msdmanuals.com)
  • Prostate cancer usually causes no symptoms until it reaches an advanced stage. (msdmanuals.com)
  • Later, prostate cancer may cause bloody urine or a sudden inability to urinate. (msdmanuals.com)
  • In some men, symptoms of prostate cancer develop only after it spreads (metastasizes). (msdmanuals.com)
  • Doctors may suspect prostate cancer based on the symptoms, the results of a digital rectal examination, or the results of screening blood tests. (msdmanuals.com)
  • This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). (bvsalud.org)
  • Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. (bvsalud.org)
  • This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. (bvsalud.org)
  • Prostate cancer bone metastasis is still not fully understood, and increased knowledge could aid in the development of better treatment options for patients in the future. (lu.se)
  • Using cell culture, animal and patient studies, we investigated the biological role of microRNA-96 (miR-96) and microRNA-379 (miR-379) in prostate cancer bone metastasis. (lu.se)
  • In Paper II, we performed an in vivo anti-miRNA library screen, and identified miR-379 as a suppressor of prostate cancer bone metastasis. (lu.se)
  • In bone metastasis samples from prostate cancer patients, miR-379 was frequently downregulated. (lu.se)
  • Using this method, we could reveal that unedited, but not edited, miR-379 was frequently downregulated in prostate cancer patients with metastasis, treatment resistance, and shorter overall survival. (lu.se)
  • The editing frequency of miR-379 was higher in prostate cancer tissues compared to benign tissues. (lu.se)
  • In Paper IV, we compared the biological functions of unedited and edited miR-379 in prostate cancer cells. (lu.se)
  • Overall, this thesis reports multiple findings and tools that can help us better understand the process of prostate cancer bone metastasis and the role that miRNAs play in this process. (lu.se)
  • Retrospective, Non-interventional Study Assessing the Real-Life Use of The Long- Acting Gonadotropin-releasing Hormone Agonist as A Treatment for Locally Advanced or Meta-static Prostate Cancer in Hong Kong. (who.int)
  • Treatment protocols for prostate cancer are provided below, including general treatment recommendations and those for localized prostate cancer, for recurrent disease, and for advanced or metastatic disease. (medscape.com)
  • See Prostate Cancer: Diagnosis and Staging , a Critical Images slideshow, to help determine the best diagnostic approach for this potentially deadly disease. (medscape.com)
  • Also, see the Advanced Prostate Cancer: Signs of Metastatic Disease slideshow for help identifying the signs of metastatic disease. (medscape.com)
  • Withholding radical therapy for a large proportion of low-risk prostate cancer until signs of progress is a comparatively new strategy, named active surveillance. (cancercentrum.se)
  • The principle aim of the randomised SAMS-FU is to investigate an alternative to the standard follow-up schedule for active surveillance for low-risk prostate cancer. (cancercentrum.se)
  • In addition, SAMS will evaluate prognostic factors, criteria for intervention and the effects of 5-alpha-reductase inhibitors, the outcome after treatment with curative intent, time to symptoms and metastases from prostate cancer, prostate cancer specific survival, and overall survival. (cancercentrum.se)
  • Hopefully, SAMS will increase our knowledge on active surveillance for low-risk prostate cancer, so that more patients with aggressive cancer will receive curative treatment and fewer patients will receive un-necessary treatment for indolent tumours and thereby maintain their quality of life better. (cancercentrum.se)
  • Two recent papers, one a systematic review of literature on COVID-19 therapies and anticancer drugs and the other a study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19, are examples of this international effort to investigate the effects of COVID-19 on cancer mortality and survival. (who.int)
  • The study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19 provides observations from a small sample of patients with prostate cancer in South Italy that seem to align with results from other regions of the world in relation to COVID-19 treatment, hormone levels, and options for the management of patients with prostate cancer who are positive for COVID-19. (who.int)
  • CANESIN G, EVANS-AXELSSON S, HELLSTEN R, KRZYZANOWSKA A, PRASAD CP, BJARTELL A and ANDERSSON T. Treatment with the Wnt5a-mimicking peptide Foxy5 effectively reduces the metastatic spread of Wnt5a-low prostate cancer cells in an orthotopic mouse model. (lu.se)
  • Can UGT1A1 Genotyping Reduce Morbidity and Mortality in Patients with Metastatic Colorectal Cancer Treated with Irinotecan? (cdc.gov)
  • Despite this excess regional burden of disease in AI/AN men, the etiology of the disparity in prostate cancer outcomes remains poorly understood. (cdc.gov)
  • Timeliness of follow-up care after an elevated PSA level may contribute to prostate cancer outcomes in AI/AN men. (cdc.gov)
  • Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. (uclahealth.org)
  • The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. (globaldata.com)
  • Patients who had no prostate-specific antigen (PSA) response or had no evidence of radiographic progression were not eligible for period 2, during which 273 patients remained and were randomized (1:1) to enzalutamide 160 mg daily, or to placebo. (jhoponline.com)
  • The researchers also created a nomogram for prostate-specific antigen (PSA) progression-free survival (PFS). (renalandurologynews.com)
  • Selecting initial treatment requires assessing the risk of the disease spreading or progressing, which is based on evaluating the patient's life expectancy, comorbidities, biopsy grade (Gleason score), clinical stage, and prostate-specific antigen (PSA) level. (medscape.com)
  • Common treatments include chemotherapy and hormone therapy. (cancerresearchuk.org)
  • Treatment includes hormone therapy, chemotherapy and radiotherapy. (cancerresearchuk.org)
  • LATITUDE was a multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial that examined the use of abiraterone acetate 1,000 mg once daily in combination with prednisone 5 mg once daily, compared to placebos in patients with newly diagnosed, metastatic high-risk CSPC who had not received prior cytotoxic chemotherapy. (nursingcenter.com)
  • The outcome in routine daily clinical practice of a cohort of unselected chemotherapy-naïve mCRPC patients treated with docetaxel plus methylprednisolone as first- and further-line treatment in a single institution was investigated. (vub.be)
  • Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. (biomedcentral.com)
  • Patients in this study had prior treatment with 1 AR-targeted therapy, and no chemotherapy. (onclive.com)
  • Predictors selected for the OS model were time since diagnosis, chemotherapy status, baseline hemoglobin, bone involvement, liver involvement, number of metastatic lesions, and mean tumor standardized uptake value (SUV mean ). (renalandurologynews.com)
  • The approval was based on recently published clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine, in patients with unresectable or metastatic LPS or LMS previously treated with an anthracycline and at least one additional chemotherapy regimen. (prnewswire.com)
  • Dr. Smith outlines the ARASENS study that tests the impact of adding darolutamide, an AR pathway inhibitor, to the standard treatment of androgen deprivation therapy (ADT) and docetaxel. (urotoday.com)
  • There's a major survival benefit in favor of the triplet therapy compared to treatment with ADT and docetaxel. (urotoday.com)
  • Should men with newly diagnosed metastatic disease receive ADT combined with docetaxel or abiraterone acetate plus prednisone? (medscape.com)
  • The TOT and TFI from the start of second-line treatment, was significantly superior in docetaxel compared to non-docetaxel treated patients. (vub.be)
  • Treatment with docetaxel was well-tolerated and only two patients were withdrawn for non-haematological toxicity during first- and further-line treatment. (vub.be)
  • Normalisation of PSA during first-line treatment with docetaxel is associated with a better survival irrespective of second- or further-line treatment used. (vub.be)
  • Retreatment with docetaxel in second- or further-line remains a treatment option in docetaxel-sensitive patients. (vub.be)
  • In the last decade, however, since the approval of docetaxel by the US Food and Drug Administration (FDA) for metastatic CRPC in 2004, 3 there has been a substantial evolution in its treatment, as several drugs introduced in quick succession show efficacy in prolonging survival. (touchoncology.com)
  • The investigators hypothesized that continuous treatment with enzalutamide may help maintain control of responsive tumor lesions and may allow the addition of docetaxel to target pathways that enhance tumor growth. (jhoponline.com)
  • These data suggest that continued treatment with enzalutamide plus docetaxel offers a clinical benefit and could be a future treatment option for some patients who progress on enzalutamide alone," said Dr Merseburger. (jhoponline.com)
  • Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival. (lu.se)
  • The objective of our study is to analyze the management of metastatic prostatic adenocarcinoma based on epidemiological, clinical, therapeutic and evolutionary aspects in developing country context. (springeropen.com)
  • In patients considering clinical trial enrollment, the risks and potential benefits of experimental treatment modalities must be clearly outlined. (medscape.com)
  • This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. (facingourrisk.org)
  • The approval is based on phase III data from the pivotal LATITUDE clinical trial, which showed abiraterone acetate in combination with prednisone reduced the risk of death by 38 percent compared to placebos in patients with metastatic high-risk CSPC. (nursingcenter.com)
  • Robust and accurate risk assessment might aid physician decision-making regarding treatment plans and clinical trial patient stratification. (renalandurologynews.com)
  • The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. (cua.org)
  • The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. (cua.org)
  • A definitive diagnosis requires a biopsy of the prostate. (wikipedia.org)
  • Pure small cell carcinoma of the prostate (SCPCa) is a very rare condition usually with poor survival after diagnosis. (karger.com)
  • This could implicate the critical role of early diagnosis in the treatment of SCPCa despite its aggressive nature. (karger.com)
  • Researchers also assessed overall survival (the period from diagnosis or treatment where patients are still alive), in which Exelixis noted that a trend toward improvement was observed, but the data were not yet of statistical significance. (curetoday.com)
  • People with the condition normally have a very good outlook when they receive an early diagnosis and treatment. (medicalnewstoday.com)
  • Before radiotherapy is given, the radiation oncologist will plan how best to give your treatment. (cancer.ie)
  • The most important and established prognosticators for prostate carcinoma include the Gleason grade, the extent of tumor volume, and the presence of capsular penetration or margin positivity at the time of prostatectomy. (medscape.com)
  • As a tumor grows beyond the prostate, it can damage nearby organs causing erectile dysfunction, blood in the urine or semen, or trouble urinating - often frequent urination and slow or weak urine stream. (wikipedia.org)
  • The Emerging Role for CAR T Cells in Solid Tumor Oncology Learn more about the exciting potential role of CAR T cells in the targeted treatment of solid tumor cancers. (medscape.com)
  • Treatment continued until disease progression. (jhoponline.com)
  • In addition, enzalutamide treatment delayed the time to PSA progression (8.4 months vs 6.2 months with placebo). (jhoponline.com)
  • According to a press release from biotechnology company Exelixis Inc. and biopharmaceutical company Ipsen, the phase 3 trial CONTACT-02 is currently evaluating Cabometyx plus Tecentriq compared with a novel hormonal therapy as treatment for patients with mCRPC and measurable soft tissue disease who have been previously treated with one novel hormonal therapy. (curetoday.com)
  • Markowski detailed that a phase 3 trial, known as VERACITY (NCT04844749), is currently underway and is evaluating 32 mg of sabizabulin for the treatment of mCRPC against an alternative AR-targeting agent. (onclive.com)
  • Hormone therapy (drugs to reduce the level of male hormones) has been the main treatment for advanced disease, but this does not work forever. (cochrane.org)
  • Medical records were abstracted for a sample of 9017 PC cases diagnosed in 2004 as a part of the Center for Disease Control and Prevention's Prostate and Breast Patterns of Care Study in seven states. (cdc.gov)
  • However, this population may still respond to secondary hormonal manipulations and ADT continues to be the gold standard for systemic treatment of men with metastatic disease. (touchoncology.com)
  • What Is Metastatic Bone Disease? (upmc.com)
  • People with metastatic bone disease have pain with activities. (upmc.com)
  • Radiation, in addition to surgery, is the standard treatment for metastatic bone disease. (upmc.com)
  • Orthopaedic treatment of metastatic bone disease does not focus on a cure. (upmc.com)
  • Upon relapse, when the disease will metastasize or spread, the disease is hormone-sensitive and androgen deprivation therapy is the cornerstone of treatment. (drugsnews.net)
  • This article presents a case of an elderly patient with internal diseases, who in the castration-resistant stage, was treated with a new generation androgen receptor blocker - apalutamide - in the first line of systemic treatment. (journalsmededu.pl)
  • Conversely, low-grade prostate tumors can also be biologically aggressive. (medscape.com)
  • Screening can also involve a digital rectal exam to feel for prominent prostate tumors. (wikipedia.org)
  • Most prostate tumors remain small and cause no health problems. (wikipedia.org)
  • Prostate tumors were initially thought to be rare, with an 1893 report describing just 50 cases in the medical literature. (wikipedia.org)
  • As surgery became more common, prostate tumors were found in surgical specimens from prostates that had enlarged with age. (wikipedia.org)
  • Screening aims to separate men with high-risk cancers who would benefit from treatment, from those whose tumors are slow-growing and unlikely to impact health. (wikipedia.org)
  • RP, combined with adjuvant or salvage treatment when needed, may result in better outcomes than RT alone, similar to the combination of RT plus HT therapy. (ommegaonline.org)
  • Our academic teams are dedicated to finding new treatments with scientific merit and the promise to improve outcomes for patients with sarcomas. (prnewswire.com)
  • When you think about your family health history, consider all breast, ovarian, prostate, and pancreatic cancers on both sides of your family. (medlineplus.gov)
  • Dear Sir, There have been a number of articles recently, addressing treatment of the primary prostate tumour in presence of metastases. (ommegaonline.org)
  • Limitations were slow recruitment, lack of enrolling patients without radical local treatment, and too short follow-up for evaluation of overall survival in patients with PSA relapse. (lu.se)
  • Previous treatment with next-generation androgen receptor (AR)-directed therapy (e.g. abiraterone, enzalutamide, apalutamide, darolutamide). (orlandohealth.com)
  • Serious treatment-emergent adverse events were observed in 49.3% of patients who received enzalutamide versus 38.5% of the patients who received placebo. (jhoponline.com)
  • In contrast, conditional activation of Stat3 prevented metastasis via Lkb1/AMPK activation, as did treatment with the approved diabetes drug metformin, a known activator of AMPK signaling. (cancercluster-salzburg.at)
  • Oct. 23, 2015 /PRNewswire/ -- Janssen Biotech, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS ® (trabectedin) for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen. (prnewswire.com)
  • Reflections on Treatment for Endometriosis-associated Pain The authors discuss the pros and cons of surgery vs. hormonal therapy for treatment of endometriosis-associated pain, focusing on the role of patient fears and misunderstanding. (medscape.com)
  • More than 330,000 patients worldwide, including 113,000 in the U.S., have received treatment with it, and it was the number one prescribed oral medication in the U.S. for patients with metastatic CRPC in 2016. (nursingcenter.com)
  • Immune checkpoint inhibitors (ICIs) are widely sought after for the treatment of different types of cancers. (news-medical.net)
  • All patients had biopsies of metastatic lesions with an evaluation for both germline and somatic mutations. (bmj.com)
  • C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. (ommegaonline.org)
  • Some prostate cancers, however, grow rapidly or spread outside the prostate. (msdmanuals.com)
  • Some prostate cancers grow so slowly that they may not require treatment. (msdmanuals.com)
  • Doctors cannot always tell which prostate cancers will be aggressive. (msdmanuals.com)
  • Prior treatment with radium-223 (Xofigo) within the past 12 weeks. (orlandohealth.com)
  • There are also two treatments in late-stage development, MDV3100 (an oral AR antagonist) and radium-223 (an isotope that creates breaks in double-stranded DNA). (touchoncology.com)
  • Formally known as Radium-223, it's the latest treatment for my husband. (hubpages.com)
  • Benign Prostatic Hyperplasia (BPH) Benign prostatic hyperplasia (BPH) is a noncancerous (benign) enlargement of the prostate gland that can make urination difficult. (msdmanuals.com)
  • The prostate gland enlarges as men age. (msdmanuals.com)
  • However, there is also an increase in severe and life-threatening side effects, likely leading to discontinued treatment, with the addition of abiraterone acetate. (cochrane.org)
  • The median duration of treatment with abiraterone acetate and prednisone was 24 months. (nursingcenter.com)
  • These symptoms can also occur with aging and an enlarged prostate. (medicalnewstoday.com)
  • In the SAMS (SAMS-FU and SAMS-ObsQoL) the quality of life and pelvic symptoms of patients on active surveillance will be investigated and compared to those of patients receiving immediate treatment with curative intent. (cancercentrum.se)